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1 Introduction 
Since its discovery over 30 years ago (1), the Human immunodeficiency virus (HIV) has 
become one of the most important infectious agents in modern medicine, and the fight 
against HIV/AIDS (acquired immunodeficiency syndrome, the resulting illness) has proven to 
be immensely challenging (2, 3). Over 60 million people have so far been infected, with 
roughly 7500 new infections occurring every day. More than 25 million have died due to 
infection with HIV (4). 
Due to the widespread effects of HIV infection on the human body, the development of a 
medical cure for HIV/AIDS is highly unlikely. Prevention is key for this disease, and the 
ultimate hope in combating HIV remains the creation of an effective vaccine. However, 
developing such a vaccine has proven very challenging due to the effective and peculiar way 
of action by which HIV affects and alters the host’s immune system (5). A variety of different 
approaches are currently being investigated, one of which is the use of nonpathogenic viral 
vectors to deliver HIV antigens and enable the body to mount an immune response against 
them (5). This work aims to evaluate such a newly developed vector system in primary safety 
and efficacy studies. 
Viral vectors for vaccine development are chosen based on pathogenicity to the target 
species, safety in use and manufacturing, but also efficacy in delivering the inserted viral 
antigens to the appropriate components of the host’s immune system to be processed. As 
an infectious agent, HIV directly targets the host’s immune system, mainly so-called T-cells. 
The virus enters the body via mucosal surfaces, and these also are the focus of primary 
contact between immune cells and the virus, as well as initial rapid virus replication. 
Therefore, creating a localized immune response in those critical mucosal surface areas 
could be very helpful in preventing HIV from gaining a foothold in the host’s body (6). A 
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recombinant viral vector containing HIV antigens would ideally accumulate and replicate in 
the same areas as live HIV, and choose the same cell types for replication, therefore leading 
to activation of the immune system at the virus’s point of entry, and eliciting a local and 
generalized immune response not only to the vector backbone, but also to the transported 
insert (7). The members of the paramyxovirus family, particularly members of the 
morbillivirus genus, share a variety of important characteristics with HIV – they enter the 
host’s body via mucosal membranes, they preferably infect lymphocytes, and their initial 
replication occurs in epithelial cells and lymphocytes on mucosal surfaces (8). While Measles 
virus is a human-pathogen member of this group, its’ very close relative Canine distemper 
virus (CDV) is completely non-pathogenic to humans and most non-human primates, but still 
shares those similarities with HIV. Attenuated vaccine strains of CDV have been established 
and used for several decades, with an excellent safety record in even the most susceptible 
target species, ferrets (9). Viruses of those strains have successfully been propagated in 
primate cell lines such as Vero cell, suggesting that these viruses, while non-pathogenic, are 
indeed capable of infecting primate and human cells (10). Such vaccine strains would 
therefore provide an excellent backbone for the design of a viral vector vaccine against HIV. 
During the investigation of novel vaccine candidates, vaccine safety and efficacy are 
paramount. Wild-type CDV is non-pathogenic to humans, and the commercially available 
vaccine strains of CDV have a longstanding safety record even in susceptible species. Any 
genetic reversion however bears a small risk of inadvertent increase in pathogenicity. To 
evaluate this risk, novel vaccine candidates are generally tested for safety in a species that 
would normally be highly susceptible to infection with wild-type virus. In the case of CDV, 
the species most susceptible to contracting the disease are mustelids, namely ferrets. 
Infection with wild-type distemper in ferrets usually results in death of the animal. The 
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course of viral infection in ferrets has been investigated, and replication pathway and cell 
tropism of CDV in ferrets are similar to those of HIV, as mentioned above (8). Several vaccine 
strains of CDV are commercially available and have safely been used in ferrets for several 
years. 
A very close, but not human-pathogenic relative to HIV is its primate sibling and presumed 
precursor, Simian immunodeficiency virus (SIV) (11). In certain primate species such as 
rhesus macaques, infection with SIV eventually leads to a clinical picture very similar to AIDS. 
SIV and HIV infect the same cell populations and demonstrate a very similar course of 
infection. It has been shown that, just as humans infected with HIV, rhesus macaques 
infected with SIV do indeed mount an immune response against SIV, albeit due to the 
unique properties of the virus unsuccessfully. The high degree of similarity to HIV, and the 
lower risk involved for humans working with the virus make SIV an excellent model for HIV 
research (11). 
The gene sequence of Gag p55 from HIV and SIV encodes for a 55 kDa full-length protein 
that is the precursor of all virus core proteins. This sequence and the resulting proteins are 
indispensible for virus replication. Gag p55 is the first sequence to be transcribed during 
replication, and is very well conserved across the various HIV and SIV strains, highlighting its 
importance for normal virus function (12). Previous studies have shown gag p55 to be highly 
immunogenic and, importantly, mediating a strong cell-based immune response, which is 
essential for controlling viral infections. Thus, gag p55 has developed into an antigen of 
special interest in SIV and HIV vaccine research (13-15). 
During this proof-of-concept study, recombinant CDV viruses with and without SIV gag 
insert, originating from a laboratory-adapted commercially available Canine distemper virus 
vaccine strain (9) were evaluated for their potential as vaccine vector candidates both in 
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vitro and in vivo. The viruses were first propagated in Vero cells to provide a large enough 
quantity of virus particles to cover further studies. The viability of the recombinant viruses 
and their ability to infect Vero cells was assessed. The recombinant viruses were then used 
in two sequential animal studies to assess safety and immunogenicity in a naturally CDV-
susceptible species. Effects of the novel vaccine candidate versus empty vector versus plain 
solvent were compared. Blood samples and swabs were obtained and clinical observations 
noted throughout the study. Animals were sacrificed at various time points and terminal 
blood and tissue samples obtained. Samples were analysed using a variety of virological and 
immunological assays. 
The research presented in this thesis shows that a viable and replication-competent 
recombinant CDV as well as recombinant CDV expressing SIVgag could be safely 
administered to CDV naïve ferrets. Presence of the recombinant viruses could be 
demonstrated in various swab and tissue samples, and it was shown that the viruses were 
able to replicate within the ferrets. Both cellular and humoral immune responses to the 
recombinant viruses could be demonstrated. 
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2 Literature review 
2.1 Human immunodeficiency virus – a virus with an impact 
The clinical syndrome now known as Acquired immunodeficiency syndrome (AIDS) was first 
observed in New York City in 1981 (16, 17), and by 1983 a causative agent, then known as 
HTLV III was found (1, 18-20). Simultaneously, two more very similar viruses were discovered 
and named lymphadenopathy-associated virus and AIDS-associated retrovirus. In 1986 it 
was determined that these three viruses were actually one and the same, and the virus was 
renamed Human immunodeficiency virus (HIV) (21).  
HIV is one of the most devastating viruses ever discovered. 6500 people get newly infected 
with HIV each day (22) and more people die from HIV/AIDS than from any other infectious 
disease. It is the fourth leading cause of death worldwide (23). At the end of 2005 almost 40 
million people were living with HIV, and during the course of 2006 more than 4 million more 
were infected (4). Studies suggest that less than 30 % of South African children will be living 
with both their parents by the end of the decade, while 20 % will be full orphans (24). 60% of 
children with HIV will not reach the age of five (25). 
A cure of HIV infections is impossible at this time and preventive and educational measures 
have slowed down the spread of infection. However it is believed that only a vaccine can end 
the pandemic of HIV infections (26). Modelling exercises have shown that even a partially 
effective vaccine with only moderate uptake would be able to protect 30 – 70 million people 
over the course of 15 years (27). 
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2.2 Human immunodeficiency virus biology 
The two types of HIV characterized to date, HIV-1 and HIV-2, belong to the genus Lentivirus 
within the order Retroviridae (28). Retroviridae are characterised by their unique replication 
mechanism. The retrovirus particles enveloped in a lipidic membrane contain the viral 
genome as positive sense single stranded viral RNA and several enzymes required for virus 
replication. Once the virus particles have entered the host cell, the virus uses its own reverse 
transcriptase as well as the host cell’s replication machinery to convert the genomic RNA 
into DNA, which is then integrated into the host cell’s genome as double stranded DNA (29). 
The virus can then become latent for several years before replicating further, resulting in 
incubation periods of up to a decade before the outbreak of clinical disease (30). The 
pathogenesis of HIV-1 infection and subsequent AIDS is largely characterized by chronic, 
generalized immune activation (31-34). Persistent viral infections dampen and exhaust the 
immune system to prevent tissue damage (35). Exhaustion occurs in both T and B cells, and 
results in reduced responsiveness of the cells, expression of down-regulatory receptors, and 
reduced function (36, 37). This ultimately leads to the depletion and collapse of virtually the 
entire immune system, resulting in the so-called Acquired immunodeficiency syndrome 
(AIDS) (38). 
The HIV-1 genome encodes only 15 proteins (39) and the virus relies on various functions of 
the host cell to establish infections (A simplified depiction of the virus particle and its 
genome can be seen in Figure 1) (40). HIV gains entry into the host cell by binding to the 
cellular receptor CD4, present on white blood cells, dendritic cells and some macrophages, 
as well as a co- receptor, either CXCR4 or CCR5. The virus particle membrane fuses with the 
membrane of the host cell, and subsequent dissolution of the viral capsid releases the viral 
genome and viral proteins reverse transcriptase (RT), integrase (IN), protease (PR), and 
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accessory proteins Vif, Nef and Vpr into the host cell. A double stranded DNA complement of 
the viral RNA is then synthesised after the viral proteins bind to host cell actin. The entire 
assembly then travels to the nucleus and enters it through a pore. Inside the nucleus, viral 
integrase binds to a host cell integration factor and the viral DNA is integrated into the host 
DNA. As the host cell apparatus transcribes viral DNA into proviral RNA, the viral factor Tat 
acts as a promoter of elongation. The viral Rev protein then assists the proviral RNA with 
nuclear export. The Gag protein is the main structural protein of HIV (41). The Gag protein is 
produced as one polypeptide but gets proteolytically cleaved into the three main structural 
proteins of the viral capsid and an accessory protein (42). Newly produced particles of both 
HIV and SIV bud directly from the host cell surface (42) and are covered in a lipid membrane 
derived from the host cell. From this surface protrude structures called spikes, which the 
virus requires to bind and enter new target cells. These spikes consist of two different viral 
glycoproteins forming a complex; gp41, which crosses the lipid membrane, and gp120, one 
of which sits on top of and around the gp41 “legs” and covers most of them up. 
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Figure 1: Schematic of a Human immunodeficiency virus virus particle and simplified 
representation of its genome. The viral RNA is protected by three layers of glycosaminoglycane 
protein derivatives: Wrapped in nucleocapsid (NC), which is enclosed by capsid (CA). The capsid is 
then encased in matrix (MA). All three components are present in many copies. Binding of the virus 
to the target cell is facilitated by envelope gene products gp41 and gp120. reverse transcriptase (RT) 
and integrase (Int) are also present in the capsid. Black vertical lines in the genome represent protein 
boundaries. 
Figure based on “Introduction to Modern Virology”; Dimmock, Easton, Leppard; fifth edition, figures 
9,8 19.3 and 19.5 
 
While gp41 is fairly well conserved, gp120 has several highly variable loops on its surface. 
Additionally, gp120 is heavily glycosylated with more than 50 % of its mass contributed by 
carbohydrates. Both these mechanisms work to effectively disguise the spikes from the 
host’s immune system and make them difficult to access for antibodies (43). Using cryoEM 
tomography of unstained, unfixed, frozen hydrated HIV and SIV, it was possible to determine 
that each spike in fact is a hexamer, consisting of three central gp41 molecules that each 
cross the viral envelope and three gp120 molecules surrounding and covering this gp41 
anchor. While gp41 does extend through the gp120 trimer only a very small portion is 
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exposed. The conserved CD4 binding site of gp120 is in direct vicinity to highly variable loop 
structures (44). In fact, HIV gp120 shows up to 35 % variation in circulating isolates (45). 
Within an infected individual, HIV generates a huge variety of quasispecies (46-48) making it 
difficult for the immune system to lock onto suitable targets to combat infection. 
 
2.3 Immunology of human immunodeficiency virus infections 
In general, the process of initiating an immune response in the human body is described as 
follows (as per (49)): Intracellular antigens, which are usually produced by a host cell, are 
presented on the surface of an antigen-presenting cell via major histocompatibiliy complex 
(MHC) class 1 molecules. Foreign antigens outside of host cells are taken up by phagocytosis, 
digested and then presented on the surface of antigen presenting cells via MHC class 2 
proteins. Antigen presenting cells then move to the regional lymph nodes. There they 
differentiate and present the foreign peptides to T cells. The T cells in turn then proliferate 
and become activated. The resulting effector cells travel to the target tissues and attack the 
source of the foreign protein. As the invasion is cleared, a portion of the T cells differentiates 
into memory cells to enable a faster response upon a repeat encounter. 
The initial HIV infection only occurs in a small number of cells (46) and only by a small 
number of virions (50, 51). Most HIV infections in naïve patients are the result of only a single 
virus (47), and only a very small subset of quasispecies present within an infected individual 
actually transmit to new hosts (46). HIV1 replicates most effectively in activated CD4+ T-cells 
when studied in vitro. Evidence suggests that HIV even selectively infects HIV-specific CD4+ 
cells (52). Natural immunity to HIV is not protective. It does not result in virus clearance or 
protect from superinfection, despite both humoral and cellular responses being generated 
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(53). Around 0.3 % of HIV infected people however are able to control virus levels, keeping 
them at low levels without any treatment for several years to decades. These are the so-
called elite controllers (54, 55). We will look at the differences in immune responses in this 
chapter. 
HIV can be neutralised by antibodies, which bind to the envelope and block contact with 
cellular receptors, or by antibodies that bind after attachment of the virus to the host cell 
and inhibit fusion (56). Sterical and kinetic hindrances however make it difficult for 
antibodies to access vulnerable sites on virus particles (57). Nearly each individual infected 
with HIV will at some point produce antibodies against virus proteins but not all of these 
antibodies are capable of neutralising the virus. The ones that are, all are directed against 
the envelope spikes. High titers are necessary to achieve neutralisation, and antibodies are 
generally of narrow specificity (58). Neutralizing antibodies only arise later on in infection, 
around 6 – 8 months into the process (59-61). Non-neutralizing antibodies may still 
contribute to the control of virus levels. After binding of the antibody to viral epitopes 
presented on host cell surfaces, the Fc portions of antibodies can interact with other 
immune cells and trigger lysis of infected cells and hence reduce virus levels. As the disease 
progresses this ability is increasingly reduced (58). In some cases patients produce a mixture 
of various polyclonal, high-affinity, broadly neutralizing antibodies (bNAbs) against several 
different envelope epitopes (62). Some of these bNAbs have been isolated from patients and 
are available as monoclonal antibodies for research. One of them was able to block a low 
dose intra vaginal challenge with SHIV, a recombinant chimera between SIV and HIV 
exhibiting HIV envelope characteristics (63, 64). These bNAbs react with epitopes on gp120, 
gp41 and the CD4 binding site on the hexamers (65, 66). Two the bNAbs were thought to be 
auto reactive, which may have explained why they are so rarely elicited in patients (67-69). 
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However, other publications suggested this not to be the case (70). Antibody-mediated 
control of other retroviruses is only possible alongside CD4 and CD8 responses, and is 
regulated by certain MHC alleles (71, 72). This is of interest in the case of HIV as there are 
several MHC alleles in humans that enable more effective control of HIV infection (73). 
The cellular response to virus exposure is generally broader than the humoral response. The 
speed and dimension of virus-specific CD4 responses largely determine the result of a 
retrovirus-infection (74). Strong responses from memory CD4+ T cells result in reduced 
rather than enhanced virus replication in SIV challenge studies (75). The pathogenesis of 
HIV2 infection is very similar to that of HIV1, but only rarely causes disease (76). The two are 
distinguished by a strong CD4 cell response to the virus in the case of HIV2 (76). By the same 
mechanism SIV in African nonhuman primates demonstrates the same pathogenesis as in 
Rhesus macaques, yet does not cause disease (77). In vivo studies have shown that only a 
minority of all HIV specific CD4+ cells are actually infected even during times of high virus 
levels (52). Proper function of CD4+ cells is important for the control of a HIV infection, since 
this cell population undertakes not only self-control but also control of the majority of other 
immune cells. A main point here is the control of CD8+ cells via IL-2. The lack of proliferation 
in CD8+ cells in chronic infection is largely due to the lack of appropriate regulation by CD4 
(78). The degree of CD8+ T cell activation seems to predict progression of HIV infection even 
more accurately than virus levels (79, 80). In vitro experiments have shown that CD8+ T cells 
from infected patients can inhibit replication of HIV-1 (81). During the primary HIV infection, 
control of the initial surge of virus replication coincides with the appearance of HIV-specific 
CD8+ T cells (82). In individuals with low virus loads and chronic non-progressive infections, 
so-called non-progressors, there is evidence of a strong HIV-specific CD8+ response (83, 84). 
In SIV-infected nonhuman primates, control of virus loads is largely dependent on CD8+ T-
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cells. In acute infections with SIV, loss of CD8+ cells results in uncontrolled viremia, lack of 
specific antibody production and rapid progression. The transient loss of CD8+ cells during 
chronic infections causes a transient increase in viremia (34). Broad SIV-specific CD8+ 
responses in monkeys can reduce virus replication after challenge (85, 86). There is a certain 
level of cytotoxic T-cells detectable after exposure with a subtype of HIV that are cross-clade 
reactive. This also occurs after exposure during vaccine trials (87, 88). This broad reactivity 
probably results from the fact that 1) cytotoxic T lymphocyte (CTL) epitopes tend to be well 
conserved, and 2) T-cell receptors are not as strictly sequence specific as their B-cell 
counterparts and tolerate a degree of sequence variation within recognized epitopes. 
Nevertheless, escape mutations in HIV CTL epitopes are not uncommon, suggesting that 
there is significant pressure exerted by the cellular immune system (89). During chronic HIV 
infection, it has been show that the presence of gag-specific cellular responses corresponds 
to lower HIV viral loads (90). Almost all patients demonstrate immune responses against HIV 
gag, even in the face of CD4+ cell depletion. Gag encodes three major structural proteins of 
HIV particles, which are proteolytically derived from it, namely capsid, matrix and 
nucleocapsid (91). All of them are focal points of an anti-HIV immune response and elicit 
strong reactions (91). Unprocessed gag protein has been found to elicit both CD4 and CD8 
responses (91). Gag specific cellular responses are associated with a stronger control of virus 
levels (78). Especially cytotoxic T cells directed against gag are able to suppress the 
replication of HIV during early natural infections and thereby reduce viral loads (82, 92, 93). 
They are potentially even able to prevent the establishment of a persistent infection (94, 95). 
Gag proteins are highly conserved across clades (12, 96) and are able to self-assemble 
without the presence of viral RNA or other viral proteins (91). All these properties have made 
HIV gag an ideal possible immunogen, and most current vaccine candidates include gag (13-
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15, 97). There is evidence that vaccine protocols including gag are also capable of inducing 
mucosal immune responses, even after mucosal delivery (98). 
 
2.4 Human immunodeficiency virus at mucosal surfaces – what chances are 
there?  
Pathogens are recognized at mucosal surfaces by antigen presenting cells, which then 
initiate an immune response. Secretory Immunoglobulin A and G (IgA and IgG) antibodies 
from B cells can capture pathogens before they enter the body (99), while mucosal CD8+ T 
cells attack virus-infected cells and can thereby control virus replication and often infection 
(100). After antigen-specific B and T cells become activated they briefly leave the mucosal 
surface to enter the lymph- and bloodstream. The majority of them return and become 
effector cells (101, 102). Immune cell aggregates at different mucosal sites communicate with 
each other in what is known as the common mucosal immune system. This enables the 
induction of immune responses at sites distant from the one of first encounter with a 
pathogen or vaccine antigen. This distant response is stronger than the response created at 
mucosal sites after systemic vaccination (103-105). 
Much research has been conducted to investigate the time course of HIV infections at 
mucosal surfaces. In the first hours to days after the initial infection with HIV, the virus 
particles cross the mucosal epithelium and infect lamina propria CD4+ T cells, the most 
common cell population in this layer. The virus preferentially infects activated or recently 
activated CD4+ cells but is also able to infect macrophages and dendritic cells. After 
establishing an infected population at the point of entry, some infected cells are spread via 
circulation to the regional lymph nodes and subsequently other lymphoid tissues (106). It 
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takes the virus a few days to reach the degree of replication at which it is self-sustaining, 
that is, each infected cell results in at least one cell being infected by virus progeny (46). By 
the end of the first week (107) the virus has reached the largest lymphoid organ in the body, 
the gastrointestinal-associated lymphoid tissue (GALT). Conditions are now ideal for a 
massive expansion resulting in the depletion of the vast majority of GALT CD4+ cells, 
particularly in the lamina propria (108). Peak viral concentrations are reached by day 10-14 
(106). This replication burst systemically activates the immune system. The activation 
however is only partially successful in controlling the virus, but crucially causes the influx of a 
new supply of uninfected cells, which enables the infection to remain established (109). At 
this point, latent infections in resting T cells have been established (110, 111) and the virus is 
escaping elimination pressure by mutating (112, 113). Elimination of HIV specific as well as 
memory CD4+ cells is ongoing (52, 114). Cellular immune responses involving cytotoxic T cells 
are only detectable from about two weeks post infection (106), and while they are robust 
enough to control the infection at the site of entry (106), the overall effect of cellular 
responses is only limited and unable to eradicate or even contain the infection (109). It is 
again the components of GALT that suffer the most (115). The ability of the virus to cause a 
latent, non-replicating infection in resting T cells means this reservoir cannot be attacked 
unless these cells become activated (110). By about the fourth week post infection, virus 
levels begin to decline (107). Studies have shown that this is a time where strong immune 
responses are not yet established, especially in the GALT (115). The conclusion is that this 
decline of viral load is largely caused by supply shortage of uninfected cells at this time (116, 
117). Significant antibody levels are only detectable after viremia has been controlled (118). 
HIV and SIV infection both result in chronic activation of the immune system, which affects 
both B cells and T cells (119-121). The degree of immune activation carries more prognostic 
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value with regards to disease progression than plasma virus levels (79). Immune activation 
caused by the virus does increase the activation of CD4+ cells, which can then become new 
virus hosts; but it also activates the immune responses countering the infection. As a result, 
virus levels are maintained at a balance between new cells being infected and the immune 
system fighting the infection (106). The events at mucosal surfaces over the acute phase of 
the infection are directly linked to the degree of immune activation and therefore disease 
progression. So called elite controllers (infected but maintaining low viral loads and high 
CD4+ cell counts), still show higher levels of T cell activation than non-infected individuals 
but present a significantly lower degree of T cell activation than those with a progressing 
disease (progressors) (122). 
The biology of HIV infection at mucosal membranes presents several critical points which 
present suitable targets for vaccine- and drug development. The efficacy of HIV infection is 
naturally very low. In SIV studies using intravaginal inoculations, researchers administered 
around one billion virus particles. When they examined cervical and vaginal tissues for 
presence of virus between 2 to 24h post inocculation only a fraction of viruses had actually 
entered the tissues (107, 109). These few dispersed cells then need to establish a productive 
focus of infection in an at this point rather small number of permissive cells (109). Once the 
infection is established and the virus is systemically distributed, the productiveness of the 
virus depends on the availability of target cells, and the limitation of immune responses 
against the virus (106). Each of these impasses is a potential target for the prevention or 
limitation of HIV infections. During HIV infection, the virus enters from the lumen, 
penetrating the protective mucous layer, and infecting dendritic and CD4+ T-cells in the 
epithelium and the lamina propria. The infected cells start to migrate and can be detected in 
regional lymph nodes within 24hours (123). However, there is very little evidence of the virus 
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replicating up to about five days post infection. Then an explosive rise in virus numbers 
occurs, accompanied by an equally dramatic increase in innate immune responses (107). This 
leaves a window of several days for vaccine-induced immune responses to prevent the 
infection from taking hold or to limit its extent. Vaccine induced antibodies of classes IgG 
and mainly IgA can capture free virus in the lumen of the organ of entry or neutralise virus 
inside epithelial cells and the lamina propria (124). Studies have shown that the presence of 
HIV/SIV-specific IgA at (genital) mucosal surfaces can prevent or reduce transmission (125-
127). Their production is therefore a main goal of HIV vaccine development. 
Infected mucosal cells can also be killed, either by direct or by antibody-mediated 
cytotoxicity. Early studies into the mucosal events of HIV infections have shown an 
inflammatory influx of lymphocytes, but also an unexpected loss of CD4+ cells (128, 129), 
which in the nonhuman primate SIV model was evident within days post infection (130). 
Phenotypic analysis of intestinal lymphocytes confirmed the specific loss of intestinal CD4+ 
cells featuring the co-receptor CCR5 (131, 132). Furthermore, flow cytometry experiments 
showed that the frequency of infection in intestinal CD4+ cells was ten times higher than in 
CD4+ cells in blood (114, 133). During the acute phase of the infection, the vast majority of all 
intestinal CD4+ cells is depleted, and the process continues into chronic infection, with the 
degree of depletion correlating with the onset of clinical AIDS (114, 134). Reconstitution of T-
cell levels in the intestinal tract is minimal in patients with HIV. Sootey mangabee monkeys, 
which are natural non-progressors however show the ability to replenish the intestinal T cell 
reservoir (135, 136). In long-term non-progressors, CD4+ counts in the intestinal tract seems 
to be kept up, while virus replication appears controlled (137). So the preservation of CD4+ 
cells by at least partially preventing infection through a vaccine is an important target. 
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Studies in SHIV-immunized macaques have shown that the main factor for the protection 
from a SIV challenge are SIV gag specific CD8+ cells (138, 139). Depletion of CD8+ cells results 
in a complete loss of protective abilities in SHIV-immunized animals. However, SIV gag 
specific CD8+ cells only proliferate within local mucosal tissues upon challenge and the 
overall immune activation is minimal (139). A higher degree of activation of the immune 
system would result in more target cells available for the virus and a higher rate of retrovirus 
replication. Hence, the degree of local availability of specific CD8+ cells as well as the degree 
of activation of the immune system affect virus levels (140). In SHIV immunized macaques, T 
cell responses to a mucosal SIV challenge have been shown to be well controlled, whereas 
unvaccinated animals respond with extensive activation (139). So the creation of gag specific 
CD8+ cells by a vaccine is a valuable target to provide efficacy of the vaccine. 
Both, protective humoral and cell-mediated immunity will be required at mucosal entry sites 
and lymphoid tissues in order to stop HIV or SIV from spreading systemically. A vaccine able 
to elicit such responses could prevent or minimize virus entry and stop an infection at the 
mucosal surfaces (124). Evidence suggests that the different immunological sites, both 
systemic and mucosal, communicate with each other to a good degree. To that effect, 
intranasal application of vectored HIV proteins in mice resulted in a higher degree of 
mucosal antibody formation than systemic administration (124). Should HIV manage to 
overcome these responses, a vaccine-induced systemic immune response would still have an 
opportunity to combat infection while the virus is in its initial non-replicating phase (140). 
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2.5 Vaccine development – an overview 
The first vaccine that successfully protected against a viral infection was developed by 
Edward Jenner in 1796. He had observed that milkmaids seemed protected against smallpox 
and concluded without any of the knowledge available today that exposure to cowpox must 
somehow result in resistance to smallpox. He then inoculated a young boy with fluid from a 
cowpox lesion and showed that the boy was protected against smallpox (141). 
A successful vaccine must fulfil three main requirements: It must be safe to use in the target 
species. It must elicit a strong and long-lasting immune response in the appropriate or even 
multiple parts of the immune system. And it must be possible to manufacture the vaccine 
reliably and affordably at industrial scale. Legal regulations must be fulfilled as well (142). 
Generally speaking, there are three main possible classes of vaccines: Inactivated virus 
vaccines, attenuated live virus vaccines and subunit vaccines. Recently added were DNA 
vaccines and virus like particles (142). 
In the case of inactivated virus vaccines, the virus has been treated, for example by use of 
chemicals or irradiation, so that it is no longer able to replicate but retains its natural shape 
(142) (for example hepatitis A). Relatively inexpensive to manufacture but also poorly 
immunogenic and only resulting in short-term immunity, (143) inactivated virus vaccines also 
do not induce cellular immunity. Often only very few neutralising antibodies are produced 
for epitopes which are often only revealed during the course of a viral life cycle (89). 
Subunit vaccines are carrier particles such as liposomes, containing one or several soluble 
antigens, as well as adjuvants (142). They are safe due to the fact that they are not complete 
viruses, but they also can be expensive to manufacture. Immunity is raised for a medium 
amount of time (144) and the focus generally lies on inducing humoral immunity, but they 
can be poorly immunogenic (89). 
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Attenuated live vaccines are viruses that have been made non-pathogenic to the target 
organism, for example by repeated passage in tissue culture (142) so that while they remain 
capable of replicating, mutations are accumulated that reduce pathogenicity. Such vaccines 
are processed via MHC class I molecules and induce both humoral and cellular immunity, 
eliciting both CD4 and CD8 responses. They generally induce strong and long-lasting 
immunity. They are inexpensive and practical to produce on a large scale, and generally have 
a well-documented safety record (142). Examples are the frequently used MMR and oral 
polio vaccines. Reversions of live attenuated vaccines to a virulent form have occasionally 
occurred (e.g. (145)) so safety concerns need to be met. 
DNA vaccines are bacterial DNA-plasmids containing immunogenic antigens of the virus in 
question. They enter the cell and the nucleus, but do not integrate themselves into the host 
genome. The enzymatic machinery present in the nucleus then expresses the viral proteins 
or peptides encoded by the plasmids. These are then presented on the surface of the cell in 
connection with MHC 1 molecules, and will therefore be recognized by the cellular immune 
system (146). While these systems are quite successful in animal models, they appear to be 
quite poorly immunogenic in humans and generally require use in a prime-boost regime (89). 
Virus-like particles use in vitro produced structural virus proteins that combine into particles 
that appear like virus particles, but cannot replicate or infect (for example papillomavirus). 
Viral proteins are produced in in vitro culture (for example Hepatitis B). These vaccines are 
processed via the MHC class II pathway and therefor do not elicit vaccine-specific CD8+ cells. 
These classical strategies for vaccine development unfortunately do not manage to create 
protective vaccines against viruses that have a high mutation rate and are thus capable of 
quickly developing variants that escape the vaccines (55). 
  20 
Over the last decade, the use of viruses as vectors for antigens from other viruses has been 
investigated (89, 143, 144). The use of live vectors had initially caused safety concerns, so 
attempts were made to develop viral vectors that are unable to replicate (147). It is not sure 
if these vectors will elicit strong and broad enough responses (142). On the other hand, the 
use of existing live-attenuated vaccine strain viruses as vectors promises to elicit profound 
responses, while showing an excellent safety record (148). Genetic engineering of existing 
live vaccine strains however raises safety concerns due to the potential of such measures to 
change vector virulence or cell tropism, which needs to be kept in mind. Additionally, since 
these vectors are commonly used as vaccines in their own right, there may be a high level of 
pre-existing immunity to these vectors, which has the potential to interfere with immune 
responses to the newly introduced immunogen (142). Research has however shown that for 
example pre-existing immunity to measles virus does not appear to reduce the response if 
used as a vector (149). Vectors based on viruses infecting animals rather than humans may 
be potential candidates for vaccine development as well. They are however usually not very 
well researched with respect to their characteristics and safety in the human body (142). 
Most effective vaccines currently available induce both humoral as well as cellular immunity. 
Newly developed vaccines may not be fully protective but should be able to greatly reduce 
virus levels and transmission. It is likely that that combination is necessary to eliminate or at 
least control an infection (150). The delivery of vaccine viruses via aerosol has been under 
much investigation over the last few years. The benefits of this would be the induction of 
immune responses on mucosal surfaces, as well as the possibility to circumvent potential 
pre-existing immunity (142). Various studies have shown that in animal models as well as 
humans, intranasal vaccination is able to induce immune responses at distant sites such as 
the genitourinary tract (151-154). A vaccine generating robust mucosal responses should 
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hence be able to successfully protect from disease (155). The use of an aerosolized measles- 
as well as a measles-rubella-vaccine has been shown to be safe and efficient in humans 
possessing pre-existing antibodies (156-158). Live attenuated vectors seem most promising. If 
the current developments are successful, they may well be precursors to the development 
of multivalent vector-based vaccines (142). 
 
2.6 Human immunodeficiency virus vaccine design – an overview 
An effective and safe vaccine against HIV would solve the problem of the HIV pandemic most 
effectively (159). An ideal vaccine would confer sterile immunity. This, however, is not even 
achieved by the majority of vaccines currently in clinical use. Instead, they prevent clinical 
disease by controlling virus replication and pushing it to subclinical levels (160). Reduced viral 
set points during HIV infection (i.e. the median plasma levels during chronic infection) are 
associated with a marked reduction in disease progression as well as transmission (54). 
HIV severely affects the host’s immune system by killing a large proportion of T-cells in the 
intestinal tract. The systemic immune activation that results from pathogen entry across 
damaged mucosal membranes may foster HIV plasma levels (46, 161). HIV prefers CD4+ T 
cells, and within the first week after infection causes massive depletion of T-cells in the gut 
(52, 114, 130). Chronic infections result in “exhausted” T and B cells. Modulation of this 
exhaustion process in the critical early stages of a HIV infection could be a possible target 
area of HIV vaccine development (161). 
Research suggests a major role for CD8+ T-cells in the defence against HIV (34). The 
appearance of virus-specific cytotoxic cells early on in the infection has resulted in an 
extensive ability to limit virus replication, and severely reduced the loss of CD4+ cells in SIV 
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studies (162). Strong cellular immunity also features in long-term non-progressing patients 
(83). Antigen-specific cytotoxic cells will recognize MHC-bound antigens, but will not respond 
to free virus particles. They will therefore limit the spread of HIV by killing infected cells and 
reducing viral load, but will not protect from infection (89, 162). 
HIV accrues mutations at an especially rapid rate, which enables it to escape humoral 
immune responses (163). The ideal for an HIV vaccine would be to raise neutralizing antibody 
titres high enough to block the infection originating from a huge diversity of sub- and 
quasispecies before it takes hold. If this proves impossible, immune responses need to be 
activated quickly enough to prevent the massive T cell depletion and persistent 
establishment occurring in early HIV infection (150). 
Compared with other illnesses, HIV requires very high concentrations of broadly neutralising 
antibodies to achieve a 50 % neutralisation rate (for example, about 500 – 5,000 x the 
concentration than would be required for influenza) (49). Several trials attempting to induce 
protective humoral immunity have failed (57). The immense variability of HIV poses a 
problem, and finding antibodies that neutralise HIV across several clades has also proven 
difficult (164). Several broadly neutralizing antibodies have been isolated from human 
samples and thoroughly investigated. They bind to gp41 or gp120 of the viral envelope, 
including some that bind directly to the CD4 binding site of gp120 (165). Combinations of 
these bNAbs result in cross-clade neutralising abilities and protective immunity in new-born 
macaques (61). Several studies have shown that the transfer of large amounts of neutralising 
antibodies results in protection from infection in primates (166). Several possible strategies 
for the design of neutralising antibodies are being investigated (57). However, primary 
isolates of HIV (i.e being passaged only once on human T-cells) are very hard to neutralize, 
even using serum from infected patients. No vaccine tested in the twenty years up to 2005 
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was able to elicit antibodies which could neutralize viruses of the majority of HIV isolates 
(167). 
The route of immunization also appears to influence the immune responses elicited. Since 
mucosal transmission appears to be the most important route of infection with HIV (168, 
169), mucosal immune responses are a main point of investigation. Evidence suggests that 
antibody presence at mucosal surfaces may be contributing to protection against a HIV 
infection (126, 170). The presence of systemic as well as mucosal virus-specific CTLs is a 
regular feature of both HIV and SIV infection (171, 172) and can contribute to reducing the 
effects of contact with HIV (173). Therefore, the induction of mucosal immune responses by 
a vaccine may be a key feature for successful immunisation against HIV, and there is 
evidence to suggest that the mucosal delivery of immunogens induces the strongest 
humoral mucosal response (174). Delivery of the vaccine does not necessarily have to occur 
at the site of infection. As mentioned above, evidence has shown that intranasal delivery of 
immunogens induces mucosal immune responses not only in the intranasal cavity and lung 
but also in the female genital tract (175-178). Vaccine candidates using this approach have 
demonstrated success (179, 180). 
An HIV vaccine needs to induce both B and T cell responses that are activated at mucosal 
surfaces during the critical first few hours of a new infection, and can control virus levels in 
chronic infection (46). HIV develops latent reservoirs very early on in infection, so vaccine-
induced immune responses such as virus-specific mucosal immune cells may need to be 
consistently activated by a successful vaccine to get a head start on the rapid progress of HIV 
in mucosal membranes (46, 161). 
The choice of immungens inserted into the delivery system also plays an important role. 
Studies suggest that vaccine candidates delivering multiple HIV antigens and containing gp41 
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and gp120 target both cellular and humoral immunity and result in very good control of the 
viral infection (181, 182). Vaccine trials targeting Gag and its individual components however 
were associated with lower plasma levels than those targeting gp41 / gp120 (90). Mutations 
of HIV may have a negative effect on virus fitness (183), particularly when they occur in Gag 
proteins since they need to self-assemble into the viral capsid (184, 185). Patients with 
cytotoxic T cells specific for Gag epitopes present with lower virus loads than patients with 
gp120-directed CD8+ cells (90). Elite controllers, who maintain very low plasma virus levels 
without medication seem to be able to do so by pushing the virus to generate mutations 
that are detrimental to viral fitness (184, 186). Research is being undertaken into the genetic 
background of patients able to control the early infection, in the hope to find new methods 
of virus limitation that might be used for vaccine development (187). 
The HIV (or SIV) Gag protein is a frequently targeted immunogen in HIV vaccine 
development. As mentioned above, Gag commonly elicits an immune response in infected 
individuals and strong responses against gag are associated with lower virus levels (see 
above and (78, 188). Additionally, gag is capable of self-assembly and exit from the host cell 
without the need for viral genome or other proteins (189, 190). 
SIV mac 239 and 251 (mac for molecular clones) are commonly used as challenge viruses in 
in Non-human primates vaccine trials since they are most similar to HIV. Like HIV their 
preferred co-receptor is CCR5, they are resistant to neutralization by antibodies, and T cell 
depletion and disease course are very similar (191). 
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2.7 Vectors for human immunodeficiency virus vaccines – candidates and 
preliminary results 
No vaccine candidate undergoing clinical studies since the discovery of HIV in 1985 was able 
to induce neutralizing antibodies effective against the majority of HIV isolates (167). Only 
two candidates have ever completed clinical trials at the time of this study ((160) and below). 
The first phase 3 trial started in 1998, using recombinant gp120 from one lab strain and one 
primary isolate, both produced in mammalian cells and fully glycosylated, adjuvanted with 
alum (167). Two studies evaluated the trial after successful completion, and both concluded 
that the vaccine did not elicit protection against a HIV infection (192, 193). 
The development of an HIV vaccine was first attempted using classical approaches. Several 
studies have shown that transfer of large amounts of neutralising antibodies results in 
protection from infection in primates (166). However, routine commercial production and 
application of such large amounts of antibodies is unfortunately not practically feasible. 
Monkeys receiving a live-attenuated SIV vaccine showed extensive ability to control virus 
replication when being challenged with SIV, as did monkeys already infected with one strain 
when superinfected with another (194). However, SIV infections could not be entirely 
blocked in either of these circumstances (194). Furthermore, SIV studies have demonstrated 
the ability of attenuated SIV to revert back to a pathogenic state. In humans live attenuated 
HIV appears to be pathogenic and causes late-onset disease (195, 196). This makes the use of 
attenuated virus for vaccination unsafe in the case of HIV (197). Live attenuated vaccines 
that show sufficient immunogenicity have also shown enough replication-capabilities to 
revert to a virulent type (198). 
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Based on research demonstrating the importance of cellular immunity in controlling viral 
load (199-201), the second main area of HIV vaccine research alongside the efforts in 
developing a vaccine inducing neutralising antibodies against HIV is the development of 
vaccine candidates aimed at eliciting cellular immunity (166). While cellular immunity does 
not confer complete virus clearance, it is able to significantly limit virus levels and 
transmission (202, 203). 
Subunit vaccine candidates based on epitopes known to stimulate T- and B-cell responses 
offer one possible solution (204). Combinations of several epitopes in one polypeptide have 
often been more successful than the expression of single peptides (205-207), which have 
been shown to antagonize each other’s efficacy if administered simultaneously (208). An 
alternative to this approach is the construction of DNA plasmids incorporating genetic 
information encoding viral proteins, which are then expressed within the host cell (209, 210). 
Antigens that are produced and processed within a host cell - as is the case with epitopes 
included in DNA vaccines - are generally presented on the surface of that cell via MHC I 
molecules. These molecules get recognised mainly by cells of the cellular immune system 
and so cause a much stronger cellular than humoral immune response. Antigens that 
originate from the outside of the host cell, such as free virus particles or extracellular 
bacteria on the other hand first need to be taken up and processed by antigen presenting 
cells, who then present these epitopes in connection with MHC II molecules. This leads to 
activation of T helper cells and to a more pronounced humoral immune response (211). This 
is the system generally exploited by subunit or peptide vaccines. 
One important pathway to the development of cell-based vaccines is the use of viral vectors 
to express antigenic peptides (212). A large amount of work in this area has been done using 
adenovirus vectors. Replication defective adenovirus 5 (Ad5) including the genetic 
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information for HIV-gag elicited high levels of antigen specific cytotoxic T-cells and induced 
interferon gamma -, interleukin 2- and tumour necrosis factor alpha - production in over 50 
% of cases (15, 143, 212-214). Adenovirus vectors are the most immunogenic viral vectors in 
HIV vaccine development so far (89). However, there is a relatively high level of pre-existing 
immunity to Ad5 in most populations (142). A recombinant Ad5 vector combination encoding 
HIV gag, nef and pol in separate vectors was the first cell-targeted vaccine to go into clinical 
trials, concluding in 2007. The study was meant to evaluate the level of reduction in 
infection rate as well as virus load for vaccinees that became infected. Analysis of the study 
results showed that the vaccine program did not protect from infection. Additionally, 
participants with a high level of pre-existing antibodies to the Adenovirus vector were 
statistically even more likely to become infected than participants without pre-existing anti 
vector immunity (215, 216). This follows phase 1 trials evidencing this vaccine program to be 
safe and immunogenic (217, 218). A possible reason for this might be that the application of 
this vaccine resulted in activation of memory T-cells against the vector, which would make 
the recipient of the vaccine more conductive to HIV replication (166). The development of 
chimeric vector backbones or the use of adenovirus vectors as the second part of a prime-
boost regime (often with a DNA prime) are concepts suggested to circumvent this (89). DNA 
prime - Ad5 boost regimes have elicited significant cellular immune responses in NHPs (214, 
219) but have not reduced virus loads or improved survival times after the primates were 
challenged with SIV (162, 217). 
Several other viruses are under development to become vectors for possible HIV vaccine 
candidates, such as attenuated poxviruses, alphaviruses, measles virus, but also replication-
competent viruses (220). The possible influence of the vector as well as vector-directed pre-
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existing immune responses as a result of vaccination and / or challenge needs to be kept in 
mind (221). 
Adeno-associated virus (AAV) does not cause any known illness in man, but 70 – 80 % of 
people possess pre-existing immunity (222). Recombinant AAV (rAAV) has the potential to 
silence tumour suppressor genes by randomly inserting itself into host DNA (223), a 
mechanism similar to that of HIV replication and a safety concern. Purified rAAV particles 
containing SIV antigens have been shown to elicit long term protective antibody and cellular 
responses after intramuscular injection (224). 
Recombinant canarypox vectors have been common candidates for the development of 
vaccines since they are inherently safe for humans and pre-existing immunity does not pose 
a problem. In 2009 a phase 3 clinical trial using a canarypox vector encoding HIV antigens 
(called ALVAC by the developers) as a prime combined with recombinant gp120 boosts was 
concluded. The vaccine protocol proved safe for the human participants, and in fact showed 
a 31 % reduction of infection rates. It did, however, have no influence on virus levels or CD4+ 
cell counts in participants that did become infected. Therefore it had no ameliorating or 
transmission-reducing effect if infection could not be prevented (225). Further research has 
shown that the efficacy of the vaccine dropped and titers fell 24 weeks after inoculation 
(226). 
Replication defective virus-like particles mimicking Venezuelan equine encephalitis virus 
(VEEV) induced protective immunity against SIV (227, 228). Since this is an animal virus, there 
is no pre-existing anti-vector immunity to be considered (142). 
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2.8 Negative sense single-strand RNA viruses – organisation and biology 
Most negative sense single strand RNA ((-) sense ss) RNA viruses display common general 
features and follow the same replication process. This includes canine distemper virus (CDV) 
as well as vesicular stomatitis virus (VSV) which has been extensively researched (29). Clarke 
et al describe the genomic organisation and replication of (-) sense ss RNA viruses as follows, 
using VSV as an example (229): 
The (-) sense ss RNA genome encodes five distinct proteins (Figure 2): N is expressed in large 
amounts and connects with the RNA to form the nucleocapsid. The P and L proteins together 
form the viral RNA polymerase, which both replicates the genomic RNA and transcribes 
genetic information into mRNA. The M protein, which is the most abundant protein within 
the viral particle, helps with virus budding and regulates host functions during replication. 




Figure 2: Schematic of a negative sense single strand RNA virus  genome. Genes for the five viral 
proteins (N, P, M, G and L) as well as 5 and 3’ ends of the RNA are labelled. 
 
After viral entry and caused by the slightly acidic pH inside the host cell, the viral 
nucleocapsid disintegrates and the viral genome and polymerase are released from the 
particle. The polymerase attaches to the 3’ end of the genome. The first step of the 
replication cycle is the production of the five viral protein mRNAs. The polymerase travels 
from 3’ to 5’, transcribing between the start and stop codons for each protein. Occasionally 
the polymerase detaches from the genome before it arrives at the 5`end, and has to start 
over at the 3`end. This means that of the genes at the 3`end, more mRNA copies are made 
  30 
and therefore more protein produced than of the ones nearer the 5`end. This corresponds 
to how much of each protein is actually required to form new virus particles – large amounts 
of N are required to form the nucleocapsid, and since the gene encoding N sits at the 3´ end 
of the genome, a multitude of transcriptions are made. The polymerase is only required in 
small amounts, and finds itself more towards the 5`end of the viral RNA. 
Once sufficient mRNA is transcribed, the polymerase switches to genome replication by an 
unknown mechanism and copies the viral RNA straight from 3`to 5` into a (+) sense strand, 
which is then used as a template to produce progeny (-) sense RNA. Additional mRNA 
transcription is being pursued from replicated RNA too. 
When a large enough amount of virus material has been produced, the progeny particles 
assemble by interaction between genomic RNA, N, M and G proteins. N protein envelops the 
RNA. The nucleocapsid then, regulated by the M protein, attaches to parts of the cell 
membrane previously enriched with G protein and the membrane envelopes the new 
particle. The particle then buds from the cell. 
VSV has been researched extensively as a vaccine candidate due to reasons equally 
applicable to most other (-) sense ss RNA viruses, and particularly the family 
paramyxoviridae. It lends itself to the design of recombinant viruses for the construction of 
vector based vaccines due to the simple and discreet organisation of its genome into distinct 
transcription units, and due to the fact that mRNA is produced following a transcription 
gradient (230, 231). This means that foreign genes can be inserted relatively easily in 
between the coding sequences of the viral RNA, and that placement of the foreign insert can 
control the amount of foreign protein being produced (232, 233). The genome of rVSV is very 
stable even after the insertion of foreign RNA (230) and during the entire replication process 
no insertion into the host genome is required (234). It expresses foreign genes without much 
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variability (229). Additionally, the virus can be propagated to large quantities in a variety of 
cultured cells (229). There is a negligible level of pre-existing immunity to VSV in the human 
population, and recombinant viruses are considered to be innocuous to humans upon 
parenteral application since despite the ability to occasionally infect, they only very rarely 
causes mild symptoms in humans (233, 235). The insertion of foreign genes into non-
segmented (-) RNA viruses also additionally attenuates such viruses (236), so the risk of 
disease is further reduced. 
Since about the mid-nineties, a protocol has been available to produce recombinant VSV by 
use of cultured cells transfected with plasmids encoding for the N, P and L proteins required 
for replication, as well as the full length VSV genome (237-239). The N protein then attaches 
to the full-length genome, and the P and L proteins assemble to form the viral polymerase 
and initiate virus transcription and replication. Newly formed particles then bud from the 
cultured cells into the supernatant and can be collected from there. This entire procedure 
goes by the name of “virus rescue” and the principle can, with slight modifications, be 
applied to a variety of RNA viruses, including paramyxoviruses (240, 241). 
 
2.9 Negative sense single-stranded RNA viruses as vectors for human/simian 
immunodeficiency virus vaccine development 
Recombinant VSV has previously been explored as a vector for HIV/SIV antigens. rVSV 
expressing HIV Gag and gp41 / gp120 (Env) dramatically slowed progression of AIDS in 
monkeys after a challenge with SHIV (233, 242). It produced significant humoral and cellular 
responses, even more so after intranasal application when compared to subcutaneous 
inoculation (243). VSV is considered a neurotropic virus, which raises safety concerns 
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regarding mucosal application in humans (142). To circumvent this, rVSV containing a 
truncated (244) or deleted G gene (242) were designed which, encoding HIV-env, have 
produced similar humoral and cellular responses as replication competent rVSV (242). 
Measles virus (MV) is a paramyxovirus, belonging to the genus morbillivirus. It is closely 
related to canine distemper virus. It causes skin rashes, fever and potentially neurological 
symptoms in humans. MV is highly infectious. It primarily enters through the upper 
respiratory system, and then continues to infect and replicate in the lymphatic organs (245, 
246). Live-attenuated MV has an outstanding long-term safety record (247) and leads to long 
lasting immune responses (248). Recombinant MV (rMV) is generated by rescuing it in cell 
culture similarly to VSV as described above. This means that plasmids containing the full-
length genome of MV are co-transfected with plasmids expressing MV proteins N, P and L 
which are required for particle production (249). Foreign genes can be included by 
genetically modifying the full-length genome (250, 251). 
Recombinant vaccine strains of MV have successfully expressed HIV/SIV antigens Gag, Pol 
and Env for example (149, 252). rMV expressing HIV gag has produced both humoral and 
cellular immune responses in laboratory mice (253). rMv expressing either native or 
truncated HIV Env gave rise to high titres of antibodies against HIV after a single injection in 
mice. The antibodies were able to neutralise homologous SHIV as well as heterologous HIV 
isolates. Significant cellular responses were also detected (253). 
Due to near ubiquitous routine measles vaccination programmes, there is a high level of pre-
existing immunity in humans to MV vectors (254). The influence of pre-existing antibodies to 
MV for the use of rMV as a vector has been repeatedly investigated. The use of rMV 
expressing HIV Env in macaques previously exposed to MV resulted in significant antibody 
titres against HIV despite pre-existing immunity to MV. The cellular response to HIV antigens 
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was not reduced either (149). A single injection of rMV containing HIV-Env produced HIV-
neutralizing antibodies in animals (149). This prompt response is likely due to the fact that 
rMV is able to infect dendritic cells and macrophages (255). Functional cellular responses 
were also elicited in mice when rMV with appropriate polyepitopes was used (256). Measles 
virus itself has been successfully used as an intranasal vaccine. This opens up the possibility 
to create rMV vectors that elicit immune responses on mucosal surfaces while at the same 
time evading any pre-existing systemic immunity (142). One study using mice demonstrated 
that pre-existing immunity to MV did not affect cellular responses generated after intranasal 
inoculation with rMV expressing SIV Gag; and that in fact the immune response to the 
foreign gene was increased under pre-existing anti-vector immunity compared to MV naïve 
animals (254). Hence a level of immunity directed against a MV vector backbone encoding 
foreign antigens does not appear to negate its efficacy as a vaccine candidate. 
 
2.10 Canine distemper virus as a vector candidate for lymphotropic viruses. 
Canine distemper virus (CDV) belongs to the virus family paramyxoviridae, and the genus 
morbillivirus. Other morbilliviruses include measles virus, peste des petits ruminants virus, 
rinderpest virus, dolphin morbillivirus, cetacean distemper virus, and phocine distemper 
virus (245). 
Morbilliviruses primarily infect the oral and upper respiratory mucosa. They then spread to 
lymphatic tissues and induce transient immunosuppression. Potential complications result in 
central nervous effects but are rare (245, 246). 
Ferrets are a natural host for CDV infections, during which they develop a skin rash, fever, 
respiratory and gastrointestinal signs and immunosuppression. Wild type infection in this 
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species often also leads to neurological signs and carries a high mortality (257). There has 
been detailed research into the pathogenesis of CDV infections as well as the response of 
the ferret immune system. Infected animals develop the above symptoms within days of 
infection. Accompanying this are leukopenia and a reduced response of the immune system, 
both in the acute and in the delayed pathway. These signs of generalized 
immunosuppression appear within a week post infection (258) and persist all through the 
acute phase of disease (259). Studies using recombinant CDV incorporating green fluorescent 
protein (GFP) have provided a detailed insight into the cellular process of CDV pathogenesis. 
Initially, the infection is limited to lymphatic tissues, mainly infecting T- and B- cells. Within 
the first week of infection, over 70 % of these populations have been shown to be infected 
(8). Systemic spread of the infection only occurs several days into the process, coinciding 
with the onset of clinical signs (260). CDV is highly immunogenic and virus clearance occurs 
through cellular immunity combined with both mucosal and systemic antibody responses, 
providing subsequent long-lasting immunity (246, 261, 262). 
Due to the high susceptibility of this species, novel CDV vaccine candidates have frequently 
been developed in the ferret model. Initial CDV vaccines followed the traditional approach 
of using inactivated versus attenuated-live virus. Both of these induced protective immunity, 
but antibody titres were lower when using the inactivated virus, while attenuated virus 
induced a degree of immunosuppression and was only effective when given intramuscularly 
(263). This is mainly an issue for highly susceptible wildlife species of the mustelid family 
where this resulted in clinical disease (257). Meanwhile, a novel live attenuated vaccine using 
the Onderstepoort strain has been developed that has been shown to be both safe and 
efficacious in the face of a virulent CDV challenge when administered to ferrets via 
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subcutaneous injection (9). This vaccine strain has by now established an impressive safety 
record even when used in mustelids (264-266). 
Several arguments stand in favour of CDV as a vector for HIV/SIV antigens: CDV is non-
pathogenic for humans (267), but is able to infect primate cell lines (10). A long established 
attenuated live vaccine strain is readily available and can be used for the engineering of a 
recombinant vector (266). A rescue system for the generation of recombinant CDV including 
foreign genes has been developed and can be employed (268). Despite close relations and 
some cross-reactivities between the two viruses, pre-existing neutralising immunity to MV 
does not prevent effective use of CDV as a vector (269-274). Most importantly, the cell 
tropism, time course and pathway of a CDV infection in the lymphatic system are strikingly 
similar to infection with HIV/SIV (8, 275, 276), making CDV a highly interesting vector for the 
delivery of HIV/SIV antigens to locations critical for the pathogenesis of infection. 
 
2.11 About this research project 
As described above, CDV shares a variety of characteristics with HIV. Most importantly, CDV 
uses mucosal surfaces as entry sites, is strongly lymphotropic and replicates to a large 
degree at sites also preferred by HIV. This leads to the hypothesis that due to those 
similarities, CDV will induce immune responses in cells and at sites important for HIV 
replication and thus would make a good vaccine vector candidate for the delivery of HIV 
antigens. CDV is also non-pathogenic to humans and therefor would be a very safe vector to 
use. 
To test this hypothesis, a recombinant CDV was rescued based on an established vaccine 
strain with an excellent safety and efficacy record. The rescued rCDV was then modified to 
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include the genomic information of SIVgag. SIVgag was chosen instead of HIVgag due to legal 
and health and safety considerations. The use of HIV or parts or genetic information of HIV is 
limited to the very final stages of vaccine development or other very specific research 
projects. 
The research project presented in this thesis aimed to evaluate the rescued rCDV-SIVgag 
vaccine candidate with view to its general biosafety, and to examine the basic 
biodistribution and immunogenicity of the candidate. 
Rescued rCDV and rCDV-SIVgag were evaluated in ferrets, since they are the species most 
susceptible to clinical distemper infection and would provide us with the most valuable 
information with regards to the safety of our recombinant viruses. Additionally, the paternal 
vaccine strain we employed to generate the recombinant viruses has a longstanding record 
of use as a vaccine against clinical distemper in ferrets and was shown to be highly 
immunogenic in this species. 
Research was devided into two separate studies. During the first study, a small number of 
animals was used to evaluate the effects of rCDV –SIVgag on the health and body condition 
of the ferrets over the course of seven days post intranasal inoculation. Additionally, swab, 
tissue and blood samples were obtained at regular intervals to assess distribution of the 
recombinant virus, the possibility of shedding, as well as the presence of cellular and 
humoral immunity. 
In a second study, a larger number of animals was used to gain a deeper insight into 
biodistribution and immunogenicity of the recombinant virus over the course of 28 days 
post inoculation. In addition to a group of animals intranasally vaccinated with rCDV-SIVgag 
and a control group, we included a group of animals that was inoculated with the viral vector 
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rCDV. All animals also received a booster after 21 days. Health and body condition of the 
animals were closely monitored. Swab and blood samples were again taken at various time 
points, and animals were euthanized and tissue samples obtained at weekly intervals. 
Samples obtained during the study were used in various virological and immunological 
assays to further explore the process and time course of biodistribution and shedding of 
both rCDV and rCDV-SIVgag, as well as the development of cellular and humoral immune 
responses to the recombinant viruses.  
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3 Materials and methods 
3.1 Origin and production of recombinant viruses rCDV and rCDV-SIVgag 
rCDV and rCDV-SIVgag were prepared within the vectors lab at the International AIDS 
Vaccine Initiative (IAVI) using a commercially available CDV Onderstepoort vaccine strain 
(Galaxy D, Schering-Plough Animal Health) and provided to me by Chris Parks and Xinsheng 
Zhang (both IAVI). Briefly, the virus had been adapted to African Green Monkey or 
“Vero”cells (ATCC) cells by serial passaging. Recombinant viruses were rescued using a 
helper virus free method described previously (240). For rCDV-SIVgag, the gene encoding SIV 
gag was inserted upstream of CDV N for maximal expression. Presence of viable infectious 
recombinant virus particles was confirmed by formation of plaques upon coculture with 
Vero cells. The presence of SIVgag protein was confirmed using Western Blot of cell lysate 
using SIVgag positive nonhuman primate serum as probe (see below for method). 
 
Figure 3: Schematic of recombinant canine distemper virus genome with the gene encoding the 
simian immune deficiency virus glycosaminoglycan protein (SIVgag) inserted upstream of the N 
protein. Genes for the five viral proteins (N, P, M, G and L) as well as 5 and 3’ ends of the RNA are 
labelled. 
 
3.1.1 Propagation of recombinant viruses 
Recombinant viruses were propagated to sufficient yield in Vero cells. Cells were seeded in 
tissue culture flasks (Corning), at a seeding density of 0.9 - 1.5 x 106 cells per 25cm2 flask 
surface in 5mL / 25 cm2 MegaVir medium supplemented with 2 mM L-Glutamine (both 
Hyclone). Number of flasks seeded depended on desired virus yield plus one flask to perform 
cell counts. Cells were incubated at 37 °C, 5 % CO2, and 85 % relative humidity in a 
ThermoScientific incubator for 24 – 48 h. At that point in time, cells should be in logarithmic 
growth phase, nearing 70 – 75 % confluency. One of the flasks was then harvested by 
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removing medium, adding 2 mL of HyQtase (Hyclone), incubating for five minutes, and 
gently scraping off the loosened cells with a cell scraper (VWR). Cells in this flask were 
counted in an automated cell counter (Beckman Coulter) to determine the cell numbers to 
be infected. The remaining cells were infected at a set multiplicity of infection (MOI), which 
determines the infectious particle : cell ratio. The MOI used for virus propagation was 
generally 0.02, with an MOI of less than 0.01 not leading to successful infection and 
selection of a too high MOI resulting in the virus not multiplying sufficiently. To perform 
infection of Vero cells with virus, medium was aspirated off the remaining flasks, and 2 mL of 
fresh medium were applied, followed by the amount of virus calculated using the formula 
(cell count x MOI) / titer of virus used for infection. Once medium and virus were applied the 
flasks were carefully rocked, placed in an incubator for one hour, being rocked gently every 
15 – 20 min. After 1 h, the total volume of medium was brought up to 5 mL / 25 cm2. The 
flasks were then incubated for the next 24 – 48 h until visual inspection showed the 
appearance of cytopathic effect (CPE). The cells were then carefully monitored until the 
maximum CPE was reached. Virus-containing cells and medium were harvested by gently 
scraping the cells off the culture flask and transferring cells and medium into 15 mL or 50 mL 
conical tubes (Falcon, VWR). The harvest was subjected to two cycles of snap-freezing in a 
dry ice / alcohol bath and thawing at 37 °C to break up cell membranes. The virus-stocks 
were clarified by centrifuging in a Sorvall centrifuge at 800 x g for 10 min at 4 oC to remove 
cellular debris. Virus was then titrated using Plaque forming units (PFU) or Tissue culture 
infective dose 50 (TCID50) assays, and aliquots were frozen and stored at – 80 °C. 
3.1.2 Preparation of virus stock 
To maintain consistency during our in vivo studies, all inoculums of rCDV and rCDV-SIVgag, 
respectively, were prepared from one batch of tissue-culture-adapted titrated virus. To 
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achieve this, virus production was gradually upscaled by repeated passaging of virus into 
larger flask sizes until a sufficient amount of virus could be harvested to cover the 
requirements of these studies. Virus-infected Vero cell harvests underwent two freeze-thaw 
cycles in a dry ice / alcohol bath to lyse cell membranes. The lysates were clarified at 800 x g 
for 10 min at 4 oC. To concentrate the virus, the clarified infection lysates were incubated 
with polyethylene glycol (PEG, Sigma) overnight at 4 oC. PEG is commonly used in a variety of 
biochemical settings to concentrate and subsequently precipitate a variety of proteins, 
including various viruses, from a variety of solvents (277). Virus was precipitated after 
centrifugation and resuspended in phosphate-buffered saline (PBS, Invitrogen) with 3 % 
sucrose (Sigma). The concentrated viral solutions were then dialyzed against 3 % sucrose in 
PBS to remove PEG. Virus was titrated by PFU and TCID50 assays. Aliquots of virus stock were 
stored at – 80 °C. 
 
3.1.3 Infectivity assays 
To determine the number of virus particles in a set batch of virus, two different assays were 
employed. Both assays are based on the ability of CDV to cause cytopathic effects in Vero 
cell cultures. PFU assays make use of the fact that where a virus has infected an individual 
cell, the infection will likely spread to the cells directly adjacent to it. Cytopathic effects 
occur in infected cells after an incubation period, forming distinct areas of damaged cells, 
called plaques. Each plaque is presumed to have arisen from one individual infected cell. The 
number of plaques in one well of tissue culture plates can therefore be taken as an 
indication of the amount of virus present in the sample. Serial dilutions of sample virus and 
setting up assays in duplicates allow conditions in which the number of plaques per well is 
neither uncountably high nor low to the point of insignificance. 
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Since differentiation of individual plaques can sometimes be difficult, small plaques may be 
overlooked when counting while gaps in the monolayer not necessarily due to CPE may 
accidentally be counted. Therefore, the results of a PFU assay can vary between assessors. A 
modified version based on the same principles is the TCID50 assay. In this assay, serial 
dilutions of sample virus are set up in multiples, and a 50% endpoint is calculated using the 
dilutions at which 50% or more and just under 50% of wells show virus-induced cytopathic 
effects. Endpoint calculations are done following the Reed-Muench formula. 
 
3.1.4 Titration of virus using plaque forming units assays 
Vero cells were seeded in 6-well plates (Corning), two wells for each virus dilution to be 
assessed. Seeding was done at 0.6 x 106 cells / well, so that cells were in logarithmic growth 
phase and about 70 – 75 % confluent by the next day. Cells were incubated overnight. The 
following day, old medium was aspirated off the cells and replaced with 0.5 mL fresh 
medium. 10-fold serial dilutions in medium starting at 1 : 10 were made of the virus batch to 
be tested, and 100 uL of each dilution added to the corresponding wells in duplicate. Cells 
were incubated for another hour. The medium containing virus was then taken off. A 1 : 1 
mixture of 2 % methycellulose (Sigma) in double-distilled water (ddH20; MilliQ) with 2 x 
minimum essential medium (MEM; Invitrogen) supplemented with 10 % fetal bovine serum 
(FBS; Invitrogen) was prepared and 2 mL of this mixture added to each well to keep CPEs 
localized. The assays were incubated for a further 2 d, after which the methylcellulose-
mixture was aspirated off and the wells washed twice with warm PBS. Cells were then fixed 
by adding 0.5 mL of 10 % formalin or 16 % paraformaldehyde (Sigma) and incubated for 30 
min. The wells were again washed twice with PBS and cells were then stained with Giemsa 
stain (Sigma) for 2 h. Wells were then rinsed with water and air dried, before plaques were 
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counted, selecting wells that present 30 – 50 plaques per well to ensure countability. Plaque 
counts were averaged over duplicates, and titers expressed as PFU / mL of virus stock. 
 
3.1.5 Titration of virus using tissue culture infective dose 50 assays 
Vero cells were seeded in 96-well plates at a density of 1.25 x 104 cells / well in 100 uL 
medium, and incubated overnight as before. 10-fold serial dilutions of the virus to be tested 
were made using Vero cell medium, and 100 uL of virus dilution were added to the existing 
100 uL medium in 8 wells per dilution. The cells were then incubated for 2 – 3 d. The 
medium was taken off and cells washes with PBS, before being fixed with 10 % formalin or 
16 % paraformaldehyde for 30 min. Cells were washed and 100 uL Giemsa stain was added 
to each well and left for 2 h. After cells were washed with water and airdried, for each 
dilution the number of wells containing CPE was determined. The titer was then calculated 
as a 50% endpoint using the Reed-Muench formula. 
 
3.2 Animals and housing 
32 outbred ferrets (Mustela putorius furo) of both sexes (15 neutered males, 17 spayed 
females) were purchased from Triple F Farms at 10 weeks of age, and housed in groups of 
two to three animals in ventilated cages (Allentown Inc.) until 7 months of age. When 
purchased, animals were not vaccinated against any diseases. 
Identification of animals was ensured by ear tags as well as subcutaneous implantation of a 
microchip that transmits an identification number, and also records and transmits the 
animals’ subcutaneous temperature (BMDS). 
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Before beginning of the study, blood samples were taken from all the animals and serum 
was used in a Virus neutralization assay to confirm absence of neutralizing antibodies 
against CDV. 
Animals were then randomly assigned into study groups, taking care to maintain balanced 
sex and weight distributions. Animals presenting with extremely high or low weights were 
assigned to control groups to avoid possible influence of body condition on results of 
inoculation. 
All animal experiments were proposed to the Institutional Animal Care and Use Committee 
of the State University of New York Downstate Medical Center and reviewed following the 
Office of Laboratory Animal Welfare’s Animal Welfare Assurance regulations. The proposed 
experiments were accepted under animal use protocol number 04-413-09. 
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3.3 Design of in vivo studies 
3.3.1 Description of study 1 to determine safety of recombinant vectors: 
Study purpose and design: 
The small-scale pilot study (Table 1) described here served to confirm that rCDV-SIVgag was 
safe to be used in a highly CDV-susceptible species, and to evaluate replication competence 
and biodistribution of the construct. 
 
 
Table 1: Experimental group setup and timeline in study 1. Each group consisted of three animals, 
two experimental and one control. D = day, BS = blood sample. Animals were inoculated intranasally 
with a set dose of 2 x 105 plaque forming units (PFU) of recombinant canine distemper virus with 
glycosaminoglycane insert (rCDV-gag) each on day 0. Tissues harvested on the day of euthanasia 
included nasal turbinates, mediastinal lymph nodes and Peyer’s patches. Animals were clinically 
observed and had temperatures checked daily. Oral swabs were taken 2 h and 1 d post inoculation, 
nasal swabs 2 h, 1 d and 3 d post inoculation, and rectal swabs 2 h, 1, 3 and 4 d post inoculation. 
  
Group Inoculate D 0 D 1 D 3 D 4 D 7 
1 2 x 10




1 animal  PBS 
0.5ml BS 
0.5ml BS 
Terminal BS & 
Tissue Harvest 
N/A N/A 
2 2 x 10
5 PFU / 100 uL 
rCDV-gag intranasally 
2 animals  
rCDV-SIVgag, 
1 animal  PBS 
0.5ml BS 
0.5ml BS 0.5 mL BS 0.5 mL BS 
Terminal BS & 
Tissue Harvest 
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3.3.2 Description of study 2 to investigate vector biology and immunogenicity 
Purpose and modifications after the first study: 
Following up on the information gathered in study 1, this study was composed to gain a 
deeper insight into vector replication and shedding, as well as cellular and humoral immune 
responses post inoculation. To be able to better observe the time course of immune 
responses, the time frame of the study was extended to 28 d. Additionally, one group of 
animals was inoculated with vector backbone without gag insert (rCDV). 
Based on the results of quantitative real time- polymerase chain reaction (qRT-PCR) and 
virus culture experiments in study 1, the dose inoculated per animal was increased to 1 x 106 
PFU/100ul in 3 % sucrose intranasally. Mock animals were inoculated with 3 % sucrose 
alone. 
We reduced the frequency of swab and blood samples. Only nasal and rectal swabs were 
taken, and instead of plasma, which repeatedly formed a gel during in vitro tests, we only 
obtained serum samples in the second part of the study (Figure 4). 
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Euthanasia time point   D 7 D 14 D 21 D 28 
Inoculum 
(100 µL intranasally) 
Naive (3 % Sucrose) 
negative control 2 ferrets 2 2 2 
1 x 106 PFU rCDV 
experimental 
3 ferrets 3 3 3 
1 x 106 PFU rCDV-SIVgag 
experimental 
3 ferrets 3 3 3 
 
 
Figure 4: Experimental group setup and timeline in study 2. The three groups included 8 negative 
control animals inoculated with phosphate buffered saline (PBS) as well as 12 animals each for the 
experimental inocculations using 1 x 106 plaque forming units of recombinant distemper virus with 
(rCDV-SIVgag) or without (rCDV) glycosaminoglykane insert, respectively. All inocculations were done 
intranasally (IN). Red arrows indicate time points of inocculations. Nasal and rectal swabs were taken 
at regular intervals (green). Animals were clinically observed and had temperatures checked daily. 
Blue arrows signify time points at which animals were sacrificed. At each time point two control 
animals and three animals from each experimental group were euthanized. Tissues harvested on the 
day of euthanasia included nasal turbinates, mediastinal lymph nodes and Peyer’s patches. 
 
Animals were assigned into three groups, and received different inoculants via intranasal 
instillation. Group 1 was a mock-treated negative control group consisting of 8 animals. 
These animals were only administered PBS with 3 % sucrose. Group 2 was inoculated with 1 
x 106 PFU of the empty recombinant CDV backbone in PBS / 3 % Sucrose, and group 3 
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received 1 x 106 PFU of rCDV with SIV-gag as an insert in PBS / 3 % Sucrose. Both groups 
consisted of 12 animals each. 
On day 21 post inoculation (p.i.), all animals present received an intranasal boost with their 
respective agent. 
2 h after inoculation, as well as after 2, 4, 7, 9, 11, 14, 18, 21, 25 and 28 d, we recorded the 
temperature of all animals present by use of the subcutaneous microchip, and obtained 
nasal and rectal swabs. On days 7, 14, 21 and 28 all animals present were weighed. After 7, 
14, 21 and 28 days, 25 % of the animals in each group were sacrificed and terminal blood 
collections and necropsies performed. Nasal turbinates, spleens, the large mesenteric lymph 
node as well as sections of the intestine that appeared rich in Peyer’s patches were 
harvested.  
Animals were continuously observed for presence of any clinical symptoms of CDV such as 
diarrhea, nasal or ocular discharge, respiratory problems, loss of appetite, rough hair coat or 
inactivity. Any signs noted for any individual animal were recorded. 
 
3.4 Experimental procedures 
3.4.1 Anesthesia of ferrets for study procedures: 
Animals were anesthetized for pre-study blood draws as well as intranasal inoculations by 
intramuscular injection of a mixture of 25 mg kg-1 dexmedetomidine hydrochloride 
(Dexdomitor®, Pfizer Animal Health) and 5 mg kg-1 ketamine hydrochloride (Ketaset®,Fort 
Dodge, now Pfizer), or alternatively 25 mg kg-1 ketamine hydrochloride and 2 mg kg-1 
xylazine hydrochloride (Anased®, Lloyd Laboratories). Dexdomitor, if used, was reversed by 
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intramuscular administration of 250 mg kg-1 atipamezole hydrochloride (Antisedan®, Pfizer 
Animal Health). 
 
3.4.2 Application of recombinant virus by intranasal inocculation: 
Upon beginning of the study, a total of 100 uL of inoculums was instilled into the animals’ 
nostrils. Inoculum was drawn up into a 0.5 mL insulin syringe with a 27 G x 1 / 2 ” needle 
(Terumo Medical Corporation). The ferret was anesthetized, held in an upright position, and 
the syringe and needle were held slightly above the animal’s nostrils. A small drop of 
inoculum was slowly applied to the opening of one nostril. We then waited until the animal 
had aspirated that droplet, before applying the following one to the other nostril. This 
alternating procedure was repeated until all of the inoculum had been administered. 
 
3.4.3 Procedure to obtain blood samples 
Animals were anesthetized as described above, and 0.5 mL of blood was sampled by 
inserting a 1 mL or 3 mL syringe and a 25 G x 1 ” needle (Becton Dickinson and Company) or 
23 G x ¾” butterfly blood collection set (Terumo Medical Corporation) into either the 
cephalic or jugular vein. Blood was then transferred into serum separator tubes (BD 
Microtainer®, Becton Dickinson and Company), kept upright at 4 °C overnight, and spun in a 
Sorvall centrifuge at 1200 x g for 15 min the following day. Serum was then taken off and 
stored in aliquots at - 30 °C until further use. 
 
3.4.4 Procedure to obtain swabs 
We prepared for swabbing of animals by pre-filling labeled 2.0 mL tubes (Axygen Scientific 
Inc.) with 1 mL of PBS / sucrose phosphate buffer with glutamine (SPG, 0.2 M sucrose, 7.0 
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mM K2HPO4, 3.8 mM KH2PO4, 5.0 mM glutamic acid) (PBS by Invitrogen, all chemicals by 
Sigma). Sterile pediatric polyester tipped swabs (Puritan Medical Products Company LLC) 
were then pre-moistened before swabbing by dipping them into the corresponding tube. 
Animals were restrained manually, and the outside of their nose and rims of the nostrils, as 
well as rectum, were swabbed with separate swabs. Swabs were then placed into the 
corresponding tubes and kept on ice until processing. Samples were processed within 2 to 4 
h of acquisition. 
 
3.4.5 Euthanasia 
Animals were euthanized at their corresponding time points by intraperitoneal injection of 
at least 100 mg kg-1 sodium pentobarbital  (Euthasol®, Virbac Animal Health Inc.) using a 18 
G x 1 ½” needle and 3 mL syringe (Becton Dickinson and Company). Death was confirmed by 
absence of reflexes and cessation of heartbeat and respiration. 
 
3.4.6 Collection of post mortem samples 
After euthanasia, an intracardial terminal blood draw was performed using Vacutainer® 
Serum Separator and Whole Blood Tubes and 21 G x 1 ½ ” needles and needle holders (all 
Becton Dickinson and Company). Necropsies were performed and nasal turbinates, spleens, 
the large mesenteric lymphnodes as well as sections of the intestine that appeared rich in 
Peyer’s patches harvested. The spleen was placed in a 50 mL conical tube (BD Biosciences) 
filled with Rosewell Park Memorial Insitute medium (RPMI; Hyclone), supplemented with 10 
% v / v FBS (Invitrogen), 1 % v / v penicillin/streptomycin (10,000 I.U. mL-1 penicillin, 10,000 
ug mL-1 streptomycin) and 1% v / v L-glutamine solution (200 mM, both Cellgro® by 
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Mediatech Inc.), on ice, while all other tissues were placed in scintillation vials (VWR), frozen 
in a dry ice-alcohol bath and kept on dry ice until processing. 
 
3.4.7 Processing of tissue samples  
Post-mortem tissue samples had to be processed in order to make them useable for further 
assays. The nasal turbinates, mesenteric lymph nodes, and large intestinal sections were 
snap-frozen, pulverized into powder and homogenized (Spex Sample Prep Freezer Mill 6870) 
to make 25 % weight / volume suspensions in SPBG buffer. Homogenised samples were 
stored at – 80 °C. 
 
3.4.8 Titration of serum or plasma samples using virus neutralization assays 
Virus neutralization (VN) assays were performed to determine the level of neutralizing 
antibodies elicited during our in vivo studies. The virus neutralizing antibody titer of a serum 
or plasma is determined as the reciprocal of the highest serum dilution in which virus 
infectivity is inhibited by 100 %. CDV specific neutralizing antibody titers were determined in 
Vero cells using 96-well microtiter plates (Corning). Ferret sera were prepared as serial 4-
fold dilutions from 1 : 4 to 1 : 16,384 in quadruplicates and incubated with 100 PFU of rCDV 
virus for 1 h before the serum / virus mixture was loaded onto Vero cells. The plates were 
evaluated for cytopathic effect after 5 d of incubation. VN titers were expressed as the 
reciprocal of the highest serum dilution at which CPE was completely inhibited in all 4 wells. 
A known positive ferret serum was used a positive control and the virus without serum used 
as negative control. 
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3.4.9 Virus detection in swabs and tissue samples 
Virus detection assays using cell culture were performed to evaluate if the samples taken 
during the in vivo studies contained infectious virus particles, and, if suitable, determine 
PFUs. Vero cells were seeded one day before swabbing in 96-well plates and in 6-well plates 
for virus detection in the swabs and tissue homogenates, respectively, and reached 
approximately 80 % confluency at the time of infection. Swab solutions were made into 10-
fold serial dilutions in Dulbecco’s modified Eagle medium (DMEM; Gibco) supplemented 
with antibiotics (Cellgro), glutamine (Hyclone) and 1 % fungizone (Cellgro). 100 uL of 
undiluted and diluted swab solutions were loaded in quadruplicates at each dilution onto 
96-well plates. Tissue homogenates were prepared at a 1 : 10 dilution in DMEM containing 1 
% fungizone. Both, neat and diluted tissue homogenates, were inoculated and incubated for 
1 h before the medium was changed to DMEM containing 0.75 % methylcellulose (Sigma) 
and 10 % FBS (Invitrogen). Plates were incubated for 4 d for rCDV and 7 d for rCDV-SIVgag 
vector exposed tissues before they were fixed with cold methanol. The cells were then 
stained with ab8352 monoclonal antibody (Abcam) and SIVgag positive monkey serum (kind 
donation from Arielle Ginsberg, Immunobiology lab, IAVI) for rCDV and rCDV-SIVgag, 
respectively. After incubation with secondary antibody-horseradish peroxidase (HRP) 
conjugates (Novus) followed by detection solution (Pierce), plaques were counted using an 
inverted light microscope. 
 
3.4.10 Detection of viral genomic material using quantitative real time-polymerase 
chain reaction 
Quantitative real time – polymerase chain reaction (qRT-PCR) was performed on swab and 
tissue samples to determine numbers of RNA copies of vaccine virus in these samples. 
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Standard curves were prepared using logarithmic dilutions of a known amount of synthetic 
oligonucleotides (Applied Biosystems) for the genes targeted. 
100 uL of the resuspended swab was removed for RNA extraction using Qiagen’s RNeasy kit. 
For tissues, each frozen tissue sample was pulverized into frozen powder using a Spex 
Sample Prep Freezer Mill 6870. Powder from each tissue was weighed and resuspended in 
PBS / SPG (Invitrogen, Gibco) to make a 20 % suspension, of which 150 uL were used to 
extract RNA. Extracted RNA was eluted in 100 uL RNase free water. All samples were set up 
in duplicates. RNA was extracted from samples using a Qiagen RNeasy kit, and following the 
protocol provided by Qiagen. RNA eluate was either processed right away, or stored at – 80 
°C in 1.5 mL Eppendorf tubes. 




 to detect genome copies. In the second step of the assay, qPCR was performed using CDV-N 
specific primers.  
Preparation for reverse transcription was undertaken in the clean room by mixing 2 uL 10 x 
reverese transcriptase (RT) buffer (Qiagen), 2 uL 5m M deoxynucleotides (dNTPs; Applied 
Biosystems), 0.4 uL 20 uM forward primer (Applied Biosystems), 1 uL 10 uM RNAseOut 
(Invitrogen), 1 uL RT enzyme (Qiagen) and 3.6 uL H20 (Qiagen) (total volume 10 uL) per test, 
and adding 10 uL per test sample to wells of an optical 96 well plate (Applied Biosystems). 
The plate was then sealed and moved to an extraction table, where 10 uL of sample RNA 
were added. Negative controls were run using water and lysis buffer from the RNA 
extraction kit. The plate was then sealed again and an Optical Cover Compression Pad 
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(Applied Biosystems) placed on top. The assembly was then centrifuged (ThermoScientific 
centrifuge) at 200 x g for 1 min. Reverse transcription was performed in a Stratagene 
Mx3005P Real-Time PCR machine, set to run at 50 °C for 45 min and 95 °C for 2 min. 
Subsequently, the produced DNA was amplified using PCR. The test samples were placed on 
ice, and a mixture of 25 uL 2 x qPCR Master Mix (Qiagen), 1 uL 20 uM forward primer 
(Applied Biosystems), 1 uL 20 uM reverse primer (Applied Biosystems), 1 uL 1 uM 5´ 
fluorophore 6-carboxyfluorescein labeled primer (Applied Biosystems) and 2 ul H2O (Qiagen) 
(total volume 30 uL per sample) was added to the test wells. The thermocycler was set to 
run once at 95 °C for 15 min, and then 44 cycles of 94 °C for 15 s followed by 60 °C for 1 min 
(total run time 1hr 45min). PCR products were analysed and quantified on a Stratagene 
Mx3005P detector using the Primer Express Software, V 3.0.  
Due to the required specialist knowledge to correctly perform this assay, John Coleman, RT-
PCR specialist in the IAVI vectors lab, performed the qRT-PCR experiments on all samples. 
 
3.4.11 Confirmation of presence of antibodies in serum samples using western blot  
Western blot analysis was used to evaluate serum samples for presence of antibodies 
against SIVgag. The assay was performed as per standard procedures. Briefly, purified 
recombinant SIVgag p55 (Protein Sciences Corp) was prepared in SDS sample buffer (with 
reducing agent) (Invitrogen) at a concentration of 35 ug protein per mL of total sample 
volume, heated for 10 min at 70 °C, and then loaded onto a 4 – 12 % Bis-Tris electrophoresis 
gel (Invitrogen). The gel was run in 1 x MOPS SDS running buffer (Invitrogen) with 
antioxidant (Invitrogen) for 46 min at 200 V. It was then blotted onto a nitrocellulose 
blotting membrane (BioRad) on a dry-blotting apparatus (Invitrogen), using program P3 (20 
V) and 7 min transfer time. The membrane was then placed in blocking buffer (Thermo 
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Scientific) on a rocking platform for 1 h at room temperature. To evaluate serum samples of 
different animals on the same membrane, we used a screening apparatus that facilitates 
screening of up to 17 samples on one membrane (Bio-Rad). 500 ul of serum sample per 
trough was added in a 1 : 500 dilution in blocking buffer. A nonhuman primate serum 
positive for SIVgag protein, as well as serum obtained from a naïve ferret housed with the 
study animals prior to the study were included as controls. The assay was incubated for 1 h 
on a rocking platform at room temperature, and then washed three times by adding PBS 
(Invitrogen) with 0.05 % Tween 20 (Bio-Rad) to all lanes and rocking for 15 min. 
Subsequently lanes were incubated with 500 uL per lane Horseradish-Peroxidase-labeled 
anti-species secondary antibodies (anti-monkey IgG by SantaCruz Biotechnology, Inc., Santa 
Cruz; and anti-ferret IgG by Novus Biologicals or by Bethyl Laboratories) diluted 1 : 5000 in 
blocking buffer for 1 h at room temperature on a rocking platform. The blot was then again 
washed three times and removed from the apparatus. 6 mL of enhanced 
chemoluminescence (ECL)-Substrate (GE Healthcare Bio-Sciences Corp.) was applied to the 
membrane and the blot incubated for 5 min before being evaluated using a bioimager (Bio-
Rad). 
 
3.4.12 Production of recombinant N protein 
CDV N protein as an antigen was produced for antibody assays, since the N protein is the 
most abundantly expressed protein in CDV infected cells and also highly immunogenic (278). 
Recombinant partial or full length Paramyxovirus N protein for use in immunological assays 
has been expressed in procaryotic BL21 Escherichia coli (E. coli) several times before) (279, 
280). We followed the principles laid out on these publications, making use of a plasmid that 
has previously worked very well for us in expressing His tagged proteins of similar size. The 
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full sequence of the CDV Onderstepoort N protein including an N-terminal sixfold Histidine 
(His6)-SUMO-tag to enable protein purification on Nickel columns was cloned into a pET-28 
based plasmid including a multiple cloning site (kind donation from the Shapiro Lab at 
Columbia University, based on the Champion pET SUMO vector by Invitrogen), transformed 
into XL10 gold Escherichia coli (E. coli) (Agilent), and the DNA of several clones isolated using 
the MiniPrep system (Qiagen). The isolated plasmids were analyzed for inserts by PCR, the 
results of which were analyzed using agarose gel electrophoresis. Positive clones were sent 
for sequencing (GeneWiz). 1 clone with a confirmed correct sequence was then used to 
transform Rosetta 2 (DE3) BL21 E. coli (Merckmillipore), which served as the expression 
strain. The bacteria were then grown in lysogeny broth (LB) medium (Sigma) with kanamycin 
(50 ug L-1, Sigma) and chloramphenicol (34 ug L-1, Sigma). Cultures were grown at 37 °C in a 
shaker (New Brunswick) until their optical density at 600 nm reached 0.6-0.8. Expression of 
the N protein was then induced by addition of 1 mM L-1 Isopropyl β-D-1-
thiogalactopyranoside (IPTG, SigmaAldrich). Since all attempts to obtain soluble protein 
failed, finally growth was continued for a further 24 h at 37 °C to drive expression in 
inclusion bodies. Cells were harvested in a Sorvall centrifuge for 15 min at 4000 x g. The 
bacterial pellet was then suspended in lysis buffer (20 mM Tris HCl pH 8, 150 mM NaCl, 20 
mM imidazole, 8 M Urea, all Sigma) and sonicated for 4 min on ice to lyse cell walls. The 
lysate was spun and filtered to remove debris, and then run over a Ni-IMAC column (GE 
Healthcare). The column was washed using lysis buffer, and bound protein was eluted off 
the column using lysis buffer containing 500 mM Imidazole. A sample of the eluate was 
loaded onto an SDS page gel (Invitrogen) and stained using Coomassie (BioRad) to check for 
expression of the correct protein. A band at 67kD confirmed expression of a protein of 
appropriate size, containing of N protein at 55kD and the purification tag at 12kD. 
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Confirmation of presence of N protein was achieved by western blot, using a commercial 
anti-HIS antibody (Qiagen) as well as a commercial anti-N protein antibody (SantaCruz) and a 
horseradish peroxidase labeled anti-mouse IgG as a secondary (for protocol, see section on 
Western Blots, substituting primary and secondary antibodies accordingly). The produced 
protein solution was then dialysed against ddH2O (MilliQ) to remove urea, since high urea 
concentrations would interfere with antigen coating of ELISA plates. As expected the protein 
precipitated during dialysis. The dialysis sample was spun down to collect the N-protein, and 
the pellet dissolved in Carbonate-Bicarbonate buffer containing 3 % SDS (Sigma). The final 
protein concentration was determined photometrically at 280 nm. This solution was 
subsequently used as a coating antigen for ELISA assays, as well as an antigen for western 
and dot blots. 
 
3.4.13 Production of recombinant H protein 
CDV H protein is the protein against which most neutralizing antibodies are elicited during 
natural infection. We hence decided to produce H protein as a backup antigen for antibody 
assays. CDV H protein is a class 2 transmembrane protein. It’s first 58 aminoacids remain 
inside the viral particle. We therefor decided to only express aminoacids 59 to the stop 
sequence. Again, to maintain the most natural confirmation, expression in a eukaryotic 
system was attempted, but likely due to its viral origin, the protein proved to be severely 
toxic to eukaryotic cells. Hence we proceeded to expression in prokaryotic BL21 DE3 cells. 
The cloning and expression protocols and controls were identical to the ones described for 
production of N protein above (3.4.12). 
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3.4.14 Origin and description of simian immunodeficiency virus glycosaminoglycan 
protein 
Purified recombinant SIVgag p55 (Protein Sciences Corp) was used as antigen for all assays 
designed to determine gag-specific antibody levels. Gag-positive serum samples from Non-
human primates (NHPs) was provided by Arielle Ginsberg (IAVI) and were used as positive 
controls. The SIVgag protein was also detected with a SIVmac251 monkey serum obtained 
from the NIH AIDS Research & Reference Reagent Program and a HRP-conjugated anti-
monkey IgG secondary antibody (Santa Cruz). 
 
3.4.15 Isolation of peripheral blood mononuclear cells  
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples to be 
used in intracellular staining and flow cytometry assays. Lymphocyte separation tubes 
(ACCU-Spin, Sigma-Aldrich) were pre-filled with 15 mL Ficoll-Paque PLUS® (GE Healthcare 
Bio-Sciences Corp.) and spun in a Sorvall centrifuge for 5 min at 485 x g to bring the gradient 
medium to the bottom of the tube. Whole blood samples obtained during terminal bleeds 
were then mixed with PBS in the separation tubes, and the tubes were spun for 30 min at 
700 x g, with the acceleration speed set to 7 out of 9, and the deceleration speed set to 1 
out of 9, to gradient-separate the PBMCs from other blood components. The interface was 
then aspirated and placed into 50 mL conical tubes (Becton Dickinson and Company). Those 
were filled up with PBS, and spun for 10 min at 485 x g with acceleration and deceleration 
speed set to 9 to wash the PBMCs. Cells were then resuspended in 2 mL ACK lysis buffer 
(Invitrogen) and incubated for 2 min at room temperature to lyse remaining red blood cells. 
Washing with PBS was repeated. Cells were then resuspended in RPMI 1640 medium 
(Invitrogen) and counted using an automated cell counter (Beckman Coulter). While cell 
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numbers and viability were obtained, cells were spun again at 485 x g for 5 min. They were 
then resuspended in commercial cell freezing medium (Invitrogen) at a density of 15 x 106 
cells per mL and aliquoted into cryo vials (Nunc A/S) at 1 mL volume per aliquot. Cells were 
frozen in a controlled rate automated freezer (ThermoScientific) and stored in liquid 
nitrogen until further use. 
 
3.4.16 Evaluating cellular immunological responses by use of stimulation assays, 
intracellular staining and flow cytometry 
To determine the distribution of different subpopulations of PBMCs as well as the level of 
response to either polyclonal stimulation or SIV gag, previously isolated PBMCs were used 
for stimulation, intracellular staining and flow cytometry assays. PBMCs were extracted from 
terminal whole blood samples using the procedure above. Cells were then resuspended in 
RPMI and counted using an automated cell counter. 0.5 x 106 PBMCs were stimulated with 
SIVgag peptide pool (NIH AIDS reagent program) or with phorbol 12-myristate 13-acetate 
(PMA) / ionocmycin (Biolegend) stimulation as a positive control. Extra sets of cells were left 
as unstimulated negative controls. Due to the lack of ferret-specific and limited sources of 
cross-reactive antibodies, PBMCs were only stained for ferret CD8 with a cross reacting 
antibody (human anti CD8, clone OKT-8 by ebiosciences) and intracellular IFNγ using anti-
bovine IFNγ antibody (Abd serotec clone cc302). Ten thousand PBMCs were analyzed of the 
0.5 x 106 stimulated and stained for each sample by flow cytometry. IFNγ+ cells were gated 
in the CD8+ PBMC population. The gate was set according to cells stained for CD8 alone. 
Data were analyzed using the Cellquest software (Becton Dickinson FACSCalibur, CA). The 
frequency of IFNγ+ cells was expressed as the percentage of these cells after background 
subtraction within the total CD8+ cells counted. 
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3.4.17 Attempt to quantify antibody levels in ferret blood by enzyme-linked 
immunosorbant assays 
Enzyme-linked immunosorbant assays (ELISAs) offer an option to semi quantitatively assess 
the amount of antibodies against a specific antigen present in serum samples. Typically, the 
antigen in question is coated onto the bottom of the wells of 96-well-plates (for example 
Corning or Nunc) by interaction between the plate material and antigenic peptides or 
proteins. Antigens can also be “trapped” by coating the plate with (ideally monoclonal) 
antibodies against this antigen, then adding antigen solution. A blocking step with a protein 
rich suspension such as bovine serum albumin (BSA, BioRad) or dry milk powder in PBS 
(Invitrogen) is performed to obstruct unoccupied areas of the plate. ELISAs can then be 
conducted in two ways. Either, test serum is directly applied to the plate in serial dilutions, 
and if antibodies against the antigen are present, they will bind to the antigen. The bound 
antibodies can then be detected by using species-specific anti-Ig antibodies conjugated with 
a functional group that, if supplied with the correct substrate, will emit a fluorescent signal 
which can be read in a plate reader (biotek). The higher the concentration of the specific 
antibody in the serum binding to the antigen, the more secondary antibody will bind and the 
stronger the fluorescence will be. Alternatively, the assay can be performed in a competitive 
manner, where antibodies in the test serum block access to antigen for a specific 
monoclonal antibody. In this case, the higher the antibody level in the test serum, the less 
monoclonal antibody will be bound and detected, and the lower the fluorescence signal will 
be. 
ELISA test kits for CDV to be used with dog sera are widely available. However, none of them 
were suitable to detect ferret antibody levels during our studies. We therefore endeavored 
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to develop our own in house ELISA in order to be able to semi quantitatively determine 
antibody levels against CDV. Since excessive amounts of work were put into developing this 
assay, and a variety of issues were encountered, a detailed description of the development 
attempts can be found in the results section of this thesis. 
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4 Results 
4.1 Virus propagation 
rCDV and rCVDgag were propagated by infection of Vero cells. Infected cells in fully 
confluent flasks were scraped into the medium and the suspension repeatedly freeze-
thawed to release viral particles. The suspension was then clarified by centrifugation to 
purify virus particles, and supernatant added to naïve 70 % confluent Vero cells. Each 
passage was individually named. Both rCDV and rCDV-SIVgag grew well in this fashion. To 
allow for most effective virus propagation, cells were infected while not fully confluent, and 
a rather low Multiplicity of Infection (MOI) (around 0.02) was used to avoid the formation of 
interfering defective particles. To further increase virus yield, flask sizes were increased from 
one passage to the other and/or multiple flasks of Vero cells infected if desired. This allowed 
for constant maintenance of the original strains selected for this study, and enabled us to 
grow enough virus per passage to complete the entire study with virus harvested from the 
same passage, therefore minimizing variation between inoculations. 
 
4.2 Viability assays and virus quantification 
Along with each virus passage, the harvested virus was assessed for viability and quantified 
using Plaque Forming Assays. A sample of the harvested virus stock was used in 10-fold 
serial dilutions to infect Vero-cells in 6-well plates. The infected cells were overlaid with 
methylcellulose-MEM-solution to aid plaque formation. After a set incubation time cells 
were washed, fixed and stained with Giemsa stain and plaques were counted. Virus titer for 
the corresponding batch was calculated and expressed in plaque-forming units per milliliter 
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(PFU / mL). The constant use of this assay allowed us to accurately observe the amount of 
virus produced and to ensure possible problems with virus productions were detected early. 
During the initial PFU assays, we evaluated the differences between using purified virus, and 
omitting the centrifugation step and adding the virus non-purified. In direct comparison, 
initially the same virus harvest titrated at a higher PFU / mL when purified than non-purified. 
However, this did not hold true in a repetition of the assay. Additionally, assays using 
purified virus showed a much higher variance between duplicates of dilutions, and it was 
much harder to distinguish plaques from unaffected areas of the monolayer as compared to 
non-purified virus assays. 
Due to the risk of adverse reactions to cell debris and other particles, we decided that non-
purified virus could not be used in the planned animal studies. Therefore, ultimately only 
purified virus was titrated and stored. Virus harvests used for this study titrated at 5 x 107 
PFU / mL. 
 
4.3 Determining distemper exposure status of study animals 
The ferrets enrolled in the two studies presented here came into our facilities as certified 
unvaccinated animals. Prior to beginning the studies, we collected blood samples from each 
ferret, allowed for clotting at 4 °C overnight, separated off the serum and performed virus 
neutralization tests for each animal in duplicates. All tests were negative, indicating the 
absence of neutralizing antibodies against CDV in these animals. 
 
  63 
4.4 Results of study 1 – vector safety  
4.4.1 Clinical observations 
Weights (Table 2) and temperatures (Table 3) of each animal were recorded on the day of 
inoculation and at each harvest time point. The presence of any clinical signs suggestive of 
CDV, such as fever, inappetence, nasal or ocular discharge, diarrhea, or rashes was recorded. 
Since over the course of these studies we planned to use subcutaneous microchips capable 
of recording body temperature, during this pilot study, a side by side comparison of rectal 
and chip temperature read-outs was performed to determine if subcutaneous temperatures 
consistently reflect actual core temperatures, and what the degree of variation would be. 
 
4.4.1.1 Development of body weights 
The animals used during this study were still very young and had not yet reached their adult 
weight. Over the seven-day course of this study, all animals except one continued to gain 
weight. The one animal that did not had briefly lost 20 g of body weight but had regained its 
starting weight by the end of the study. So in summary, vaccination with rCDV-gag did not 
affect body weight. 
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Table 2: Weight developments of individual animals during study 1. D = Day, m = male, f = female. 
Animals #3 and 6 were mock-treated negative controls. Clinical distemper infection would usually 
cause weight loss. No decrease in body weight can be seen in any of the animals over the course of 
the study. 
 
4.4.1.2 Development of body temperatures 
Body temperatures in healthy ferrets vary significantly over the course of the day and with 
different activity levels. However, generally, temperatures > 40.5 °C are considered above 
normal. During the course of this study, none of the animals ever presented with 
temperatures above that level, and temperature curves remained fairly steady throughout, 
indicating that inoculation with CDV did not cause a systemic reaction leading to the 
development of fever. When comparing microchip and rectal readings, care had to be taken 
to ensure that readings were taken at the same time. Variations of more than 1 °C occurred 
on three occasions, where animals had been woken from a sleep and then became active 
and warmed up quickly, making the reading noted first significantly lower than the reading 
taken second. In all other cases though, chip readings remained within 0.5 °C of rectal 
readings. The average difference between subcutaneous and rectal readings was 0.57°C, 
with the subcutaneous temperatures regularly being the higher reading. We therefore 
considered the chip to be an easy, convenient and reliable way to attain an accurate picture 
of the animals’ body temperatures. 
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Table 3: Comparison of simultaneous rectal and subcutaneous chip measurements of body 
temperature in ferrets over the course of study 1. D = day, S = subcutaneous, R = rectal. Animals #3 
and 6 were mock-treated negative controls. Normal temperatures in ferrets vary between 36 and 
40.5°C. Clinical distemper infection would usually cause significantly elevated body temperatures of 
40.5-42°C. None of the animals showed temperatures within elevated range at any point during the 
study. This table also compares results of rectal measurement of body temperature with 
measurements using microchips implanted subcutaneously. Rectal and subcutaneous measurements 
differ by a minimum of 0.0°C and a maximum of 2.2°C with an average of 0.57°C. Subcutaneous 
measurements were usually higher than rectal measurements. 
 
4.4.1.3 Recording and evaluation of clinical symptoms suggestive of distemper infection 
No animals showed any clinical signs, including diarrhea, discharges, rashes or abnormal 
behavior, or significant temperature increases during the study, suggesting that the 
recombinant virus was sufficiently attenuated to not cause clinical symptoms in this highly 
susceptible species. 
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4.4.2 Swab and tissue samples 
4.4.2.1 Detection of recombinant virus in swabs by plaque assay in Vero cells 
Briefly, 100 uL of swab sample medium was added onto a monolayer of Vero cells grown in 
96 well plates in quadruplicates and incubated for 1 h. Samples were then aspirated and 
replaced with fresh media. Wells were monitored for plaque formation (Table 4). No plaque 
formation was observed in any of the samples, indicating that there was not enough virus 
present in the swab samples to establish a productive infection. 
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Table 4: Individual results of plaque assays performed on swab samples throughout study 1, given 
as number of plaques counted. Nasal, oral and rectal swabs were taken from each study animal 2h, 
1, 3, 4 and 7 days post inoculation. Animals in group 1 were euthanized at D3 post inoculation, 
animals in group 2 at D7 post inoculation. Animals #3 and 6 were mock-treated negative controls. 
Swabs were then used to conduct plaque assays. No swab samples resulted in plaque formation, 
indicating that not enough infectious virus was present in any of the samples to result in a productive 
infection. 
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4.4.2.2 Detection of recombinant virus in nasal turbinate and ileum tissues by plaque assay 
Briefly, powdered tissue samples were aliquoted into microcentrifuge tubes and weighed. 
Aliquots for nasal turbinates weighed between 30 and 70 mg, and for ileal tissue 30 to 150 
mg. Approximately 130 uL medium was added to each sample and vortexed. 100 uL of this 
suspension, as well as a 1:10 dilution of the suspension was added to a monolayer of Vero 
cells grown in 6-well plates and incubated at 37 °C for 1 h. Samples were then aspirated and 
replaced with media and plates incubated for 4 d. Wells were monitored for plaque 
formation (Table 5). No plaques were formed in any of the samples harvested on either D3 or 
D7, indicating an insufficient amount of virus to create a productive infection. 
 
 
Table 5: Results of plaque assays performed on tissue samples during study 1 to detect the 
presence of infectious particles at D7 post infection. Results given as number of plaques counted. 
30 – 70 mg tissue powder resuspended in 130 uL of medium were used for the nasal turbinate 
samples. 30 – 150 mg tissue powder resuspended in the same volume were used for the ileum 
samples. Animals #3 and 6 were mock-treated negative controls. No plaques could be detected from 
any of the tissue samples, indicating the tissue samples did not contain enough infectious virus to 
produce a productive infection. 
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4.4.2.3 Detection of viral genetic material in swab and tissue samples obtained during study 
1 using quantitative real time – polymerase chain reaction 
Briefly, 100 uL of the resuspended swab medium or 200 uL of a 10 % suspension of 
homogenized tissue in PBS were used for RNA extraction using Qiagen’s RNeasy kit. 
Extracted RNA was eluted in 100 uL RNase free water. 
In the first step of qRT-PCR, 10 uL of RNA was used for cDNA synthesis by reverse 
transcription using the CDV-N forward primer to detect genome copies. In the second step 
of the assay, qRT-PCR was performed using CDV-N specific primers. 
Using swab medium, low levels of CDV genome were detected mainly in two animals (#1 and 
4) with the exception of rectal swabs where genomic copies were detectable in one 
additional animal on D1 post inoculation (Figure 5). These results indicate that a low degree 
of virus shedding does occur for at least 4 d post inoculation. However, no viral genome 
could be detected in oral and nasal swabs of animals # 2 and 5, which shared the cage with # 
1 and 4, respectively. Animal # 6 is a mock treated animal that was kept in a different cage 
yet viral copies were detected in one rectal swap. Since no viral genome was detected in 
swabs of this animal at any other time point, nor was any viral DNA detected in tissue 
samples from this animal, there is a significant possibility that this positive swab result stems 
from cross contamination.  
qRT-PCR analysis of nasal turbinate samples revealed presence of viral genomic material in 
one of two experimental animals sacrificed at either time point, suggesting persistent 
presence of virus in the nasal cavity over the duration of the study. The qRT-PCR assay 
detected significant levels of CDV genomes in gut mucosal tissue of inoculated ferrets of 
both experimental groups but not the mock group at D7 (Figure 6). Since no copies were 
detected in the same tissues at D3, it can be inferred that this represents replication of the 
inoculum. 
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Figure 5: Graph of numbers of genomic copies of distemper N protein RNA in swab samples by 
quantitative real time – polymerase chain reaction. Number of genomic copies of distemper N 
protein detected in A nasal swabs, B oral swabs and C rectal swabs at 2 h, 1 d, 3 d and 4 d post 
inoculation. Annotations on the x-axis corresponds to animal IDs. Animal numbers 3 and 6 were 
mock-treated negative controls. Values below the detection limit of 10 copies of genomic RNA were 
not plotted. Genomic copies were detectable at different time points in swabs from 50% of the 
experimental animals. Highest numbers were detected in nasal swabs within 24h of inoculation. 
Detection of genomic RNA copies in other locations sampled indicates that the recombinant virus 
does spread throughout the body. On one occasion, genomic copies of N protein RNA were detected 
in a mock infected animal (rectal swab on d1). Since no positive results were obtained from this 
animal at any other time point or from any other location, this is likely the result of accidental cross-
contamination. 
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Figure 6: Genomic copies of distemper N protein RNA in tissue samples analysed by Quantitative 
Real-Time Polymerase Chain Reaction. Number of genomic copies of distemper N protein RNA in 
tissues harvested A on D3 and B on D7. Annotations on x-axis correspond to animal IDs. Animal 
numbers 3 and 6 were mock-treated negative controls. Values below the detection limit of 10 copies 
were not plotted. Copies of viral RNA were detectable in nasal turbinates of one of two experimental 
animals sacrificed at d3 and d7, indicating persistent presence of viral material in the location of 
inoculation. Detection of signifikant amounts of viral RNA within the ileal samples of both 
experimental animals sacrificed at d7 but not d3 indicates replication distant from the inoculation 
site. 
 
4.4.3 Analysis of blood samples 
4.4.3.1 Intracellular cytokine staining of PBMCs to detect cellular responses to simian 
immunodeficiency virus glycosaminoglycan 
Briefly, whole blood samples from animals euthanized at D7 were prepared to isolate 
PBMCs. These were incubated with overlapping peptides covering the gag open reading 
frame (ORF), PMA/ionomycin, or no stimulant for 9 h at 37 °C. Samples were stained with 
monoclonal antibodies against CD8 and IFN-γ. Analysis was performed on an LSRII Flow 
Cytometer using FACSDiva Software. There was no noticeable IFN-γ production after mock 
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stimulation, and significant IFN-γ production after polyclonal stimulation with PMA. There 
was an increase of IFN-γ production after stimulation with gag ORF, but there was no 
significant difference between vaccinated and sham treated animals at this time point. The 
negative and positive controls worked well in this assay, but no significant gag specific 
response was detectable at the D7 time point (Figure 7). 
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Figure 7: Scatter plots of flow-cytometric analysis of peripheral blood mononuclear cells harvested 
on D7 of study 1, stained for CD8 and IFN-γ. Numbers across the top represent animal ID numbers. 
A Glykosaminoglykane stimulated samples of all animals sacrificed at D7. B Polyclonally stimulated 
samples, positive control. C Mock-stimulated samples, negative control. Note the increased number 
of cells in bottom and top right quadrants of PMA stimulated animals, and the slight increase in cell 
numbers in the top right quadrant in glycosaminoglykane stimulated samples, indicating an increase 
in cells double-positive for both CD8 as well as IFNg. This suggests the presence of antigen specific 
CD8 cells at d7 post inoculation. 
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4.5 Results of study 2 – vector biology and immunogenicity 
4.5.1 Clinical observations 
4.5.1.1 Development of body weights 
Individual animals mostly maintained their body weight throughout the duration of the 
study (Figure 8 and Figure 9). There was no obvious tendency for development of body weight 
within any of the treatment groups. 
To minimize possible effects of different body weights on the outcome of the study, animals 
with highest and lowest weights within the study were assigned into the mock group. 
One female animal within the experimental group inoculated with rCDV was found to be 
consistently loosing weight. This animal was also noticed for presenting with ocular 
discharge from D7 p.i. onwards as well as occasional soft stool. It was, however, eating, 
drinking, active and alert over the entire course of the study. It did not present with any 
temperatures higher than 39.3 °C. Her cage mates did not show any weight loss, increased 
temperature, decreased appetite or activity level, or any other symptoms possibly related to 
CDV infection at any time. This animal had initially arrived with a weight closer to her 
endpoint weight, but had gained 200g until the beginning of the study with no signs of 
illness. We therefore decided to keep this animal in the study. 
Comparing the development of the average of body weights of all animals in one treatment 
group with the average of weights in the other groups reveals no significant differences 
between the two experimental groups (rCDV vs rCDV-SIVgag). There were also no 
tendencies towards weight gain nor weight loss detectable for any of the groups. Body 
weights remained relatively constant over the course of the study in all treatment groups. 
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The relatively high level of average body weights for the mock group up to D14 p.i. and then 
at a lower level up to D21 p.i. is likely due to the influence of two particularly heavy animals 
assigned to this group, which were sacrificed on D14 and D21. 
The increase in average body weights of the rCDV group on D28 is an effect of chance. The 
animals of this group remaining until D28 happened to be the heaviest animals of this group, 
and the lack of balance by lighter animals results in the sudden increase. 
These very constant data on development of body weight confirm our observations that all 
animals in the study had normal appetite, were able to get to and take up their food and 
were eating and drinking over the the entire course of the study. 
 
Figure 8: Body weight of all 32 individual animals over the course of this study. Blue lines represent 
animals inoculated with empty vector, red lines represent animals inoculated with recombinant 
distemper including glykosaminoglykane insert; green lines represent the control group. Individual 
animals are designated by different labels along the lines. Definite weight loss can only be noted in 
one animal within the empty vector group. This animal presented no other signs of possible illness. 
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Figure 9: Average body weights within treatment groups. Weights of the individual animals within 
each treatment group were averaged for each time point. Blue line signifies empty vector group, red 
line recombinant distemper with glykosaminoglykane insert, green line control group. On average no 
significant changes in body weight can be noted in any of the groups.  
 
4.5.1.2 Development of body temperatures 
The normal body temperature in ferrets is generally assumed to be between 38 and 40 °C, 
but varies greatly depending on both the environment and the activity of the animals. In 
sleeping animals it regularly drops below 38 °C, and in active and excited animals it quickly 
rises up to 40.5 °C. Activation of the immune system is also known to result in a temporary 
increase of body temperature of up to 1 °C in mammals. During our study, no animal ever 
showed temperatures > 40.5 °C (Figure 10). On D0 all animals were anesthetized for 
inoculation, which limits their ability to maintain normal body temperature and can explain 
the relatively low values for that reading. 
For the graph below, body temperatures of all animals within one treatment group were 
averaged for each time point and the treatment groups plotted against each other to 
average effects of activity- or sleep-induced temperature rises or falls. This graph illustrates 
that the overall body temperatures were within the normal range of 38 – 40 °C at all times 
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and for all groups. For the first 10 d post inoculation, animals in experimental groups showed 
slightly higher temperatures than animals in the mock group, which might indicate activation 
of the immune system. 
 
 
Figure 10: Average body temperature in treatment groups. Temperatures of animals within each 
treatment group were averaged for each time point. Blue line signifies empty vector group, red line 
recombinant distemper with glykosaminoglykane insert, green line control group. Clinical distemper 
infection usually causes temperatures of above 40.5°C especially in the first days post infection. This 
was not observed for any of the groups. Both experimental groups produced average temperatures 
above the average of the control group for the first ten days post inoculation which could suggest 
activation of the immune system. 
 
4.5.1.3 Recording and evaluation of clinical symptoms suggestive of distemper infection 
Animals were observed for symptoms indicative of a CDV infection, such as discharges from 
nose or eyes, changes in fecal consistency, appetite or behavior, and central nervous signs 
(Figure 11). The only symptoms ever noticed were changes in consistency of feces, and 
secretions from nose or eyes and occasional sneezing. Those symptoms were therefore 
classified into two major groups, “intestinal symptoms” and “discharges”, and plotted for 
each group on each day observations were recorded. 
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One animal in the mock group repeatedly presented with rather soft stool compared to its 
cage mate, but was otherwise without observations. All other mock animals did not show 
any symptoms at any given time. 
A member of the rCDV group was repeatedly noticed with discharge, and on two occasions 
also soft stool. This animal also presented with continuous weight loss over the course of the 
study, but appeared otherwise healthy. Body temperatures remained normal throughout 
the study. 
Aside from those two individuals which repeatedly presented with specific slight 
observations, symptoms possibly linked to inoculation with CDV were only noted on D7 p.i., 
which is a relatively short time after the prime inoculation, and on D25 p.i., which equals 4 d 
post boost inoculation. They were also only noted in animals from experimental groups at 
those times, but not from the mock group. Four different animals from the rCDV-SIVgag 
group were observed showing either intestinal symptoms or discharge, while in addition to 
the frequently noted animal only one other ferret in the rCDV group presented with possible 
symptoms. It was observed as having slightly watery eyes on D7 before it was sacrificed. 
Clinical alterations in such relatively close proximity to inoculations could indicate a reaction 
towards the respective inoculum in some animals. We observed a higher number of 
individuals in the rCDV-SIVgag group presenting with possible symptoms than in the rCDV 
group, which might suggest that animals receiving the vector including insert were more 
affected by the inoculum, although this difference was marginal. 
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Figure 11: Number of animals with clinical symptoms per group. Occurrence of clinical signs of 
possible CDV infection in experimental groups in number of animals in each group noted with either 
intestinal symptoms or discharges. No other symptoms such as rash or central nervous signs were 
noted at any point in the study.  Discharges included watery eyes or nose. Blue columns signify 
animals in the empty vector group, red columns recombinant distemper with glykosaminoglykane 
insert, green columns control group. All occurances plotted for the control group originated from the 
same animal and presented as soft stools. It can be noted that no animals showed any severe or 
continous clinical changes. 
 
4.5.2 Analysis of swab samples 
4.5.2.1 Detection of infectious particles in swab samples using tissue culture infectious dose 
50% assays 
While this assay was technically functional and routinely used for virus titrations and 
detections, and both positive and negative control samples presented the expected results, 
no CPE could be observed in any of the experimental samples despite some non-specific 
artifacts in the cell monolayers (data not shown). 
 
  80 
4.5.2.2 Detection of viral genetic material in swab samples using quantitative real time- 
polymerase chain reaction 
qRT-PCR was performed to look for genomic copies of CDV-N, initially using rectal swabs 
from all time points (Figure 12). All time points in all samples were analyzed, including those 
of mock-treated animals. Copy numbers detected in mock control animals were on par with 
the highest level of detection in rCDV vaccinated animals, suggesting a contamination error. 
Proper precautions against cross contamination were taken during the conduction of the 
study by housing ferrets in intra-group pairs in fully sealed and ventilated cages, and 
ensuring that any and all housekeeping, handling and study procedures were performed in 
an order that would prevent cross-contamination. Full personal protective equipment was 
worn at all times, and changed in between study groups. All materials were disinfected or 
discarded in between study groups. These protocols were maintained at the time of swab 
collection but seemingly not at the time of aliquoting and/or processing, which was 
performed on a bench used for CDV work. Likely sources of the CDV contamination include 
the pipettes used to aliquot samples and forceps used to remove swabs from tubes. 
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Figure 12: Numbers of genomic copies of distemper N protein RNA in rectal swabs taken during 
this study. A Samples for animals sacrificed on D21. B Samples for animals sacrificed on D28. Copy 
numbers of samples taken from all three groups were averaged for each time point. Blue bars signify 
empty vector group, yellow bars recombinant distemper with glykosaminoglykane insert, red bars 
control group. Lightblue cross-bar: Detection limit. Note the consistent presence of high levels of 
genomic RNA in control animals, indicating likely cross-contamination issues during sample 
processing. This assay could not be evaluated. 
It is impossible to draw any conclusions from this data set because of the apparent 
contamination. In light of these data suggesting a high likelihood of cross contamination, 
nasal swab samples were not analyzed for the presence of genomic DNA. 
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4.5.3 Analysis of tissue samples 
4.5.3.1 Virus detection and quantification in ferret tissues by plaque assay 
This assay was also established previously and routinely used for titration of virus harvests. 
Positive and negative controls gave the expected results (Figure 13). During the setup of 
assays analyzing tissue samples from animals euthanized at D7, the viscosity of tissue 
homogenates presented a problem. Tissue debris made it impossible to collect the correct 
amounts required for evaluation of neat tissue homogenates. 1 : 10 dilutions were set up 
instead. For samples gathered on subsequent time points, the homogenates were spun 
down before removing samples for both the neat sample and the 1:10 dilution assays. For 
D7 samples, strong responses were observed for Peyer’s patches and mesenteric lymph 
nodes in all samples from animals in the rCDV backbone group. Plaques were also observed 
in the same tissue samples from the rCDV-SIVgag group, although at a significantly lower 
level. No plaques were noted in any of the samples from nasal turbinates, or any samples 
from mock-treated animals.  Zero plaques were observed for D14, D21 and D28 samples. It is 
unclear why no plaques were observed in tissue samples that contained as many as ten 
million CDV genome copies per gram tissue. A few different mechanisms are possible. Not 
every copy of viral genomic information will eventually mature into a fully infectious and 
functioning viral particle. The recombinant virus may be replication competent but the 
newly produced particles not as infectious. Cell-associated virus could also have been 
removed from the assay in the additional centrifugation step prior to plaque assays.  
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Figure 13: Virus infectivity titration in ferret tissues. Results of plaque assays using processed 
samples of mesenteric lymph nodes (MLN), Peyer’s patches (PP), and nasal turbinates (NT). 
Infectious virus was only detected in tissues collected seven days post vaccination. Blue columns 
empty vector group, red columns vector including insert group. No plaques were detected for the 
control group. Average plaque forming units (PFU) were generated from all ferrets in each treatment 
group. No infectious virus was detected in Nasal turbinates at D7 p.i. in any animal, but at both sites 
distant from the inoculation site. This suggests the ability of both inoculates to spread and replicate 
in the ferret body. Samples from animals inoculated with empty vector produced significantly more 
plaques than those from animals inoculated with vector including insert. This would suggest that, 
while both inoculates are able to replicate and produce infectious particles distant from the site of 
inoculation, empty vector seems to replicate more productively. 
 
4.5.3.2 Detection of viral genomic material in tissue samples using quantitative real time – 
polymerase chain reaction 
qRT-PCR on nasal turbinates, Peyer’s patches and mesenteric lymph nodes was performed to 
detect genomic copies of CDV-N in both the rCDV vaccinated as well as the rCDV-SIVgag 
vaccinated animals (Figure 14 and Figure 15). Genomic RNA levels of CDV-N remained above 
the detection limit until D21 for nasal turbinates, and throughout the study right up until 
D28 for Peyer’s patches and mesenteric lymph nodes for both rCDV and rCDV-SIVgag 
samples. Peyer’s patches and mesenteric lymph nodes consistently presented higher copy 
numbers than nasal turbinates, suggesting the intestinal tract as primary site of amplification 
of the recombinant virus. Genomic RNA levels of CDV-N were about 2 log higher in the rCDV 
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than in the rCDV-SIVgag group. The peak of virus load was at D7 for all samples, then 
gradually reducing up until D28. A slight upward trend was noted in D21 samples. 
 
 
Figure 14: Numbers of genomic copies of distemper N protein RNA in processed tissue samples 
from ferrets infected with empty distemper vector. Samples were taken at weekly intervals (red 
columns d7, blue columns d14, yellow columns d21, black columns d28). Numbers detected in 
samples from individual animals were averaged. Genomic copies of N protein RNA were detected in 
all three tissue types to be analyzed. Numbers were highest for all three tissues at d7, indicating the 
empty vector spreads and replicates most actively around this time. While numbers in nasal 
turbinates then dropped, numbers in Peyer`s patches and mesenteric lymph nodes remained several 
orders of magnitude higher, suggesting a resident replicating virus population at these sites. 
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Figure 15: Numbers of genomic copies of distemper N protein RNA in processed tissue samples 
from ferrets infected with distemper vector with glykosaminoglykane insert. Samples were taken at 
weekly intervals (red columns d7, blue columns d14, yellow columns d21, black columns d28). 
Numbers detected in samples from individual animals were averaged. Genomic copies of N protein 
RNA were detected in all three tissue types to be analyzed. Numbers were highest for all three 
tissues at d7, indicating the vector including insert spreads and replicates most actively around this 
time. While numbers in nasal turbinates then dropped, numbers in Peyer`s patches and mesenteric 
lymph nodes remained significantly higher, suggesting a resident replicating virus population at these 
sites. This follows the pattern determined for the empty distemper vector, indicating that the 
insertion of glucosaminoglycane does not affect vector viability. 
 
4.5.3.3 Detection of genomic copies of simian immunodeficiency virus glycosaminoglycan 
protein in tissue samples using quantitative real time – polymerase chain reaction 
Detection of genomic copies of SIVgag was performed in parallel to detection of CDV-N to 
demonstrate that the insert was propagated as well (Figure 16). All tissues that were positive 
for CDV-N were also positive for SIVgag. Graph profiles of copy numbers of SIVgag over the 
course of time mirrored those of CDV-N. The copy numbers of SIVgag detected in animals 
vaccinated with rCDV-SIVgag were around 0.5 - 1.0 log lower than the copy numbers of CDV-
N in the same animals. This difference could potentially be attributed to the fact that these 
samples were freeze/thawed several times as multiple assays have been performed and 
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could reflect degradation of RNA.  The copy numbers of SIVgag detected in Peyer’s patches 
and mesenteric lymph nodes were above the detection limit until the end of the study (D28), 
as was the case for CDV-N. 
 
 
Figure 16: Numbers of genomic copies of Simian immunodeficiency virus glucosaminoglycane 
protein RNA in processed tissue samples from ferrets infected with distemper vector with 
glykosaminoglykane insert. Samples were taken at weekly intervals (red columns d7, blue columns 
d14, yellow columns d21, black columns d28). Numbers detected in samples from individual animals 
were averaged. Genomic copies of glucosaminoglycane RNA were detected in all three tissue types 
to be analyzed. Numbers were highest for all three tissues at d7, indicating insert is multiplied most 
actively around this time. While numbers in nasal turbinates then dropped, numbers in Peyer`s 
patches and mesenteric lymph nodes remained significantly higher, suggesting multiplication of the 
insert genome at these sites. This follows the pattern determined for the vector backbone, indicating 
that the insert is conserved during virus spread and replication. 
 
4.5.4 Lymphocyte and splenocyte assays 
4.5.4.1 Determining cellular responses to simian immunodeficiency virus glycosaminoglycan 
protein in ferret peripheral blood mononuclear cells using intracellular interferone 
gamma staining 
Proliferation of PBMCs in response to specific peptides or peptide pools is often used as a 
measure to determine the extent of cellular immunity against those peptides. PBMCs 
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isolated from all groups during terminal blood draws were treated with the polyclonal 
stimulant PMA/Ionomycin, SIVgag peptide pool, or mock treated, and then incubated for 9 
h. Cells were subsequently stained with antibodies against IFNg, Ki67 (marker of cell 
proliferation), and CD8 (Figure 17, Figure 18, Figure 19 and Figure 20). There was a small but 
significant increase in the percentage of cells from rCDV-SIVgag immunized animals that 
secreted IFNg after stimulation with the gag peptide pool compared to the same cells 
without stimulation, and compared to cells from mock animals stimulated with SIVgag. The 
increase in cell numbers was in the range of 0.2 - 0.4 %. There was an unpredicted increase 
in Ki67 intensity observed in cells from D28 samples of the parental rCDV group stimulated 
with SIVgag. This response could possibly have been due to a generalized immune activation 
at this time point, resulting from the booster vaccinations on D21. This data set gives an 
indication of a gag specific cellular immune response. 
 
 
Figure 17: Flow cytometry of peripheral blood mononuclear cell samples from animals inoculated 
with vector including glucosaminoglycane insert. Shown are scatter plots of specific cellular 
immune responses after stimulation with a simian immunodeficiency virus glucosaminoglycane 
peptide pool. Of interest was the frequency of interferone gamma positive cells within the CD8 
positive population at three different time points (D7, D14, D21). Note the increase of interferone 
positive cells on d14, with counts on d21 still remaining above those for d7. This suggests that 
antigen specific CD8 positive cells against simian immunodeficiency virus glucosaminoglycane 
peptides are being produced and responding to antigen stimulation by d14 post inoculation. 
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Figure 18: Flow cytometry results of peripheral blood mononuclear cells from animals sacrificed at 
D28, mock stimulated only. Cells were stained for CD8 and either interferone gamma, evidencing 
antigen specific activation (left column) or KI67, indicating unspecific cell proliferation only (right 
column). Order of plots from top to bottom: control group (pooled), empty vector (pooled), vector 
including insert (individual animals). Note that mock stimulation does not result in significant 
numbers of cells in the right half of the plots, indicating that neither specific nor unspecific 
stimulation have occurred. 
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Figure 19: Flow cytometry results of Peripheral blood mononuclear cells from animals sacrificed at 
D28, stimulated with simian immunodeficiency virus glucosaminoglycane peptides. Cells were 
stained for CD8 and either interferone gamma, evidencing antigen specific activation (left column) or 
KI67, indicating unspecific cell proliferation only (right column). Order of plots from top to bottom: 
control group (pooled), empty vector (pooled), vector including insert (individual animals). Note that 
all samples stained for Ki67 (right column) show an increase of cell frequency in the right half of the 
plots, indicating the cells were able to proliferate when faced with foreign peptides. Note that this 
increase is significant in all samples from the vector including insert group, but also in the sample 
from the empty vector group. This may be caused by generalized activation of the immune system 
due to the booster inoculations the animals had received on d21. Also note in the left column the 
small increase in frequency of cells in the right half of plots for all three animals in the vector 
including insert group. This demonstrates that upon stimulation with glucosaminoglycane, these cells 
become increasingly positive for interferone gamma. The increase in frequency was between 0.2 and 
0.4% in these samples. This suggests that at d28, cells from these animals are able to mount an 
antigen specific response to glucosaminoglycane peptide exposure.  
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Figure 20: Flow cytometry results of peripheral blood mononuclear cells from animals sacrificed at 
D28, stimulated with a polyclonal stimulant (PMA). Cells were stained for CD8 and either 
interferone gamma, evidencing antigen specific activation (left column) or KI67, indicating unspecific 
cell proliferation only (right column). Order of plots from top to bottom: control group (pooled), 
empty vector (pooled), vector including insert (individual animals). Note that in all samples, the 
frequency of cells in the right half of the plots increases dramatically. This indicates that the cells 
used in this assay were viable and able to respond to stimulation. 
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4.5.5 Analysis of serum samples 
4.5.5.1 Detection of neutralizing antibodies in serum samples collected at euthanasia using 
virus neutralization tests 
To evaluate serum samples for the presence of neutralizing antibodies, a virus neutralization 
(VN) test was employed. To facilitate assay readout, a recombinant CDV expressing 
enhanced green fluorescent protein (rCDV-eGFP) virus previously established and 
generously provided by Jason Zhang (IAVI) was used. All samples were set up in 
quadruplicates of serial 2-fold dilutions. rCDV-eGFP virus grew slower than parental rCDV, so 
assays were incubated for 5 d before being analyzed. The lowest dilution at which none of 
the quadruplicate wells showed any more fluorescence upon microscopic examination was 
taken as the neutralizing antibody titer (Table 6 and Figure 21). The first neutralizing 
antibodies were detected in samples acquired on D14. On average, VN titers against CDV 
were 4-fold lower in serum of rCDV-SIVgag vaccinated ferrets than in that of parental rCDV 
ferrets at each time point. Both viruses however were shown to produce neutralizing 
antibodies against CDV. 
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Table 6: Detection and titration of neutralizing antibodies against distemper in ferret serum 
samples. Serum samples taken at the four euthanasia time points from the animals within each 
group were analyzed for their ability to neutralize distemper virus. Samples were set up in twofold 
dilutions for titration. The reciprocal highest dilution at which virus neutralization was achieved is 
given. No neutralization was achieved in the control group (second column). Neutralizing antibodies 
were present in all animals in both the empty vector group (third column) and the vector plus insert 
group (fourth column) from d14 onwards. Titers increased further for both groups by d21, and then 
held steady or increased by the end of the study. Titers in the vector including insert group ranged 
two dilution levels below those for the empty vector group, but mirrored their development. This 
suggests that both empty vector and vector including insert lead to the formation of neutralizing 
antibodies against the vector backbone within 14d post inoculation. 
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Figure 21: Average distemper virus neutralizing antibody responses at 7, 14, 21, and 28 days post 
vaccination. Titers determined in Table 6 above are averaged within groups, and averages plotted. 
Blue line symbolizes control group, red line empty vector group and green line vector plus insert 
group. Again it can be noted that both in empty vector and the vector plus insert groups, neutralizing 
antibodies against the distemper backbone are present from d14 onwards and continue to increase 
until the end of the study. 
 
4.5.5.2 Detection of viral genomic material in serum samples using quantitative real time – 
polymerase chain reaction 
Serum samples from all animals collected during terminal blood draws were evaluated for 
the presence of viral genome using qRT-PCR for CDV-N (Figure 22). 2 of 3 animals vaccinated 
with rCDV and one animal vaccinated with rCDV-gag produced detectable viral copy 
numbers on D21 of the study. One animal in each group had detectable genomic DNA on 
D28. Copy numbers detected were 2 to 16x the detection limit for the assay. No genomic 
copy levels above the detection limit were found at any of the earlier time points. These 
data suggest that at least in part of the animals, vaccination with both rCDV as well as rCDV-
gag results in mild to moderate viremia at those two timepoints after primary vaccination. 
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Figure 22: Numbers of genomic copies of distemper N protein RNA in serum samples taken during 
euthanasia. Samples were taken at all four euthanasia time points, but on d7 and d14 none of the 
samples contained RNA copy numbers above the detection limit. They are therefore not plotted. On 
D21 the sera of two empty vector (orange columns) and one vector including insert (yellow columns) 
inoculated animals were positive for viral genomic RNA. On D28 only one animal from each group 
tested positive. This suggests that during these two timepoints, a mild to moderate viremia is present 
in at least part of the animals. 
 
4.5.5.3 Detection of antibodies against simian immunodeficiency virus glycosaminoglycan 
protein in serum samples using western blot 
We were interested to find out if the animals had been able to develop antibodies 
recognizing the SIVgag protein (also referred to as p55), whose gene was inserted into the 
rCDV genome. In the end, development of such antibodies would be a hallmark of the 
success of this study. One would expect the mock and rCDV inoculated animals to have no 
antibodies recognizing the gag component p55. The rCDV-SIVgag inoculated animals on the 
other hand should, if they had mounted an immune response to SIVgag, possess antibodies 
recognizing p55. Since analysis by ELISA proved intractable (see chapter on ELISA 
development), we opted for a Western Blot setting. Recombinant p55 was purchased and 
used as described in the materials and methods section. To understand at which point in 
time the animals had sufficient antibodies in their sera, samples from all animals sacrificed 
on D7, 14, 21 and 28 were tested for their ability to detect the 55 kDa SIVgag protein (Figure 
23). 
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Figure 23: Western blot of serum samples to assess presence of antibodies able to bind to simian 
immunodeficiency virus glucosaminoglycane. A review of the study timeline with inoculation time 
points at d0 and d21 can be found across the top. Sera were obtained on A: D7, B: D14, C: D21 and D: 
D28 p.i. and tested for their ability to detect p55. Two gag-positive nonhuman primate sera 
stemming from an SIV infected animal were used as positive controls, giving rise to very strong 
responses (lanes +1 and +2). Serum of a 7 month-old naïve ferret (lane -) was used as a negative 
control. Subsequent lanes represent serum samples from two control animals (labelled mock), three 
animals inoculated with empty vector (labelled rCDV) and three animals inoculated with vector 
including insert (labelled rCDV-SIVgag). M: MagicMark protein standard, molecular weights given in 
kDa. Red arrows indicate running height of Simian immunodeficiency virus glucosaminoglycane. Note 
the darkened lines at the height of the red arrow in all three lanes labelled rCDv-SIVgag in blot D. 
There is also a slight darkening at the same position for the same lanes in blot C. This indicates that 
antibodies able to bind simian immunodeficiency virus glucosaminoglycane are present in serum 
samples from animals inoculated with vector including insert at d28, and likely as early as d21. 
 
As expected the positive non-human primate sera reacted strongly with p55. Laddering in 
those samples could indicate protein degradation of the commercial sample or previous 
exposure to other peptides as part of their vaccination protocol. The naïve ferret (negative 
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control) as well as the mock treated and rCDV inoculated animals showed no response to 
the antigen at any time point. The mock treated and rCDV inoculated animals served as a 
control for specificity of p55 detection and possible cross-contamination with rCDV-SIVgag 
during the study. Bands detected at 60 kDa are likely serum albumin. Analysis of the rCDV-
SIVgag inoculated animal sera showed that there are no antibodies against p55 on D7 and 
D14. Results for D21 varied and they were sometimes positive, sometimes not. This may 
indicate that the antibody titers are right around the detection limit. On D28 however these 
animals were all clearly positive for p55 antibodies. It is not clear whether the additional 
time or booster contributed to this result, but it is likely a combination of both. 
To confirm the data, the western blots were repeated using the rCDV-SIVgag inoculated 
animal sera (Figure 24). 
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Figure 24: Western blot of serum samples to assess presence of antibodies able to bind to simian 
immunodeficiency virus glucosaminoglycane. The sera from all twelve animals inoculated with 
vector including insert were tested again for their ability to recognize simian immunodeficiency virus 
glucosaminoglycane. Two glucosaminoglycane positive nonhuman primate sera from simian 
immunodeficiency virus infected animals and a rabbit polyclonal antibody recognizing the 
glucosaminoglycane were used as positive controls (lanes +1, +2 and +3, respectively).  Serum of a 7 
month-old naïve ferret (lane -) was used as a negative control. Three samples each obtained at d7, 
d14, d21 and d28 are then plotted in sequence and labelled accordingly. M: MagicMark protein 
standard, molecular weights given in kDa. Red arrow indicates running height of glucosaminoglycane. 
Note again the darkened lines at level of the red arrow for the d28 samples, as well as the faint 
darkening at the same level for samples obtained at d21. This indicates that antibodies able to bind 
simian immunodeficiency virus glucosaminoglycane are present in serum samples from animals 
inoculated with vector including insert at d28, and likely as early as d21. 
 
In this repeat assay it could again be shown that a robust (with respect to this assay) 
antibody titer is present after D21 (in the D28 samples). It could therefore be demonstrated 
that by D28, antibodies reactive to SIVgag p55 are present in ferret serum when immunized 
intranasally with rCDV-SIVgag. 
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4.6 Development of enzyme-linked immunosorbent assays for the detection 
and quantification of antibodies in ferret blood samples 
 
To be able to quantify the humoral immune responses developed over the course of the 
studies conducted, we attempted to establish ELISAs against a set of relevant polypeptides. 
As described previously (281), the proteins most interesting with regards to development of 
antibodies against CDV are the nucleoprotein (N protein, N) and hemaglutinin (H protein, H). 
The nucleoprotein is the most abundantly expressed of all CDV proteins, and the majority of 
antibodies produced during clinical CDV infection are directed against N. These antibodies, 
while very useful for the purpose of diagnosing exposure to CDV, have very little value with 
regards to combating the infection. Antibodies directed against the H protein carry the 
strongest capability to neutralize virus particles. The presence and level of these antibodies 
therefor is indicative of the mounting of an effective immune response. 
The studies presented in this thesis employ a CDV backbone including the genetic sequence 
of the SIVgag protein. This protein is the most immunogenic of all SIV proteins, and is hence 
commonly used for the diagnosis and qualification of immune responses to an SIV infection. 
During our studies, one aim of our research was the detection and quantification of humoral 
responses directed against both the CDV proteins as well as the SIVgag insert. 
Detection of CDV antibodies is a very well established method for use with canine samples 
(278) and in-house test kits are commercially available. Literature on the use of this assay in 
ferrets and related species is very limited (278, 282). The assays described previously use 
either whole virus lysate (282) or lysate of recombinant baculovirus infected Heliothis 
virescens larvae or Sf9 insect cell culture (278). In order to be able to semi-quantify the 
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overall level of antibody production, as well as the amount of potentially neutralizing 
antibodies produced, we decided to aim to assess antibody levels to the CDV N and CDV H 
proteins separately. Both the use of virus culture lysate as well as insect cell or larvae lysate 
as antigens for an ELISA will result in a vast array of CDV- and non-CDV proteins present for 
antibody-binding, giving a high chance of unspecific binding and possibly false-positive 
results. To reduce this risk, we attempted to establish ELISA assays using purified 
recombinant N and H proteins as antigens. Detailed information on the production, 
purification as well as confirmation of identity of these proteins can be found in the 
materials and methods section, 3.4.12 and 3.4.13. ELISA assays using gag p55 as an antigen 
to assess gag specific antibody levels have previously been established in our lab for the 
main laboratory animal species. Similar protocols have also been published elsewhere (283). 
We therefor attempted to modify existing protocols to create a stable assay using ferret 
blood samples. 
The data presented in this chapter are a selection of examples of collected data only. Since 
we tested a wide variety of different conditions, and each condition was repeated several 
times, in identical settings or with minor modifications, the presentation of the complete 
data would by far exceed the limits of this thesis. Since our attempts to create functioning 
ELISA assays using ferret blood samples were not successful, the purpose of this chapter is 
not to present data collected during such assays, but instead to detail and exemplify any 
materials and conditions tested during the development phase. 
 
4.6.1 Basic assay setup 
Since purified denatured protein was used as an antigen for assay development, an indirect 
ELISA was considered the most useful method for the development of the CDV ELISA (Figure 
  100 
25). The SIVgag ELISA protocol already in use in our lab was also based on this principle. 
Briefly, the antigen, dissolved in a buffer solution, is coated directly onto the peptide-binding 
surface of the wells of ELISA plates. After an incubation period, the plates are washed to 
remove excess antigen. The sample sera as well as positive and negative controls are then 
added to the wells in serial dilutions. Incubation and wash steps are repeated. Commercially 
available, fluorochrome-labelled secondary antibodies, directed against one or more 
immunoglobulin (Ig) classes of the test species, are then added to all wells at a constant 
concentration. After incubation, the plates are again washed, and fluorochrome-specific 
substrate is added, which will cause development of fluorochrome-specific colour, 
dependent on the amount of primary and therefore secondary antibody bound to the 
antigen. The colour intensity is detected using a plate reader and converted into optical 
density (OD) units, which can then be used to plot the results of the assay and determine 
antibody titers. 
 
Figure 25: Schematic representation of the most common types of ELISA. An indirect ELISA was 
used in this study. 
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4.6.2 Development of an enzyme linked immunosorbent assay to detect and 
quantify antibodies against distemper N protein in serum samples 
4.6.2.1 Antigen production 
We produced purified proteins for use as antigen to minimize the likelihood of unspecific 
and false-positive binding. We chose E. coli BL21-DE3 cells as an expression system since it is 
a fast, easy and reliable expression system and has previously been used successfully for 
paramyxovirus N proteins (279, 280) as well as for several other proteins within our lab. 
Expression in eukaryotic cells in order to stay close to the natural mechanism of N protein 
production was attempted, however, the protein proved to be severely toxic to eukaryotic 
cell lines. We initially attempted to express the protein in its native form. This however 
resulted in consistent precipitation of unpurified product, due to the large size of the protein 
(58 kDa + 12 kDa His6-tag), and the fact that in vivo N protein will self-aggregate to form the 
nucleocapsid complex with other CDV proteins. To circumvent this issue, we decided to 
overexpress the protein in cytoplasmic inclusion bodies, from where it can then be purified. 
In the process of cell lysis and protein purification, the inclusion bodies are dissolved 
through the use of buffers containing 8 M Urea. High urea content denatures and linearizes 
the protein, hence maintaining it in solution. Steps to refold the protein into its natural 
structure were considered, but since these processes generally produce a very low yield, and 
linearized protein will likely result in making smaller epitopes easily accessible for antibody 
binding, this step was not taken. 
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Influence of different plates 
Based on the large size of the N protein and the presence of numerous primary amines in its 
sequence, two plates where chosen for comparison. Corning Costar 3690 High-binding 
96well clear polystyrene plates are designed to bind proteins larger than 10 kDa possessing 
ionic and/or hydrophobic groups. This plate was routinely used for ELISAs during other 
projects in our lab. Pierce Maleic Anhydride Activated clear 96well plates are coated with 
maleic anhydride, a compound which covalently binds amine groups in proteins and 
peptides at pH > 7. In repeat side by side comparisons running exactly the same assay 
protocol using the same reagents and buffers on both plates, Costar plates consistently 
produced higher background optical densities (ODs) for negative and stage controls, as well 
as a less clear distinction between positive and negative samples (Table 7 and Table 8). Nunc 
Maxisorp (Sigma-Aldrich) plates were also tried but gave results very similar to Costar plates. 
Maleic Anhydride plates therefor became the preferred choice for N protein ELISAs, 
although availability and cost occasionally were an issue. 
 
 
Table 7: Raw data of an enzyme-linked immunosorbant assay on a Maleic Anhydride plate. N 
protein is coated at constant dilution across the plate serving as the antigen, duplicates of 2 sera 
(rows A and B, and C and D, respectively), are diluted 2-fold across the plate, column 12 receives no 
serum and serves as background control. Secondary antibody is added to all wells at constant 
dilution. Data are given as optical density readouts. Values of a maximum of 1,1 are generally 
regarded as rather low readings. 
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Table 8: Raw data of an enzyme-linked immunosorbant assay on a Costar plate. The same assay as 
above gave slightly higher overall readouts but around 3x higher background as evidenced by the 
values in the blank wells. 
 
4.6.2.2 Confirmation of presence of antigen on the plate 
During the initial stages of assay development, one priority was to confirm the presence of 
antigen on the plate after the coating process. This was done by several means to ensure 
correct function. First, the protein used for coating still contained a His6-tag. So, the use of 
an anti-His4 and species-appropriate secondary antibody, both at constant concentrations, 
posed an elegant way of confirming antigen presence. Second, we were able to obtain a 
large quantity of serum from one CDV vaccinated ferret, which tested positive for antibodies 
to our antigen preparation using western blot and dot blot techniques. Third, commercial 
bicinchoninic acid (BCA) assay kits (Pierce) were employed to detect the amount of protein 
present on the plates. Their functionality however was limited. Examples for the use of these 
methods can be found in the figures accompanying subsequent sections (for example Table 
14 and Table 15). Finally, commercial monoclonal antibodies (mAbs) were available which 
claimed to detect CDV N protein (clone DV12-2, mouse anti-CDV N, Santa Cruz). 
Unfortunately, this antibody did not bind to the protein coated on the plate (Table 9). Before 
this, we had also attempted to use this mAB as a capture antibody, which was also 
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unsuccessful (4.6.5, Figure 70 and Table 17). Upon further research, we found that the same 
clone is marketed by other companies (for example Abd Serotec) as a general anti-CDV 
antibody, and as per their datasheets detects a variety of CDV proteins. This insufficient 
affinity and specificity caused us to abolish this mAB as a control in ELISA assays. 
 
 
Table 9: Optical density readouts of enzyme-linked immunosorbant assay using monoclonal 
antibody DV12-2 (bottom) compared with blot-confirmed positive ferret serum (top) as primary 
antibodies. Plate coated with N protein solution at a constant concentration, primaries were added 
in serial dilution as stated above, column 12 received no primary. Readouts of wells containing DV12-
2 are near identical to readouts in the blank wells. This suggests that this antibody does not bind to N 
protein and cannot be used as a positive control. 
4.6.2.3 Influence of different antigen preparation and coating conditions 
Since it was feared that the high urea content in the antigen stock might interfere with 
coating, several levels of dialyzed protein stock with urea content between 800 mM and 8 M 
were produced for evaluation. Attempts to entirely remove the urea component resulted in 
complete precipitation of the protein. The stepwise addition of sodium-dodecyl-sulfate (SDS) 
to re-solubilize the protein was successful, however the protein appeared to break down 
when in SDS-containing buffer, and the coating efficiency decreased to below the level of 
urea-based buffers. The ratio of background to sample ODs was also higher in plates coated 
with antigen in SDS buffer compared with urea buffer (Table 10 and Table 11). 
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Table 10: Optical density readouts of a checkerboard assay using N protein in 
sodiumdodecylsulfate buffer. Antigen was coated in serial dilutions from row A-G. Row H received 
no antigen. Serum positive for antibodies to N protein (confirmed by western blot) was then added 
in serial dilutions across column 1-11. Column 12 received no serum. All wells received secondary 
antibody at a constant concentration. Overall readout values are low, and no definite titration can be 
seen down the columns. 
 
Table 11 Optical density readouts of a checkerboard assay using N protein in urea buffer. The same 
assay as above in with the exception of N protein being resuspended in urea buffer. Note overall 
higher readouts whilst background readouts (row H no antigen, column 12 no serum) remained 
similar. Titration of antigen down the columns is more easily visible. This antigen suspension is more 
suitable for use in subsequent assays. 
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To enhance the overall OD values obtained during ELISA assays, the effect of different 
buffers for the dilution of antigen solution on coating were evaluated. For Maleic Anhydride 
plates, alkaline buffers were required, so a Carbonate-Bicarbonate buffer at pH 9.6 was tried 
first. As an alternative, PBS pH 7.4 was employed. Since the N protein had a tendency to 
precipitate in these buffers during coating, Costar plates were additionally coated using 500 
mM NaCl and 20 mM Tris-aminomethane (Tris). Since Tris competes with the N protein for 
binding to the Maleic Anhydride plate, its use with those plates is not recommended. The 
condition was however still included in our evaluation. 
In order to obtain more accurate information about the amounts of antigen actually present 
after coating under these different conditions, a bicinchoninic acid (BCA) assay (Pierce) was 
performed for each. This assay measures protein concentrations using a colorimetric 
method. Results of this assay are again given as OD after readout at 562 nm. The results can 
then be compared to a standard curve prepared from known amounts of protein to obtain 
information about the exact amount of protein present. For our purpose it was generally 
sufficient to identify which conditions yielded the highest ODs and therefore highest amount 
of protein on the plate. A bovine serum albumin (BSA) standard curve for the two different 
plates was established alongside the assay, using known amounts of protein for coating. 
Data from BCA assays evaluating the different coating buffers and conditions are given 
below (Table 12, Table 13, Table 14 and Table 15). 
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Table 12: Bovine serum albumin standard assay using known amounts of albumin coated on a 
Malein-Anhydride plate, comparing two different buffers used during coating. Note the near-
identical values between carbonate-bicarbonate buffer (rows C and D) and Tris-NaCl buffer (rows A 
and B). None of these buffers helps to bind more or less protein on the plate than the other 
 
 
Table 13: Bovine serum albumin standard assay using known amounts of albumin coated on a 
Costar plate, comparing two different buffers used during coating. Readouts between buffers were 
again very similar. 
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Table 14: Bicinchoninic acid assay of N protein coated in serial dilutions onto a Malein Anhydride 
plate to determine amount of protein present on the plate after coating. Protein resuspended in 
buffer containing sodiumdodecylsulfate or urea, and coated in buffer containing carbonate-
bicarbonate or Tris-NaCl. Note in particular the high readout values and visible titration across 
dilutions for N protein resuspended in urea and coated in carbonate-bicarbonate buffer (rows 1 and 
2). This condition proved most successful for coating antigen onto the plate. 
 
 
Table 15: Bicinchoninic acid assay of N protein coated in serial dilutions onto a Costar plate to 
determine amount of protein present on the plate after coating. Protein resuspended in buffer 
containing sodiumdodecylsulfate or urea, and coated in buffer containing carbonate-bicarbonate or 
Tris-NaCl. Note in particular the high readout values and visible titration across dilutions for N 
protein resuspended in urea and coated in carbonate-bicarbonate buffer (rows 1 and 2). Values for 
this condition were still significantly lower on a Costar than on a Malein Anhydride Plate, indicating 
that coating was not as efficient. 
 
As noted previously, coating with N protein dissolved in SDS buffer resulted in overall lower 
ODs, with background levels playing a larger part, regardless of the plate type used. Using N 
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protein in urea buffer, overall ODs were higher and background slightly lower using Maleic 
Anhydride plates. On both Costar and Maleic Anhydride plates, using N protein in urea 
buffer, and diluting in carbonate-bicarbonate buffer when coating, resulted in highest ODs.  
To further optimize coating conditions, we compared results after coating, using buffer pre-
warmed to 40 °C versus buffer at room temperature. Plates were left at room temperature 
for 1 h after coating and then placed in the fridge overnight in either case. The results of this 
process were inconsistent despite repeating the same conditions with the same samples. 
There did not appear to be any benefit from warming the coating buffer. 
In summary, the most efficient coating conditions were found to be the use Maleic 
Anhydride Plates and N protein in urea buffer, diluted in carbonate-bicarbonate buffer for 
coating. 
4.6.2.4 Influence of using different coating dilutions 
Most suitable dilutions of antigen for coating were determined using checkerboard 
titrations, which employ serial dilutions of both antigen and primary antibody in 
perpendicular directions. That is, antigen will be serially diluted down the rows of the plate, 
and serum across the columns of the plate, or vice versa. This helps to determine the 
optimal combination of dilutions. Repeated checkerboard assays consistently showed an 
antigen dilution of 1 : 20 to 1 : 40 gave the best results (Figure 26 and Figure 27). Using these 
dilutions, ODs were highest at lower dilutions of serum, titration of serum samples was 
steady, and values within multiples of the same samples were consistent. Dilutions both 
lower and higher than 1:20 - 1:40 were less consistent and produced less valuable titration 
curves.  
A dilution of 1 : 20 was slightly more consistent than 1 : 40, and since supply of antigen was 
not an issue, this dilution was used. 
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Figure 26: N protein coating conditions, low dilutions. Checkerboard titration of 1 : 10, 1 : 20 and 1 : 
40 dilutions of N protein for coating, paired with serial 2-fold dilutions of distemper N-positive ferret 
serum (x-axis). Y-axis denotes readouts generated. Note the higher variation of values for lower 
serum dilutions for N 1 : 10. 
 
Figure 27: N protein coating conditions, higher dilutions. Checkerboard titration of 1 : 20, 1 : 80, and 
1 : 1600 dilutions of N protein for coating, paired with serial 2-fold dilutions of distemper N-positive 
ferret serum (x-axis). Y-axis denotes readouts generated. Note the overall lower readouts and 
significantly increased variation between duplicates compared to lower dilutions. 
4.6.2.5 Influence of using different blocking conditions 
In order to improve background values and increase specificity of the assay, various methods 
of blocking were evaluated using plates coated with a 1 : 20 dilution of N protein and serial 
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ODs compared to blocking with 3 % BSA in PBS which is a standard blocking regime, but 
increased background values by 200 – 250 %. The use of both goat serum and 10 % dry milk 
in PBS (w/v) reduced background values to 20 % and 30 % of BSA blocked plates, 
respectively, but also resulted in much lower overall OD values and a rapid drop of serum 
OD values, which would lead to much lower titers. A limited number of test runs performed 
during this study also reduced the differentiation between positive and negative samples, 
with ODs at starting dilutions of serum samples ranging around 1.5 for positive and 0.6 - 0.7 
for negative samples when blocking with BSA (Figure 28, Figure 29 and Figure 30); and 
changing to 1.0 and 0.7 - 0.8 for blocking with dry milk in PBS, respectively. While blocking 
with goat serum kept negative sample ODs at about 50 % of positive sample values, goat 
serum was an important negative control agent during the development of this assay, and 
was therefore not used for blocking. 
 
Figure 28: Comparison of blocking using bovine serum albumin or rabbit serum. Graph for assay 
readouts comparing the use of 3% albumin in phosphate buffered saline versus plain rabbit serum 
for blocking. N protein was coated in constant 1 : 20 dilution, the primary antibody used was 
distemper N positive ferret serum in serial 2fold dilutions (x-axis). Y-axis denotes readout values. 
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Figure 29: Comparison of blocking using bovine serum albumin or goat serum. Graph for assay 
readouts comparing the use of 3% albumin in phosphate buffered saline versus plain goat serum for 
blocking. N protein was coated in constant 1 : 20 dilution, the primary antibody used was distemper 
N positive ferret serum in serial 2fold dilutions (x-axis). Y-axis denotes readout values. Note generally 
lower readouts and faster decrease of values when blocking with goat serum. 
 
Figure 30: Comparison of blocking using bovine serum albumin or a 10% dry milk solution. Graph 
for assay readouts comparing the use of 3% albumin in phosphate buffered saline versus a 10% 
solution of dry milk in phosphate buffered saline for blocking. N protein was coated in constant 1 : 20 
dilution, the primary antibody used was distemper N positive ferret serum in serial 2fold dilutions (x-
axis). Y-axis denotes readout values. Note generally lower readouts with high variability in lower 
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4.6.2.6 Influence of primary antibodies 
Primary antibodies in an indirect ELISA are responsible for binding to and detecting the 
antigen on the plate. Serum samples to be tested for certain antibodies are employed as 
primaries; as are specific antibodies used as controls. 
 
4.6.2.6.1 Effects of using different control primaries: 
A commercially available mouse anti-HIS antibody was used as a control primary to confirm 
availability of N protein for detection, since the protein carries a HIS tag. 
Below is a graph of ODs produced when coating various dilutions of N protein and detecting 
the protein with anti-HIS antibody (Figure 31). 
 
 
Figure 31: Use of mouse anti-HIS antibody as a control primary. Average readouts of various 
dilutions of N protein (x-axis) were detected with a constant concentration of mouse anti-HIS 
antibody as a primary. Secondary antibody used was an anti-mouse IgG. “Blank” wells were coated 
but did not receive primary antibody. This antibody works best at a dilution of 1:100 for the purpose 
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A monoclonal antibody stated to be directed against CDV N protein was employed as a 
control primary to further confirm the presence of N protein on the plate. Problems with the 
use of this antibody have been outlined above (see 4.6.2.2 “Confirmation of presence of 
antigen on the plate”). 
 
4.6.2.7 Determination of suitable dilution of serum samples as primaries 
The most appropriate starting dilution for sera was determined using checkerboard 
titrations (Table 10 and Table 11). 2-fold serial dilutions were performed across the plate in 
order to get accurate titration results. Due to overall consistently low ODs during assay 
development, we decided to use only a low starting dilution. The use of serum at starting 
dilutions of 1 : 10 was discussed, but due to the limited availability and very small volume of 
samples it was decided to only use this dilution if absolutely necessary. Taking into account 
the small differences in ODs between 1 : 8 and 1 : 32 dilutions tested, we decided to use a 
serum starting dilution of 1 : 20 for assays unless otherwise required.  
Had assay results suggested that the titer of test samples was higher than what was covered 
using this setup, either the starting dilution or dilution factor across the plate would have 
been increased to cover a larger range of titers. Samples were diluted in PBS with 0.02 % 
Tween (v/v). 
 
4.6.2.7.1 Controls using positive and negative ferret serum 
We were able to acquire sera of both CDV vaccinated as well as CDV naïve ferrets for use as 
control sera for antibody detection (Triple F Farms). To ensure assay consistency, we aimed 
to use samples of the same serum batches as controls throughout the assays. Positivity or 
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negativity of the sera were confirmed using dot blot assays, which involve placing a dot of 
the protein solution in question onto a nitrocellulose membrane, and then continuing with 
blocking, washing, and detection steps as described for western blots (Figure 32). We 
employed the antigen solution used for coating, and added samples of the positive and 
negative control sera for detection. Bound antibodies were subsequently detected with HRP-
labeled anti-ferret Ig, following the protocol for western blots. 
 
 
Figure 32: Dot blot assay to confirm the presence of anti-N antibodies in ferret serum. Results of 
dot blots of serum reported to be positive for distemper N protein antibodies (top) alongside positive 
control using anti-HIS antibody as primary (bottom). Both dots gave positive readouts indicating the 
presence of antibodies against distemper N protein. 
 
Ferret sera thus confirmed to either contain or be free from antibodies against CDV N 
protein were subsequently used to determine the ability of the tested setups to discriminate 
between positive and negative samples.  
We had obtained a large volume of serum from a terminal bleed of a CDV vaccinated ferret, 
which was confirmed by dot blot to contain antibodies to CDV proteins. Aliquots of this 
particular serum sample were used as a positive control in most subsequent ELISA assays, to 
ensure comparability of results (Figure 33). 
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Figure 33: Comparison of negative versus positive ferret serum during enzyme-linked 
immunosorbant assay. Plot of readouts of negative (blue, red, green and purple lines) versus 
positive (light blue and orange lines) ferret sera on a plate coated with distemper N protein. A 
polyclonal anti-ferret IgG served as the secondary antibody. Goat serum was used as a negative 
primary control (dark blue and burgundy lines). The difference between the negative control and 
importantly the negative serum and the positive serum is obvious until a 1:640 dilution is reached. 
 
4.6.2.7.2 Controls using rabbit serum 
During the development of the ELISA assay, we frequently encountered low overall OD 
values with only moderate titration curves visible, and no clear distinction between known-
positive and known-negative samples.  
To exclude the possibility of components of the ferret serum binding unspecifically, we 
decided to employ serum of an unrelated species, not susceptible to CDV or related viruses, 
as a control. Since rabbit serum was readily available in a large enough volume from one 
animal, and since rabbits are well known for their ability to quickly mount antibodies in large 
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Figure 34: Use of rabbit serum as a control for unspecific binding in an enzyme-linked 
immunosorbant assay using distemper N protein. Rabbit serum (red and blue lines) was tested 
against a known negative (orange and light blue lines, running on top of each other) and a known 
positive (green and purple lines) ferret serum to evaluate the use of rabbit serum as anon-related 
negative control. Unfortunately, these trials demonstrated a considerable reactivity of naïve rabbit 
serum to the CDV N protein. ODs especially in low dilutions were unacceptably high for a non–
related negative control, and titration was evident, indicating that serum components were 
responsible for creating the signal. 
 
4.6.2.7.3 Controls using nonhuman primate serum 
Nonhuman primate serum was originally employed as a positive and negative control in the 
development of gag ELISAs. Once we discovered the results obtained when using rabbit 
serum and anti-rabbit secondaries, we decided to assess nonhuman primate sera for their 
response to CDV proteins as well. The interest in evaluating NHP sera in CDV ELISAs was 
increased further due to a frequently debated antigenic relationship between measles virus 
– which the majority of NHP colonies are being vaccinated against - and CDV. NHP serum 
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Figure 35: Use of rabbit serum as a control for unspecific binding in an enzyme-linked 
immunosorbant assay using distemper N protein. Nonhuman primate serum (teal line) was tested 
against a known negative (purple and green lines, running on top of each other) and a known 
positive (red and blue lines) ferret serum to evaluate the use of rabbit serum as a non-related 
negative control, nonhuman primate serum gave readouts and titration curves similar to those of 
distemper negative ferret serum. Again, the presence of a titration curve suggests that serum 
components were responsible for this reaction.  
 
4.6.2.7.4 Controls using goat serum 
Goat serum was employed as a negative control since the secondary antibody that was 
selected for use in ELISA assays is derived from goat serum. So, in addition to a “no serum” 
blank control, this allowed for a second check of unspecific binding of the secondary.  
The use of goat serum as a primary in connection with an anti-ferret secondary served the 
second purpose of controlling for non-species specific binding and hence false positive 
detection of our secondary. 
Since this combination consistently provided ODs equivalent to zero detection, it was 
included as a routine negative assay control in the ELISA development. See Figure 33 and 
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4.6.2.7.5 Effects of using plasma versus serum 
Upon noticing the consistent difficulty with unspecifically high ODs during the assay 
development, we evaluated the use of heat-inactivated serum as well as plasma compared 
to plain serum for use as primary antibody source (Figure 36). 
 
Figure 36: Comparison of readouts for plasma, serum and heat-inactivated serum (serum HI) from 
the same animal in an enzyme-linked immunosorbant assay. This animal was confirmed to be 
distemper N positive in a previous assay. (Plasma red and blue lines, Serum green and purple lines, 
Heat-inactivated serum teal and orange lines). Goat serum with anti-ferret secondary served as a 
negative assay control (dark blue and burgundy lines). This combination gave suitably low readouts. 
Heat-inactivated Serum resulted in the highest readouts and low variability, but also comparably high 
background. Plasma demonstrated very high variability. 
 
The comparison of these three different conditions showed that for N protein ELISAs, heat 
inactivated serum produced the highest ODs. It also however produced the highest 
background. Plasma demonstrated a very high intra-assay variation.  
While the serum samples in this particular assay showed some disturbance in the lower 
dilutions, serum from this same animal was routinely used as a positive control for N protein 
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for examples, where the same serum was used as positive control. The protocol used for this 
particular assay was the same as was routinely used during later stages of assay 
development. What caused the irregularities of the serum titration curves is unclear, but 
symptomatic for the process of developing this assay. 
 
4.6.2.8 Fluorochrome based detection of bound primary antibody by secondary antibodies 
4.6.2.8.1 Effects of different secondaries tested 
During assay development, we tested several secondary antibodies that were described to 
be anti-ferret secondaries, or directed against related species but crossreactive with ferret 
Igs. Initially, we had planned to create a repertoire of anti-ferret secondaries labelled with a 
variety of fluorochromes, so that we could use them in various antibody assays, and in 
parallel if required. In order to achieve this, we ordered plain anti-ferret IgG, IgM and IgA 
(KPL) and conjugated them with various fluorochromes using DyLight antibody conjugation 
kits (Pierce) and following manufacturer’s instructions. However, when employed in an ELISA 




Table 16: Readouts of enzyme-linked immunosorbant assay using DyeLight conjugated secondary 
antibodies. Several different dilutions of N protein (vertical index) and 2-fold serial dilutions of ferret 
serum (horizontal index) were used and detected with a constant concentration of DyLight 493 – 
conjugated anti-ferret IgG. This secondary did not function. 
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We then proceeded to test various commercially available pre-labeled secondary antibodies. 
Each antibody was tested at the low end and the high end of their recommended dilution 
ranges. Secondaries were first evaluated for general function using our so far established 
standard setup (antigen diluted 1 : 20, and the standard positive control serum applied in 
serial 2-fold dilutions starting at 1 : 40). We then tested the lowest level of detection for 
each antibody by using the same serum at dilutions starting from 1 : 100. Subsequently, 
secondary antibodies were evaluated for consistency of detection by running quadruplicates 
of the same assay using our standard positive control serum. Finally, the secondaries were 
tested for their ability to differentiate the standard known-positive from a known-negative 
serum. 
Commercially available secondaries assessed included: Alkaline phosphatase (AP) 
conjugated anti –ferret IgG by Rockland, KPL and Lifespan; horseradish peroxidase (HRP) 
conjugated anti – ferret IgG by KPL, Lifespan, Acris, Genetex, Novus and Bethyl; as well as 
HRP conjugated IgM and IgG/IgA/IgM, both by Acris (Figure 37, Figure 38, Figure 39, Figure 40 
and Figure 41). 
 
It became evident very quickly that AP conjugated secondaries did not give any meaningful 
OD readouts, while most HRP conjugated sets gave convincingly high OD’s in identical 
setups. Ultimately, we had determined two equally well performing secondaries, and chose 
to use the slightly less expensive one of the two as our routine secondary anti-ferret 
antibody. 
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Figure 37: Readouts of enzyme-linked immunosorbant assay using KPL anti-ferret IgG, alkaline 
phosphatase conjugated, as a secondary antibody. Functional evaluation of an AP conjugated anti-
ferret IgG (KPL) against N protein and CDV N positive ferret serum, two different dilutions, 1 : 100 
(red, blue and green lines) and 1 : 500 (purple, light blue and orange lines), as suggested by the 
manufacturer. A row not receiving secondary was used as a negative control (dark blue line). This 
secondary produced rather low overall readouts.  
 
 
Figure 38: No serum control, KPL anti-ferret IgG, alkaline phosphatase conjugated. The same 
secondary as above (KPL) on wells with antigen only but no serum, to establish background values for 
no secondary, secondary at 1 : 100 dilution and secondary at 1 : 500 dilution. Background values for 
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Figure 39: Functional evaluation of a Bethyl Labs horseradish peroxidase conjugated anti-ferret 
IgG. This antibody was tested as a secondary antibody in an enzyme-linked immunosorbant assay 
using distemper N protein as the antigen and distemper N positive ferret serum as a primary. Two 
different dilutions, 1 : 10,000 (blue, red and green lines) and 1 : 100,000 (purple, teal and orange 
lines), were evaluated as suggested by the manufacturer. A row without secondary was used as a 
negative control (dark blue line). The 1 : 10, 000 dilution resulted in good readout values and an 
easily visible titration. 
 
Figure 40: No serum control assay using Bethyl horseradish peroxidase conjugated anti-ferret IgG. 
Same secondary as above (Bethyl) on wells with antigen only but no serum, to establish background 
values for no secondary, secondary at 1 : 10,000 dilution and secondary at 1 : 100,000 dilution. While 
the 1 : 10, 000 dilution resulted in background values more than twice as high as the 1 : 100, 000 
dilution, the background still only accounted for about 10% of the maximum readout values reached 
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Figure 41: Direct comparison of horseradish peroxidase-conjugated anti-ferret IgG from Bethyl (top 
graph) and Novus (bottom graph). Distemper N protein positive (green line) and negative (red and 
blue line) samples were used for this enyzme-linked Immunosorbant assay using distemper N protein 
as antigen. The secondary antibodies were both used at a dilution of 1 : 10,000. A comparison was 
made with regards do overall readouts, discrimination of positive and negative samples, and “no 
serum” background readouts. Note the near-identical results for both secondaries. 
 
When evaluating the above figures, it can be noted that, while both the KPL and the Bethyl 
antibody produce similar titer curves, the ODs achieved are very different (0.5 to 1.8 
maximum, respectively). This has a strong effect on the ability of the antibodies to 







1:40 1:80 1:160 1:320 1:640 1:1280 1:2560 1:5120 1:10240 1:20480 1:40960 1:81920neg	serum neg	serum pos	serum no	serum
  125 
While the antibody made by KPL numerically produces lower background (0.1 compared to 
0.18, respectively), it does account for a higher percentage of total maximum OD (25% 
compared to 10% respectively). These background values are still very high, but likely not 
solely due to the secondary antibody, since this problem recurred consistently to various 
degrees during the entire process of CDV N ELISA development. 
 
Since IgG antibodies are commonly only produced in an established infection, we also 
assessed secondaries directed against ferret IgM or ferret IgM/A/G, to have the option to 
confirm the status of infection early on after vaccination. These were only available to us 
produced by Acris. Based on our experience with anti-IgG secondaries, we chose to evaluate 
HRP-conjugated sets (Figure 42, Figure 43, Figure 44 and Figure 45). 
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Figure 42: Test assay using an anti-ferret IgM antibody at a 1 : 10,000 dilution. Enzyme-linked 
immunosorbant assay using positive (blue, red, green and purple lines) and negative (teal and 
orange lines) serum, as well as goat serum as an assay control, with goat anti-ferret IgM (Acris), 
dilution 1 : 10,000 (light blue and pink lines). Note the lack of distinction between positive and 
negative samples especially at low primary dilutions. From a dilution of primary of 1 : 80 and 
upwards, distinction becomes much more evident. Variation between the positive samples (all using 
the same serum) is considerable. 
 
Figure 43: Test assay using the same anti-ferret IgM antibody at a 1 : 50,000 dilution. Enzyme-
linked immunosorbant assay using positive (blue, red, green and purple lines) and negative (teal and 
orange lines) serum, as well as goat serum as an assay control, with goat anti-ferret IgM (Acris), 
dilution 1 : 50,000 (light blue and pink lines). Distinction of positive and negative samples is a lot 
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This secondary does show significant intra-assay variability especially at lower serum 
dilutions, but is still able to discriminate between positive and negative sera in an ELISA for 
CDV N antibodies, if used at the higher dilution of 1 : 50,000. 
 
Figure 44: Test assay using an anti-ferret IgM/G/A antibody at a 1 : 10,000 dilution. Enzyme-linked 
immunosorbant assay against distemper N protein using positive (blue, red, green and purple lines) 
and negative (teal and orange lines) serum, as well as goat serum as an assay control, with goat anti-
ferret IgM/G/A (Acris), dilution 1 : 10,000 (light blue and pink lines). This secondary provides 
acceptable distinction between positive and negative samples for the lower half of primary dilutions, 
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Figure 45: Test assay using an anti-ferret IgM/G/A antibody at a 1 : 50,000 dilution. Enzyme-linked 
immunosorbant assay against distemper N protein using positive (blue, red, green and purple lines) 
and negative (teal and orange lines) serum, as well as goat serum as an assay control, with goat anti-
ferret IgM/G/A (Acris), dilution 1 : 50,000 (light blue and pink lines). Distinction between positive and 
negative samples is present for low dilutions of primary but fades very quickly, and overall readout 
values are very low. 
 
This goat anti-ferret IgM/A/G does show an ability to differentiate between positive and 
negative sera, particularly at lower serum dilutions, but titration curves approach each other 
very quickly, which would make differentiation of positive and negative sera based on titer 
impossible. 
 
In summary two of the antibodies tested, HRP-conjugated anti-ferret IgG made by Bethyl 
and Novus, consistently resulted in near identical results of equally high quality. A direct 
comparison of the two during the same assay can be found in Figure 41. Note near identical 
starting ODs, titer curves and background values.  
These antibodies were the most suitable anti-IgG secondaries. Since the antibody made by 
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IgG assays. The HRP conjugated anti-ferret IgM by Acris also provided useful results and was 
occasionally employed to attempt to detect antibodies in the early stages post vaccination. 
 
4.6.2.9 Alternative strategies to investigate and reduce unspecific binding 
In order to shed light on the reasons behind the significant amount of unspecific binding and 
variability occurring throughout the assay development, and even with unrelated, CDV naïve 
serum samples, we performed several control assays using alternative antigen preparations 
and pretreated serum samples to assess the role plaid by accompanying proteins in the 
cause of unspecific binding. 
 
4.6.2.9.1 Effect of using “mock protein” from empty bacterial vectors as coating antigen 
To assess the possibility of serum antibodies reacting to any substances carried into the 
antigen preparation during the production and purification process, we performed a full 
transformation, production and purification process using the plasmid pLys we had 
employed for cloning and expression, but without any insert. The plasmid and transformed 
BL21 cells were treated exactly as the ones containing the genomic information for the CDV 
N protein, and incubation, harvest and purification of mock protein also followed the exact 
protocol employed for N protein production. The eluate was kept in the same buffer and 
used under the same conditions as the N protein used as an antigen (Figure 46). 
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Figure 46: Coating with N protein versus a mock protein preparation using empty plasmid pLys to 
assess possible reasons for unspecific binding. Comparison of assays using identical serum samples 
(standard positive control) and secondaries, run on plates coated with N protein (red and blue lines) 
or a mock-preparation using plasmid pLys (green and purple lines). Although the background noise 
resulting from the preparation from the empty plasmid gives significant readout values for the 
lowest serum dilutions, it quickly reaches “blank” values and should not influence readout values in 
actual assays. 
The data obtained in this experiment suggest that while unspecific binding to substances in 
the mock-preparation does contribute significantly to ODs formed at lower serum dilutions, 
this effect disappears fairly rapidly, and should not influence the results of titer 
determination or discrimination of positive versus negative sera. It also does not appear to 
contribute significantly to high background ODs, since blank values are equivalent to those 
gained when plates filled with plain ddH2O are measured. 
 
4.6.2.9.2 Effect of attempting to reduce unspecific binding by pre-absorbtion of serum samples 
against bovine serum albumin beads 
Since plates were routinely blocked using BSA, we questioned whether the unspecific and 
variable binding and relatively high background we observed could be due to serum samples 
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sepharose beads (GE Healthcare) following the manufacturer’s instructions, and pre-
absorbed serum samples with those beads prior to using them in an ELISA. Any serum 
components binding to BSA should this way remain bound to the beads, and the post-
absorption serum should not show any unspecific binding with the blocking agent during the 
ELISA (Figure 47). 
 
 
Figure 47: Enzyme-linked immunosorbant assay using plain serum and serum pre-absorbed with 
bovine serum albumin beads in an attempt to reduce unspecific binding. N protein was used as 
antigen, and the same known N-positive serum was used in serial dilutions in plain (red and blue 
lines) or pre-absorbed (green and purple lines) form to attempt to remove unspecific signal. There is 
no visible difference between the two conditions. 
 
Incubating serum samples with BSA-coupled sepharose beads prior to use within the routine 
ELISA protocol did not make a noticeable difference to the resulting ODs or background 
values. It can hence be concluded that unspecific binding to the blocking agent is not the 
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4.6.2.9.3 Effect of attempting to reduce unspecific binding by pr-eabsorbtion of serum samples 
against bacterial lipopolysaccharide 
Since the protein employed as antigen during the ELISA development process was derived 
from bacterial lysate, it was questioned if unspecific binding of serum components to 
bacterial LPS might be a cause for the high background values and variability of this assay. So 
a second batch of sepharose beads was coupled to LPS (Sigma-Aldrich), and serum samples 
were again incubated with the coupled beads prior to use in CDV N protein ELISA (Figure 48). 
 
 
Figure 48: Enzyme-linked immunosorbant assay using plain serum and serum pre-absorbed with 
beads coated with bacterial lipopolysaccharide in an attempt to reduce unspecific binding. N 
protein was used as antigen, and the same known N-positive serum was used in serial dilutions in 
plain (red and blue lines) or pre-absorbed (green and purple lines) form to attempt to remove 
unspecific signal. There is no visible difference between the two conditions. 
 
To further explore the possible influence of LPS on serum ODs, we also used LPS at a 
concentration of 10 ug / well as coating antigen, replacing N protein in the routine ELISA 
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Figure 49: Assay using N protein positive serum used on a plate coated with either N protein or 
bacterial lipopolysaccharide to evaluate the source of unspecific signal. Comparison of readouts 
achieved when running the standard positive control serum on a plate coated with distemper N 
protein (red and blue lines) or with bacterial lipopolysaccharide (green and purple lines). There is a 
very clear distinction between the two conditions, indicating that unspecific binding against bacterial 
lipopolysaccharide is not an issue.  
 
Pre-treatment of sera with LPS-coupled sepharose beads did not result in any reduction of 
ODs. Similarly, the use of LPS as a coating antigen did not give rise to significant ODs, and 
background values were equivalent to those of plain ddH2O. This suggests that unspecific 
binding to LPS does not play a role in causing the relatively high background ODs and 
variability encountered in developing this assay. 
 
4.6.3 Development of an enzyme-linked immunosorbant assay to detect and 
quantify antibodies against distemper H protein 
While during infection with CDV the largest percentage of antibodies produced is directed 
against CDV N, which can be used for the detection of an established infection, antibodies 
directed against the CDV H protein are of interest due to their ability to neutralize viral 
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We attempted to establish an ELISA assay for the semi-quantitative detection of antibodies 
against CDV H from ferret blood samples, with the aim to explore responses in both 
established as well as recent infections, by testing for anti-H IgG and IgM, respectively. 
 
4.6.3.1 Antigen production and preparation 
CDV H protein production in eukaryotic cells was attempted, but again likely due to its viral 
origins expression failed due to severe cytotoxicity. CDV H protein was subsequently 
expressed in E. coli BL21 DE3 cells as described previously (284). Presence and purity of the 
protein were confirmed as for N protein. 
 
4.6.3.2 Development of assay protocol and determination of suitable antigen dilutions 
Detection of antibodies against CDV H was attempted using an indirect ELISA, as described 
above (Chapter 4.6.1) and modified from Chan et al., (284). Most effective dilutions of 
coating antigen were again determined using checkerboard titrations (see Chapter 4.6.2.4 
for details). Repeated checkerboard assays showed that a dilution of 1 : 2.5 to 1 : 5 antigen 
stock : buffer slightly outperformed the other dilutions tested. While all dilutions produced 
very nice curves, a 1 : 2.5 and 1 : 5 dilution gave very slightly higher maximum ODs and the 
titration curves dropped slightly slower than the others (Figure 50 and Figure 51). In light of 
the high similarity of curves produced and in an attempt to conserve antigen, a dilution of 1 : 
5 was chosen for further assay development. The possibility of increased background and 
unspecific binding at lower dilutions was also taken into consideration. 
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Figure 50: Determining suitable concentrations of distemper H protein as a coating antigen, low 
protein dilutions. Checkerboard titration of distemper H protein diluted 1 : 2.5, 1 : 5 and 1 : 10  
against 2-fold serial dilutions of distemper positive ferret serum. Note higher readouts but also 
higher intra-assay variability of the 1 : 2.5 dilution. Also note overall low readout values. Also 
compare Fig. 50 for further data on 1 : 5 dilutions. 
 
 
Figure 51: Determining suitable concentrations of distemper H protein as a coating antigen, high 
protein dilutions. Checkerboard titration of distemper H protein diluted 1 : 5, 1 : 20 and 1 : 40  
against 2-fold serial dilutions of distemper positive ferret serum. Note slightly higher maximum 
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4.6.3.3 Determination of suitable positive and negative controls 
Within the same dot blot described in Chapter 4.6.2.7.1 we also tested serum samples from 
CDV vaccinated or naïve ferrets for their reactivity to CDV H protein. Samples shown to be 
clearly positive and clearly negative were subsequently used as positive and negative 
controls during assay development. For examples of their use, see Figure 52 here and in 
Chapter 4.6.2.8, “Secondaries”. Distinctions of positive and negative sera were clearly visible 
for lower dilutions of sera, however, titration curves approached each other quickly, making 
differentiation based on titer difficult. 
 
 
Figure 52: Evaluation of known positive versus negative ferret sera in an enzyme-linked 
immunosorbant assay using two different dilutions of distemper H protein.  Antigen dilutions used 
were 1 : 5 and 1 : 10. Goat serum was used as a negative control (blue and red lines). Positive serum 
1 : 5 teal line, 1 : 10 orange line. Negative serum 1 : 5 green line, 1 : 10 purple line. Distinction 
between positive and negative samples is visible but only in very low serum dilutions, and the overall 
readouts are very low. 
 
4.6.3.4 Determination of suitable Inter-species controls to control against unspecific binding 
To control for unspecific binding of ubiquitous serum components, serum samples of 
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employed for reasons detailed above (see Chapter 4.6.2.7). After the results of testing rabbit 
serum as a negative control cast doubt on the viability of the assay, nonhuman primate 
serum was not tested. 
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4.6.3.4.1 Effects of using rabbit serum as a control 
 
 
Figure 53: Evaluating the use of naïve rabbit serum as a negative control in distemper H protein 
enzyme-linked immunosorbant assays. Comparison of readouts for a known-positive ferret serum 
and serum of a distemper-naïve rabbit with species-specific secondaries in an assay using distemper 
H protein as the antigen. Note the y-axis maximum is 3.5 for this graph. Also note the serum from a 
distemper negative rabbit gave up to seven times higher readouts than a blot-positive ferret serum. 
Titration is also evident. Rabbit serum will not be useful as a negative control due to this high 
unspecific binding. 
 
The use of CDV naïve rabbit serum in CDV H ELISAs consistently resulted in ODs five to eight 
times higher than the CDV positive ferret control serum (Figure 53). The reasons for this are 
not known. 
 
4.6.3.4.2 Effects of using goat serum as a control 
Goat serum was again used with an anti-ferret secondary as described above (Chapter 
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Figure 54: Evaluating the use of naïve goat serum as a negative control in distemper H protein 
enzyme-linked immunosorbant assays. Comparison of readouts for a known-positive ferret serum 
and serum of a distemper-naïve goat with species-specific secondaries in an assay using distemper H 
protein as the antigen. Note the consistent near-zero readouts for the goat serum. This serum will be 
useable as a negative control. 
 
4.6.3.5 Use of serum versus heat-inactivated serum versus plasma 
As with CDV N protein, we also assessed the CDV H ELISA for differences between the use of 
serum, heat-inactivated serum or plasma as a source of primary antibodies (Figure 55). Heat-
inactivated serum produced slightly higher ODs for a known positive sample. Sera were 
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Figure 55: Comparison of readouts for plasma, serum and heat-inactivated serum (serum HI) from 
the same animal in an enzyme-linked immunosorbant assay using distemper H protein as an 
antigen. The ferret was confirmed to be distemper H positive in a previous blot assay. (Plasma red 
and blue lines, serum green and purple lines, heat-inactivated serum teal and orange lines.) Goat 
serum with anti-ferret secondary served as a negative assay control (dark blue and burgundy lines). 
This combination gave suitably low readouts. Heat-inactivated serum resulted in the highest 
readouts and low variability in higher serum dilutions. Plasma and serum showed low variability but 
much lower readouts. 
 
4.6.3.6 Comparison of different secondary antibodies 
To find the most suitable secondary antibodies, we tested all the anti-IgG secondaries 
evaluated above (Chapter 4.6.2.8) for their use in H protein ELISAs. The HRP conjugated 
goat-anti ferret IgGs made by Bethyl and Novus gave best results again, very similar to their 
behavior in CDV N ELISAs (Figure 57). Of these two brands, Novus anti-ferret IgG was chosen 
as standard secondary for economic reasons. The overall lower ODs in these assays 
compared to the CDV N assays are very likely due to the much lower amount of CDV H 
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Figure 56: Enzyme-linked immunosorbant assay against distemper H protein using Lifespan 
horseradish peroxidase conjugated secondary antibody at two dilutions. This assay employed a 
constant concentration of antigen, serial 2-fold dilutions of a known positive serum, and Lifespan 
goat anti-ferret IgG conjugated to HRP at two different dilutions as recommended by the 
manufacturer. Note the near-zero readout values for all conditions. This secondary antibody did not 
function. 
 
The secondary antibody provided by Lifespan did not recognize any ferret antibodies at all, 
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Figure 57: Direct comparison of horseradish peroxidase-conjugated anti-ferret IgG from Novus (top 
graph) and Bethyl (bottom graph). Distemper H protein at constant dilution and confirmed positive 
(green lines) and negative (blue and red lines) ferret sera in 2-fold dilutions were used for this assay. 
The secondary antibodies were both used at a dilution of 1 : 10,000 as recommended by the 
manufacturer. A row with no serum was used as a negative control (purple line). A comparison was 
made with regards do overall readouts, discrimination of positive and negative samples, and “no 
serum” background readouts. Note the near-identical results, giving good discrimination of positive 
and negative samples at lower serum dilutions, and very low background. 
 
We also assessed secondary goat anti-ferret antibodies directed against ferret IgM or ferret 
IgM/A/G (both made by Acris), to have the option to confirm the status of infection early on 
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Figure 58: Test of an anti-ferret IgM secondary antibody at a 1 : 10,000 dilution in an enzyme-
linked immunosorbant assay against distemper H protein. Blot confirmed positive (blue, red, green 
and purple lines) and negative (teal and orange lines) ferret serum were used as primaries, as well as 
goat serum as an assay control, with goat anti-ferret IgM (Acris), dilution 1 : 10,000 (light blue and 
pink lines). This secondary resulted in relatively high overall readouts and a very good distinction 
between positive and negative samples with comparably low background. It would be very useful for 
this assay. 
 
Figure 59: Test of an anti-ferret IgM secondary antibody at a 1 : 50,000 dilution in an enzyme-
linked immunosorbant assay against distemper H protein. Blot confirmed positive (blue, red, green 
and purple lines) and negative (teal and orange lines) ferret serum were used as primaries, as well as 
goat serum as an assay control, with goat anti-ferret IgM (Acris), dilution 1 : 50,000 (light blue and 
pink lines). This higher dilution of the same antibody as above resulted in acceptable distinction 
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The Acris anti ferret IgM secondary antibody in an assay directed against CDV H resulted in 
good quality ODs and low intra-assay variability while enabling discrimination of positive and 
negative sera based on titration curve, if maybe not based on titer, if used at the 1 : 10,000 
dilution. Used at 1 : 50,000 dilution, the intra-assay variability became high and overall ODs 
low, resulting in limited use of this condition. 
 
 
Figure 60: Test assay using an anti-ferret IgM/G/A antibody at a 1 : 10,000 dilution. Enzyme-linked 
immunosorbant assay against distemper H protein using positive (blue, red, green and purple lines) 
and negative (teal and orange lines) serum, as well as goat serum as an assay control, with goat anti-
ferret IgM/G/A (Acris), dilution 1 : 10,000 (light blue and pink lines). This secondary does not 
distinguish between positive and negative samples.  
 
The anti IgM/A/G antibody made by Acris was not able to discriminate positive or negative 
sera in an ass using CDV H protein. 
 
4.6.3.7 Alternative strategies to pinpoint and reduce unspecific binding 
As with CDV N protein (see Chapter 4.6.2.9), we assessed CDV H ELISAs for possible sources 
of unspecific background, by coating with a mock-preparation of the empty plasmid, which 
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values for positive serum (at this point not heat inactivated yet) used against CDV H resulting 
in typical ODs around 0.5, while the values for positive serum used against empty plasmid 
being a significant (albeit on the graph barely visible) 20% less in the region of 0.4. It also 
confirmed again the previously seen very high ODs for naïve rabbit serum, even just on a 
plate coated with a preparation made from an empty plasmid (Figure 61). 
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Figure 61: Enzyme-linked immunosorbant assay using ferret, goat and rabbit serum against a mock 
protein purification of empty plasmid pLys as an antigen, and using confirmed-positive ferret 
serum against distemper H protein as an antigen to evaluate origins of unspecific binding. Of 
particular interest is the comparison between known-positive ferret serum tested against distemper 
H protein (dark green and dark purple lines) and the same serum tested against the mock 
preparation from the empty plasmid (blue, red, green and purple lines), both using and anti-ferret 
secondary. The goat serum tested against the mock preparation with an anti-ferret secondary (teal 
and orange lines) and the rabbit serum tested against the mock preparation with an anti-rabbit 
secondary (dark blue and dark red lines) served as assay controls. Note the rabbit serum gave the 
highest readouts, indicating a strong unspecific reactivity of rabbit serum against peptides contained 
in the empty plasmid preparation. Further note the near identical graphs of both conditions using 
ferret serum. A distinction between samples tested against distemper H protein and those tested 
against the mock preparation cannot be made. This suggests that the signal obtained when using the 
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4.6.3.8 Examples of enzyme-linked immunosorbant assays against distemper H protein 
using study serum samples 
A test assay was run against the CDV H protein using serum samples gained on D0 and D7 of 
our first study. Samples from D0 were collected before inoculation, and represent naïve 
animals. Due to the short time frame of the study, we expected to likely not see IgG being 
formed yet, so samples were assessed for presence of IgM as well. See Figure 62, Figure 63 
and Figure 64 for the results. 
 
 
Figure 62: Enzyme-linked immunosorbant assay against distemper H protein using serum from a 
recombinant distemper vaccinated ferret, detecting IgG in samples obtained on d0 and d7 post 
inoculation. Serum samples from d0 (red and blue lines) and d7 (green and purple lines) were 
compared with a known-positive ferret serum sample (teal and orange lines), and a goat serum 
negative control (dark blue and burgundy lines). Note that samples obtained on d0 resulted in near-
identical readouts to samples from d7 and positive control samples. The ferrets enrolled in the study 
were previously confirmed to not possess antibodies against distemper. The d0 samples should have 
provided much lower readouts. 
 
The results of these trial runs showed surprisingly high ODs for the test samples. ODs for 
both the D0 as well as the D7 sample were near identical to the OD of the positive control 
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had previously assessed our positive control serum via dot blot and found it strongly 
positive, the assumption was that the ODs for the positive serum were correct. However, the 
exact same serum had in previous assays (see Figure 52 in Chapter 4.6.3.3 “Positive and 
negative controls”) under the same conditions resulted in ODs of around 1.0, twice as high 
as in the test assays with study samples. In the assays comparing positive and negative sera, 
it was the negative sera that presented ODs of around 0.5. Since the entire batch of positive 
control serum was aliquoted and labelled at the same time after confirming its status, and 
had still produced ODs of around 0.5 rather than 1.0 in several assays, a mix up of samples 
could be excluded. 
The use of anti-IgM secondary to analyze appearance of early-appearing IgM antibodies 
revealed a similar picture and confirmed again the variability of ODs reached by the known-
positive serum when assayed against CDV H. See Figure 63 and Figure 64 below for a 
comparison of one mock treated and one rCDV vaccinated animal, tested in the same run, 
using the exact same positive control. 
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Figure 63: Enzyme-linked immunosorbant assay against distemper H protein using d0 and d7 serum 
from a ferret vaccinated with recombinant distemper, detecting IgM. Serum samples from a ferret 
vaccinated with recombinant distemper, collected at d0 (red and blue lines) and d7 (green and 
purple lines) post vaccination, compared with results of a known-positive serum sample (teal and 
orange lines). Note again the near-identical results for all samples. Since ferrets enrolled in the study 
were previously confirmed to not possess antibodies against distemper. Samples obtained on d0 
should produce much lower readouts. 
 
Figure 64: Enzyme-linked immunosorbant assay against distemper H protein using d0 and d7 serum 
samples from a mock vaccinated control ferret and an IgM positive control, detecting IgM. Assay 
using test sera of a control ferret obtained on d0 (red and blue lines) and d7 (green and purple lines) 
as well as a known positive serum (teal and orange lines). Note readouts for positive control being 
higher than in Figs 62 and 63, while remaining readouts are very similar, despite the same control 














1:20 1:40 1:80 1:160 1:320 1:640 1:1280 1:2560 1:5120 1:10240 1:20480 BLANKMock	d0	IgM Mock	d7	IgM Ferret	(pos)	IgM
  150 
4.6.4 Development of an enzyme-linked immunosorbant assay to detect and 
quantify antibodies against simian immunodeficiency virus 
glycosaminoglycan protein 
4.6.4.1 Description of assay protocol and antigen dilutions 
SIVgag ELISAs were set up according to the standard protocol used in the lab. This protocol 
was successfully adapted for several laboratory animal species prior to the use in ferrets. It 
was also, apart from the changed antigen, identical to the protocol for detecting antibodies 
to HIVgag in sera from pre-clinical studies. 
For this protocol, Costar or Nunc Maxisorp plates were coated with SIVgag p55 protein 
diluted to 2.5 ug / mL in PBS for an hour. After washing, plates were blocked with PBS 
containing 3 % BSA (w/v) for 1 h. They were then washed and serum samples and controls 
added in serial dilutions. After incubating the plates were washed and species-specific 
labeled anti-IgG or IgM secondary antibodies were added. Plates were again incubated and 
washed, then substrate was prepared and added to all wells, and after appropriate 
development intervals, plates were read in an automated reader. 
 
4.6.4.2 Origin of antigen and monoclonal antibodies used during the assay 
The SIVp55 protein used as an antigen is a full-length recombinant protein derived from a 
baculovirus expression system and commercially available through Protein Sciences Corp. 
Occasionally, an unconjugated monoclonal antibody against a proteolytic fragment of gag 
p55, the smaller protein p27, was used as a positive control or capture antibody. This 
antibody was the mouse anti-SIV mac251 strain p27 gag mAb, clone SF8-6F5, sourced from 
Advanced Biotechnologies Inc.. 
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4.6.4.3 Determination of suitable secondary antibodies 
For ferret samples, we continued to employ the secondaries we had successfully established 
during CDV ELISA development. Secondaries for use with control sera (Nonhuman primate 
and rabbit) and monoclonal antibodies were used as recommended by the original assay 
protocol. Anti-Rhesus macaque IgG by Santa Cruz was used with nonhuman primate serum, 
and anti-rabbit IgG by Jackson was used with rabbit samples. 
 
4.6.4.4 Determination of suitable positive and negative controls 
Since no ferret sera confirmed positive for SIVgag were available to use as controls during 
assay development, we had to resort to positive controls originating from another species. 
This assay had originally been developed for use with nonhuman primate samples, and was 
very well established in this context. We were kindly provided with standardized nonhuman 
primate positive and negative control sera that were used for nonhuman primate assays 
(kindly supplied by A. Ginsberg, IAVI). In order to be able to validate results gained from 
ferret samples, we directly compared samples taken from the same animal but at different 
time points. D0 samples, taken prior to inoculation, served as the negative controls, and 
were used as a baseline to compare results of later time points of the same animal. A non-
study ferret serum was also used as a negative control. Based on experiences during CDV 
assay development, we decided to include rabbit serum and anti-rabbit secondary as an 
interspecies negative control, and goat serum with anti-ferret secondary as the standard 
zero-value control (see Chapter 4.6.2.7 for details). 
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Figure 65: Comparison of different assay controls in an enzyme-linked immunosorbant assay 
against simian immunodeficiency virus glucosaminoglycane. Serum samples employed originated 
from goat (red and blue lines), a confirmed-positive nonhuman primate (green and purple lines), a 
naïve rabbit (teal and orange lines) and a naïve ferret (dark blue and burgundy lines). Goat serum as 
a negative control and a confirmed-positive nonhuman primate serum as a positive control worked 
very well. Note however the high readouts for the naïve non-study ferret sample. This sample should 
give much lower values. There appears to be a degree of unspecific binding present. 
 
As can be seen in Figure 65, the positive control as well as both inter-species controls used in 
this assay worked very well. However, the ferret specific control, which consisted of serum 
of one unrelated, SIVgag naïve, non-study ferret, showed considerable maximum ODs and 
titration. 
4.6.4.5 Effects of using plasma versus serum versus heat-inactivated serum 
As for CDV ELISAs, we also attempted to establish which antibody source would best be used 
as a primary. This assay was established using serum, but since we had experienced two 
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Figure 66: Enzyme-linked immunosorbant assay against simian immunodeficiency virus 
glucosaminoglycane, comparing the use of plasma versus serum versus heat-inactivated serum. 
Naive ferret plasma (blue and red lines), serum (green and purple lines) and heat inactivated serum 
(teal and orange lines) were used in twofold dilutions, employing naïve goat serum as a negative 
control (light blue and pink lines) and glucosaminoglycane antibody positive nonhuman primate 
serum as a positive control (light green and light purple lines). There was no notable difference 
between the three assay conditions, but all showed high variability and overall low readouts. 
 
As seen in Figure 66, there were no major differences between the three different substrates, 
but all substrates showed a high degree of intra-assay variability, which would make it hard 
to get clear results. 
 
4.6.4.6 Exemplary assay data 
The data sets in this section serve to highlight the problems of non-reproducibility and 
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issues encountered in establishing positive and negative controls. The naïve ferret serum 
employed throughout this assay development came from an individual that was not a 
member of any of our studies, and resided at a facility that does not have access to SIV, HIV, 
or the individual immunogenic proteins thereof. In reference to Figure 68, all the data are 
repeats of the same assay, using the same conditions and reagents. Of note are the very 
varied ODs obtained for the same samples in the individual assays, the marked differences in 
titration curves between assays, and the variable degree of intra-assay variation. The OD of 
the naïve ferret negative control also continues to be at a significant level. 
 
 
Figure 67: Experimental enzyme-linked immunosorbant assay against simian imunodeficiency virus 
glucosaminoglycane. Test of our assay protocol using serum samples from two different ferrets from 
this study, taken at D7 (green and purple and teal and orange lines, respectively), one serum of a 
glucosaminoglycane antibody positive nonhuman primate as a positive control (red and blue lines), 
and a naïve ferret (dark blue and burgundy lines) as a negative control. Note the high readouts 
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Figure 68: Comparison of three repetitions of an enzyme-linked immunosorbants assay against 
simian immunodeficiency virus glucosaminoglycane. Direct comparison of three identical assays 
using the same samples taken from ferrets inoculated with vector with glucosaminoglycane insert on 
d28 post inoculation (labelled 29/F29 and 30/F30 in the graphs). Serum from one naïve ferret 
(labelled such in the graphs) as well as two rows with no serum (labelled blank in the graphs) were 
used as negative controls in each of the assays. One confirmed-positive nonhuman primate serum 
(labelled Pos in the graphs) was used as a positive control in each repetition. Identical materials and 
methods, equipment and protocols were employed for each repetition. Note the high variability in 
results for the same samples from repetition to repetition. 
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4.6.5 Crossreactivities observed 
During the development of ELISA assays using ferret samples, several unexpected 
interactions of secondary antibodies with other assay components were discovered. 
When performing checkerboard titrations to determine most suitable antigen and serum 
dilutions while using Rockland AP conjugated anti-ferret IgG as a secondary, it was notable 
that the assay resulted in unusually constant OD values for each N protein dilution, 
irrespective of the dilution factor of serum. These ODs were even maintained in the wells 
that did not contain any serum. The wells that contained no antigen consistently produced 
very similar near-zero ODs irrespective of the serum dilution. This suggests that Rockland AP 
conjugated anti-ferret IgG in fact detects CDV N protein or binds non-specifically to the 
plates (see Figure 69). 
 
Figure 69: Exemplary data of Rockland alkaline phosphatase conjugated anti-ferret IgG as a 
secondary antibody in an enzyme-linked immunosorbant assay against distemper N protein. 
Checkerboard titration assay for CDV N using various dilutions of N protein between 1 : 50 to 1 : 3200 
(individual data plots) with serial dilutions of a known-positive serum (x-axis) and a constant 
concentration of the secondary. A row with no antigen (dark red line) was used as a negative control. 
Note the absence of titration curves, as well as the OD values for “no serum” data points. Also note 
the identical results irrespective of dilution of antigen. This secondary was not useable as it 
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As an alternative strategy to overcome the issues in assay development, a capture ELISA was 
attempted to detect antibodies to CDV N protein. For that purpose, ELISA plates were 
coated with DV12-2 anti-CDV N monoclonal antibody. N protein was then added in various 
dilutions, followed by serum samples in serial dilutions. The bound antibodies would then be 
detected using AP conjugated goat anti-ferret IgG (Rockland). Again, the assay produced 
consistent, very high OD values irrespective of the dilution or even presence of serum, but 
also regardless of the dilution or even presence of N protein (see Figure 70). This suggests 
that the secondary antibody did in fact bind and detect the capture monoclonal antibody. 
 
Figure 70: Attempt to develop a capture enzyme-linked immunosorbant assay employing 
distemper N protein as the antigen being captured. Plates were coated with anti-N protein 
monoclonal antibody DV12-2. Then N protein was added in various dilutions between 1 : 1, 000 and 
1 : 10, 000 (individual plots), followed by known-positive ferret serum in serial 2-fold dilutions (x-axis) 
and secondary antibody (Rockland Alkaline phosphatase-conjugated anti-ferret IgG) at a constant 
concentration. A row not receiving antigen was included as a negative control (labelled No N 
Protein). Note the absence of titration across the different serum dilutions, as well as the absence of 
difference between plots using different amounts of N protein. Also note the high values for the no 
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Since the established protocol for an indirect ELISA for the detection of antibodies to SIV gag 
could not be transferred successfully, we attempted to develop a five stage capture ELISA for 
this purpose. The principle of this assay was as follows: 
 Plate 
 Anti-ferret IgG (Novus, unconjugated) 
 Serum samples 
 Gag p55 peptide pool (gifted from A. Ginsberg, IAVI) 
 Mouse anti-gag p27 mAB (Advanced Biotechnologies) 
 HRP-labelled goat anti-mouse IgG (Thermo) 
This assay was controlled at every stage. If the plate was coated with capture AB, it 
produced near-zero values only, if detection secondary AB was missing. It produced ODs at 
around 50% of the full setup, if anti-gag p27 Antibody was missing. Lack of serum or lack of 
gag p55 did not affect ODs. This suggested that the secondary detection antibody had 
partial, and the monoclonal anti-gag p27 even had full affinity to the capture antibody. 
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Table 17: Attempt to develop a 5-stage capture enzyme-linked immunosorbant assay using simian 
immunodeficiency virus glucosaminoglycane, raw data. Principle of this assay: anti-ferret IgG was 
coated on the plate as capture antibody. Test serum was added (labelled Fx, Fy and Fz in the table), 
then glucosaminoglycane protein, then mouse anti-p27 monoclonal AB to bind the 
glucosaminoglycane, finally the bound monoclonal is detected with Horseradish peroxidase-
conjugated goat anti-mouse IgG. Control steps employed were as follows: The top plate was coated 
with anti-ferret IgG, the bottom was plate not coated. Each plate had four controls of two columns 
each employing no glucosaminoglycane, no monoclonal antibody, no serum and no anti-mouse 
secondary. Two columns employing only glucosaminoglycane and anti-mouse secondary, and no 
other stages, were also tested. Each condition was run in quadruplicates. Wells containing no anti-
mouse secondary, no capture antibody and no anti-p27, or only glucosaminoglycane and secondary 
all resulted in near-zero readouts. Omitting the addition of serum or glucosaminoglycane did not 
reduce readout values. This suggests significant crossreactivities between the anti-mouse secondary, 
the monoclonal anti-p27 antibody and the capture antibody as well as the plate. 
 
To evaluate this further, we ran the assay without coating the plate with capture antibody. 
The empty plate was blocked and the assay continued as described. The assay still produced 
full ODs if all other components were present, but also, if serum or gag p55 were missing. 
The assay gave a strongly reduced OD, if only gag p55 and detection secondary were 
present, suggesting a mild interaction between these two components. The assay only gave 
near zero values if either detection antibody, or gag p27mAB were absent (see Table 17). This 
would likely suggest that despite the plate being blocked, anti p27 mAB and to a smaller 
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degree secondary detection antibody still bind to the plate and create very high false 
positive ODs. 
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5 Discussion 
This thesis describes the first series of in vivo studies of a novel candidate for the 
development of an HIV/SIV vaccine. A Canine distemper virus vector derived from a 
commercially available CDV Onderstepoort vaccine strain and containing the gene for the 
highly immunogenic SIVgag protein was delivered to CDV-naïve ferrets, and biosafety, 
efficacy and immunogenicity of the vaccine candidate in this highly susceptible in vivo model 
were evaluated. 
5.1 Virus growth and quantification 
The recombinant distemper virus with and without gag insert grew well in Vero cell culture. 
The insertion of foreign genomic information did not negatively affect virus replication to a 
noticeable degree; titers of rCDV-SIVgag reached 5x107 PFU, which enabled us to use one 
single virus harvest to inoculate all animals at the desired dose of 2x105 PFU. This reduced 
the possibility of variations between inoculates. Viruses used for inoculation had previously 
been sequenced and showed no alteration of protein sequence compared to the paternal 
Onderstepoort strain, which was important since the paternal strain had been shown to be 
non-pathogenic when used in ferrets (266). So the recombinant viruses used in this study 
were not expected to cause clinical distemper when administered to the ferrets. 
5.2 Screening of ferrets for pre-existing antibodies to canine distemper virus 
The ferrets used in these studies were purchased at a very young age and as per our 
requirements not vaccinated against CDV. They were housed in ventilated cages at our 
facility until they had reached an age at which maternal antibodies were expected to have 
faded. Prior to enrolling ferrets in the in vivo studies, all animals were blood sampled and 
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serum samples used in virus neutralisation tests (VNTs) to confirm the absence of antibodies 
to CDV. VNTs for all animals were negative, which indicated that none of the animals 
possessed any neutralising antibodies against CDV – maternal or otherwise – that could 
affect the immunological responses of the ferrets towards inoculation with rCDV constructs. 
5.3 Study 1 - Biosafety, biodistributrion and basic immunogenicity of the 
vaccine candidate 
The pilot study included six animals, four of which were intranasally inoculated with 2x105 
PFU rCDV-SIVgag, and two of which served as controls. Animals were monitored for clinical 
signs of CDV infection daily over the course of the seven-day study, and swabbed nasally, 
orally and rectally at 2 h, 1 d, 3 d, 4 d and 7 d post inoculation. Blood samples were taken 
alongside swab samples. 50 % of animals in each group were sacrificed on day three and day 
seven of the study, respectively. Post mortems were performed and nasal turbinates, ileum 
and mesenteric lymph nodes were harvested. This study focused on determining the safety 
and biodistribution of rCDV with the insert encoding for SIVgag when applied to a highly 
CDV-susceptible species. 
Canine distemper in ferrets is a highly virulent and often lethal disease. It commonly 
presents with high temperatures, rashes, nasal discharges, diarrhoea, weight loss and in 
later stages behavioural and neurological changes. During our study, no neurological or 
behavioural changes were noted, and none of the animals presented with any rashes, 
continuous weight loss or increased body temperature. Only individual transient cases of 
mild soft stools and minor nasal discharge were noted, which cleared up quickly without 
intervention. This demonstrated that our vaccine candidate rCDV-SIVgag did not cause 
clinical disease in ferrets, a highly susceptible species. This finding is in line with our 
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expectations, since the parental strain of the recombinant vector is a commercially available 
Onderstepoort vaccine strain with several years of excellent safety records when used in 
ferrets, and the SIVgag gene, when expressed alone, does not give rise to a pathogenic 
product. 
Swab samples of nose and rectum and tissue samples of nasal turbinates, spleen, large 
intestinal lymphnode and Peyer’s patches obtained during the study were analysed in vitro 
for the presence of infectious virus particles using plaque assays. No plaques were detected 
in any of the samples at any point of the study. This suggests that only minimal, if any, 
amounts of recombinant virus were present in the samples, and secretions of animals 
inoculated with rCDV-SIVgag did not contain sufficient amounts of recombinant virus to 
infect other systems such as tissue cultures. The samples were furthermore examined for 
the presence of genomic copies of rCDV-SIVgag using qRT-PCR.  This assay is able to detect 
genetic material of the recombinant virus even if it stems from replication defective 
particles, and will have a lower detection limit than assays based on infectivity. Two of the 
four ferrets inoculated with rCDV-SIVgag, one sacrificed on day 3 and one sacrificed on day 
7, showed genomic copies of the inoculate in all swab samples, ranging in number from 10 
to over 100 copies. Highest copy numbers were obtained in nasal swabs. One control animal 
presented with a moderate number of copies in a rectal swab collected on day 1 post 
inoculation. In light of the fact that this animal did not test positive in any other samples 
examined, this data is likely a result of post-collection cross-contamination and not a true 
finding. During qRT-PCR analysis of tissue samples, three out of four ferrets inoculated with 
rCDV-SIVgag showed presence of genomic copies of the inoculate in at least one tissue. Both 
experimental animals sacrificed on day 7 showed genomic RNA (gRNA) of the inoculate in 
the ileum, with copy numbers ranging between 104 and 105. One of the animals sacrificed on 
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day 7 also showed gRNA in the nasal turbinates, alongside one animal sacrificed at day 3. 
Copy numbers for these samples ranged from 100 to just under 1,000. Control animals were 
consistently negative for gRNA in tissue samples. 
rCDV-SIVgag was designed to be a replication-competent vector, and in previous in vitro 
assays was shown to actively replicate and induce cytopathic effects in Vero cells. Thus, we 
expected the virus to replicate in the ferrets after inoculation. Animals were inoculated 
intranasally. The presence of viral gRNA in nasal turbinates on day 3, especially in connection 
with positive nasal swabs on that day for that same animal, suggests that replication of 
recombinant virus is happening early on post vaccination at the inoculation site. A positive 
rectal swab taken prior to euthanasia in this individual, alongside positive samples of the 
ileum for both animals sacrificed on day 7 demonstrates that rCDV-SIVgag does spread 
systemically within seven days after intranasal application and is indeed able to replicate. 
Peripheral blood mononuclear cells (PBMCs) were collected from blood samples of all 
animals sacrificed on day 7, and were subjected to intracellular cytokine staining using 
monoclonal antibodies to T-cell surface marker CD8 and Interferon gamma. Samples were 
set up in triplicates, and stimulated with either SIV gag open reading frame peptide pool 
(Protein Biosciences), PMA/ionomiycin as positive control, or not at all as negative control, 
respectively, before being stained. Samples were then analysed using Flow Cytometry to 
determine numbers of CD8-positive T-cells and secretion of IFNg in response to the different 
stimulants. If the animals had already established cellular immune responses to the SIVgag 
insert within seven days, the expected result of this assay would be an increase in cells 
positive for both CD8 and IFNg, as gag-specific T cells are stimulated to expand and IFNg 
production is induced. In our analysis, there was indeed a slight increase of double-positive 
cells from animals inoculated with rCDV-SIVgag after stimulation with gag peptides 
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compared to non-stimulated samples; however, this increase was too small to allow for a 
definitive analysis. 
To summarize, in a seven-day study of ferrets inoculated intranasally with rCDV-SIVgag, the 
recombinant vector with insert did not induce any adverse reactions or signs of clinical 
disease. Systemic distribution and replication of the antigen was demonstrated, but 
cytopathic recombinant virus could not be cultured from any samples throughout the study, 
indicating that shedding of the recombinant virus was minimal and not sufficient to infect 
other systems. Cellular immune responses to gag peptides could not definitely be shown, 
but a low degree of response to stimulation after seven days was present. 
5.4 Study 2 – Replication abilities of vaccine candidates in host tissues and 
cellular and humoral immune responses 
The second study described in this thesis was designed to further evaluate the replication 
ability of the construct as well as the immunological responses generated after vaccination. 
To evaluate effects of the vector backbone versus effects of the full insert, three groups of 
animals were used. One group was inoculated with rCDV-SIVgag, one with just rCDV, and 
one was mock-inoculated with PBS. The study was extended to 28 days, with animals being 
intranasally vaccinated on d 0 and boosted again on d 21. Clinical observations were 
performed daily. Nasal and rectal swabs were obtained and temperatures controlled every 
two to three days, and weights were taken weekly. Two animals of each group were 
sacrificed every seven days. Terminal blood draws were performed prior to euthanasia. 
Nasal turbinates, mesenteric lymph nodes and Peyer’s patches were harvested for further 
analysis. 
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Over the course of the study, none of the enrolled animals ever presented with body 
temperatures outwith the normal range of 38-40 °C. Body weights remained stable during 
the study, and there was no significant difference in body weight noted between members 
of different groups. Observation for clinical signs included nasal and ocular discharge, 
diarrhoea, lethargy, behavioural or neurological abnormalities in addition to fever and 
weight loss. Of note were mild discharges and soft stools in a small number of experimental 
animals but not the mock group on day 7 and on day 25, which corresponds to four days 
post booster inoculation. Four animals that had received rCDV-SIVgag were affected over 
the course of the study, while only two animals from the rCDV group showed any clinical 
changes. These changes were not persistent. None of these animals progressed to more 
severe respiratory symptoms or manifest diarrhoea, and none of the study animals showed 
any other clinical signs linked to a CDV infection. While this may indicate that animals 
receiving rCDV-SIVgag were slightly more affected, neither rCDV nor rCDV-SIVgag caused 
clinical distemper in ferrets over the course of 28 days. 
Virus culture and titration was attempted from swab samples as well as tissue samples to 
evaluate the presence and distribution of infectious recombinant virus particles. No 
cytopathic effects indicating the presence of infectious particles were observed using any of 
the swab samples. Tissue samples obtained from Peyer’s patches and mesenteric lymph 
nodes from animals sampled on day 7 produced cytopathic effects for all animals that had 
received rCDV, and one animal that had received rCDV-SIVgag. From mesenteric lymph 
nodes 8,500 and under 500 plaques per gram tissue were generated for animals inoculated 
with rCDV and rCDV-SIVgag, respectively. For Peyer’s patches, these numbers were 12,500 
(rCDV) and under 200 (rCDV-SIVgag) plaques per gram tissue. Samples obtained from nasal 
turbinates of the same animals did not result in formation of plaques. No cytopathic effects 
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were observed for experimental animals at any of the other time points, nor at any point at 
all in mock inoculated animals. This suggests that live infectious virus particles are present in 
lymphatic tissues distant from the inoculation site one week post first inoculation, but not 
after the booster inoculation. Inoculation with rCDV resulted in higher numbers of infectious 
particles being produced than inoculation with rCDV-SIVgag, indicating that rCDV-SIVgag 
may be further attenuated than the parental strain, but still able to give rise to infectious 
particles distant from the inoculation site. Mock-inoculated animals did not show any 
evidence of infectious particles. 
Quantitative real time polymerase chain reaction (qRT-PCR) was employed to detect 
genomic copies of CDV N protein in swab and tissue samples obtained over the course of the 
study. Whilst performing the assay using rectal samples, it became evident that copies of 
genomic DNA could be detected in all samples obtained, including the samples taken from 
mock-inoculated animals. We determined the likely reason for this to be cross-
contamination caused by errors in the post-collection phase while preparing the swabs for 
subsequent assays. We therefore did not proceed to analyse the nasal swab samples that 
had been processed in the same way. Tissue samples taken from Peyer’s patches, 
mesenteric lymph nodes and nasal turbinates of terminated ferrets were processed ensuring 
strict sterility and separation between groups to avoid this issue in subsequent analyses. 
Genomic copies encoding CDV N protein were detected in significant numbers in all three 
tissues and across all time points, for both the rCDV and the rCDV-SIVgag group. Copy 
numbers consistently reached a maximum on day 7 and then proceeded to gradually 
decline. In animals inoculated with rCDV, genome numbers in all tissues demonstrated a 
slight peak on day 21, which was only present in Peyer’s patches for animals inoculated with 
rCDV-SIVgag. The animals harvested on day 21 had not received a booster inoculation. Copy 
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numbers detected were consistently higher in animals inoculated with rCDV than those 
inoculated with rCDV-SIVgag. The highest number of copies in the rCDV group was detected 
in Peyer’s patches, reaching 3.38 x 109 copies per gram on day 7; equivalent samples of 
rCDV-SIVgag inoculated animals reached a maximum of 9.16 x 105 copies per gram. Samples 
obtained from mesenteric lymph nodes resulted in the highest number of copies in the 
rCDV-SIVgag inoculated ferrets, reaching a maximum of 107 copies per gram. This was still 
lower than the equivalent samples of the rCDV treated animals reaching 9.77 x 108 copies / 
g. Samples obtained from nasal turbinates gave the lowest number of genome copies for 
both groups, resulting in a maximum of 1.83 x 107 (rCDV) and 4.44 x 104 (rCDV-SIVgag) copies 
/ g, respectively. Taken together, these findings confirm again that, while rCDV-SIVgag 
appears to be more attenuated than rCDV, both constructs are indeed able to replicate not 
only at the inoculation site, but even more so at remote lymphatic tissues, fulfilling the 
expectation that the constructs will maintain the lymphotropic characteristics of the 
parental strain. The gradual decrease of genome copies detected over the course of time 
also suggests a level of control of infection within the ferrets, likely due to the development 
of an immune response. 
Parallel to the qRT-PCR for CDV N genome, samples from animals inoculated with rCDV-
SIVgag were also analysed using qRT-PCR for SIVgag genome. The course of genomic copy 
numbers over time and between different tissues paralleled that of CDV N in this group. 
Genomic copy numbers ranged from about 0.5 to 1 orders of magnitude lower than copy 
numbers for CDV N in the same animals. The detection of genomic copies of SIVgag not only 
in nasal turbinates but also in remote lymphatic organs demonstrates that during replication 
and distribution of the vector, the insert is conserved and does not disappear. The lower 
copy numbers of SIVgag compared with CDV N suggest that likely not every replicated 
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particle retains the insert, but there are still significant numbers of SIVgag genome present 
in lymphatic tissues over the course of the study. 
Serum samples of all animals, obtained just prior to euthanasia, were also evaluated for the 
presence of viral genomes using qRT-PCR. Genomic DNA encoding for the CDV N protein 
could not be detected in any of the control animals at any time point. No copies were 
detected in the experimental groups on days 7 and 14. On day 21, genomic DNA encoding 
for CDV N was evident in two animals inoculated with rCDV, with copies numbers of 500 and 
1,200 copies / mL respectively, and in one animal inoculated with rCDV-SIVgag, where 3,250 
cppies / mL could be detected. On day 28 one animal of the rCDV group and one animal of 
the rCDV-SIVgag group presented with detectable copies of CDV N, reaching 2,150 copies / 
mL and 1,890 copies / mL respectively. This indicates that both inoculates cause a mild 
viremia in some but not all inoculated animals around day 21 to 28. 
PBMCs from blood samples obtained upon euthanasia were employed in intracellular 
cytokine staining assays to evaluate the level of cellular responses to stimulation with a 
polyclonal positive control stimulant, mock stimulation, or stimulation with SIV gag peptides. 
PBMCs were isolated from samples using Ficoll gradient separation, and subsequently 
aliquots were incubated with the described stimulants. Stimulated cells were then stained 
for T-cell surface marker CD8, cell proliferation marker Ki67, and the cytokine Interferon 
gamma (IFNg), which is released during cellular immune responses to an antigen. Samples 
were then analysed using flow cytometry. Stimulation with SIVgag peptides resulted in 0.2 - 
0.4 % increased secretion of IFNg in samples from the rCDV-SIVgag group compared to 
unstimulated samples or samples from the Mock group. The highest increases were noticed 
on day 14 and day 28 post inoculation. There was an unpredicted increase of the 
proliferation marker Ki67 in gag-stimulated samples obtained from rCDV-inoculated ferrets 
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on day 28, which can likely be attributed to a general activation of the immune system 
following the booster inoculations on day 21. That is consistent with the highest levels of 
IFNg release on day 28 for gag-stimulated samples from the rCDV-SIVgag group. 
Virus neutralisation assays were performed on serum samples of all animals collected during 
terminal blood sampling to assess the presence and levels of antibodies against CDV. 
Antibodies could not be detected at any time point in the control group, but were present in 
both the group inoculated with rCDV and the group inoculated with rCDV-SIVgag from day 
14 onwards. Titres for animals receiving rCDV were four times higher than those of animals 
receiving rCDV-SIVgag in samples taken on day 14 and 21. This correlation became less strict 
in samples taken on day 28, and titres of the majority of animals sampled on that day were 
no higher than those of animals sampled on day 21. Since different animals were sampled at 
each time point, it cannot be stated that antibody titres reach a plateau on day 21, but there 
does not appear to be a trend for significantly higher titres on day 28. While rCDV does 
appear to induce a significantly stronger humoral response towards CDV, neutralising 
antibodies to CDV are definitely present and developing at the same speed in animals 
inoculated with rCDV-SIVgag. 
Western blot assays were used to examine the same serum samples for the presence of 
antibodies to SIVgag. To this end, a commercially available SIVgag p55 protein of the size of 
55 kDa was blotted onto a nitrocellulose membrane, and serum samples from the study 
along with known positive and negative control sera were used as primary antibodies during 
the blot. The appearance of a dark band at the appropriate level of 55 kDa upon detection 
indicated the presence of antibodies to SIVgag in the sample. Controls in this assay worked 
very well and very reliably. No bands could be detected for mock-treated or rCDV inoculated 
ferrets at any time, nor for any of the rCDV-SIVgag inoculated ferrets at day 7 or 14. Bands 
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were however definitely and repeatedly present at the 55 kDa level in samples from rCDV-
SIVgag inoculated animals on day 28, and faint bands appeared in some repeats of the assay 
in samples obtained on day 21. This indicates that binding antibodies against SIV gag are 
indeed being produced in ferrets after inoculation with rCDV-SIVgag. While detection of 
antibodies on day 21 is variable, they are consistently present on day 28. 
In order to be able to quantify humoral immune responses directed towards the vector 
backbone as well as the insert, we attempted to develop ELISA assays using CDV N and H 
proteins as well as SIV gag. Antibodies directed against CDV N are most abundantly 
produced during CDV infection (285) and are routinely used for titre determination in other 
species (278, 286, 287), while those directed against CDV H have the strongest neutralising 
ability (288), which is why humoral responses to both these antigens were of interest to us. A 
detailed description of the assay development process can be found in Chapter 4.6, 
“Development of Enzyme-linked immunosorbent assays for the detection of antibodies in 
ferret blood samples”. Initial attempts to establish the ELISA assays with CDV proteins were 
made using previously described protocols (Chapter 4.6) and purified CDV proteins produced 
in E. coli. We decided to produce and employ purified proteins rather than the previously 
described whole virus lysate or insect larvae lysate in order to reduce the possibility of 
unspecific binding. Assays performed using these methods did however not achieve useful 
results. High background values and unclear discrimination between known positive and 
negative samples combined with overall low signals were noted repeatedly. Abundant 
modifications were undertaken at all stages of the assay. Antigen purity, availability and 
binding capabilities were confirmed. Protein- and purification tag-specific monoclonal 
antibodies were used as primaries in place of serum to evaluate assay mechanics. Control 
sera were employed in dot blot assays us
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positivity and negativity. A variety of secondary antibodies were tested. The use of serum, 
heat-inactivated serum as well as plasma was compared. Different blocking protocols were 
employed. Different assay strategies were tested. Mock assays were run using bovine serum 
albumin (BSA) or lipopolysaccharides (LPS) as coating antigens to evaluate the possibility of 
background being caused by unspecific binding to accompanying antigen in the purified 
protein solution. Test samples were pre-absorbed against BSA or LPS before being used in 
the assay with the same goal. Serum samples of non-CDV susceptible species were used as 
another negative control. However, it was noted that these foreign species samples 
produced very high signals. We are not sure as to the reasons for this result. The issue of 
high background, false positive results for naïve samples from other species, and insufficient 
discrimination between positive and negative samples could not be solved despite our best 
efforts. 
For ELISAs using SIV gag as an antigen, we based the assay development on protocols 
already in existence in our lab, and routinely used with serum samples from various 
laboratory animal species. This assay produced higher signals than the assays using CDV 
proteins, but showed a very high degree of variability between repeats of identical assays, 
despite using not only the same protocol but also the same reagents, materials and samples. 
This occurred for repetitions performed by the same as well as different researchers. A 
capture assay was attempted as an alternative assay strategy, but failed due to unexpected 
cross-reactivities of reagents at various stages of the assay. On various occasions, naïve 
ferret serum used as negative control produced higher signals than any of the assay sera. 
The reasons for this were not clear. Due to increasing pressure to obtain information about 
humoral responses to SIV gag, we decided to change to a different technique at this point, 
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and successfully employed the Western Blots described above to qualitatively assess the 
presence of SIV gag antibodies. 
 
To summarise, the series of in vivo studies described in this thesis demonstrated that a 
recombinant CDV vector containing the SIV gag gene can safely be used in a highly CDV 
susceptible species. The vector does not cause clinical CDV, but is able to distribute and 
replicate within the host. Replication is reduced for rCDV-SIVgag compared to the empty 
vector, but rCDV-SIVgag retains the lymphotropic characteristics of the vector. Mild viremia 
was detected for both vaccine candidates during the second half of the 28 day study, but no 
live virus could be cultured from any of the swab samples taken, indicating that no 
significant shedding of infectious particles occurs. Humoral responses against both CDV and 
SIV gag could be demonstrated, and there was evidence that cellular responses to SIV gag 
were being established. 
5.5 Further research 
Since the end of the studies described here the vaccine candidate rCDV-SIVgag has been 
employed in further studies. The qRT-PCR methodology to detect viral particles has been 
further improved and a paper published on its use (289). From personal communication with 
Xingsheng Zhang and Joanne DeStefano, both at IAVI, I have learned that rCDV-SIVgag has 
successfully passed further stages of in vivo evaluation in ferrets, including studies using 
rCDV expressing GAG and rCDV expressing SIV ENV simultaneously. Both vectors were able 
to replicate equally well when applied singly or in combination, and genomic RNA of the 
vector was detectable in the gut-associated lymphatic tissue for a significant time period. 
The recombinant CDV vectors have since advanced to being administered to Rhesus 
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macacques, which were then to be challenged with SIV. The vectors have proven safe for use 
in primates, and have been shown to control virus loads and confer a significant degree of 
protection upon challenge. A degree of immunity could also be detected. At the current 
stage, rCDV vectors expressing the complete SIV proteome are undergoing evaluation in 
nonhuman primates in an effort to increase immunogenicity. These vectors will be 
undergoing challenge shortly, and a significant degree of protection from challenge is 
expected. This stage of nonhuman primate challenge studies represents one of the final 
stages of pre-clinical testing of novel vaccine candidates before proceeding into clinical 
studies. The progressing of a vaccine candidate to that stage makes it a very successful 
construct. Additionally, rCDV vectors also hold potential as possible therapeutic mechanism 
in HIV infections. CDV overlaps with SIV/HIV in tissue and cell tropisms. Therefor the vectors 
may be able to target SIV/HIV infected cells, and if replicating sufficiently, they may be able 
to utilise viral or immunological mechanisms to destroy these cells, leading to a reduction in 
virus load. 
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6 Summary 
Recombinant canine distemper virus as a possible vector for the delivery of SIV antigens – 
establishment and evaluation of biosafety and immunogenicity of rCDV and rCDV-SIVgag in 
the ferret model 
HIV/AIDS has been termed one of the most devastating diseases of mankind. Due to the 
unique pathogenesis of this infection, medical therapy can only slow down the disease 
progress but is unable to cure it. Preventative measures including improved education, 
supply and use of condoms and microbicides, and the use of antiretroviral drugs during 
pregnancy and breastfeeding of infected women have slowed the infection rates globally, 
but ultimately only a vaccine is believed to be able to control the pandemic. Simian 
immunodeficiency virus (SIV), a close relative of HIV that leads to comparable disease 
processes in Rhesus monkeys, has been employed to study pathogenesis, treatment and 
prevention of HIV infection, since it is non-pathogenic to humans. Development of potential 
vaccine candidates is posing a significant challenge to the research community. Various 
pathways have been explored; with viral vectors having shown considerable success over 
the last few years. Mucosal delivery of vector based vaccines is stipulated to elicit improved 
immune responses at mucosal virus entry sites. Ideal viral vectors share their main 
replication characteristics such as cell tropism and location of replication with the 
pathogenic virus in question, which enables them to deliver the included foreign antigens to 
the site of natural infection and replication. Members of the genus morbillivirus enter the 
host through mucosal membranes, infect preferably T cells in the gastrointestinal lymphoid 
tissue and cause significant immunosuppression in a susceptible host. This research study 
employs a live attenuated vaccine strain of canine distemper virus (CDV), a morbillivirus non-
pathogenic to humans but able to replicate in primate cells, that was rescued using reverse 
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genetics and subsequently genetically engineered to contain the genetic information 
encoding the SIV gag protein, which is the most immunogenic of HIV/SIV proteins. The two 
recombinant viruses were evaluated in vitro to ensure infectivity and ability to replicate. The 
presence of the 55 kDa protein gag was confirmed. The recombinant viruses were then 
intranasally applied to ferrets, a species highly susceptible to canine distemper infection, to 
evaluate the safety and efficacy of the recombinant viruses. The ferrets were closely 
observed for clinical signs of distemper. Blood and tissue samples were taken at various time 
points post inoculation, and evaluated for the presence of recombinant virus and levels of 
immune responses elicited. The recombinant canine distemper virus vector containing SIV 
Gag proved to be clinically safe when administered to a highly susceptible species. The 
recombinant virus was able to replicate in the host, and both humoral and cellular immune 
responses to the virus backbone as well as the insert were evident. This suggests that 
recombinant canine distemper virus containing SIV antigens is a promising candidate for the 
development of an effective vaccine. Further studies have been conducted since the 
completion of the work included in this thesis, and recombinant CDV containing SIV gag has 
been successfully employed in several additional in vivo studies in ferrets as well as 
subsequently nonhuman primates. Data obtained in these studies suggest that the construct 
induces significant immune responses. At the time of writing, the construct is being 
employed in nonhuman primate challenge studies using a chimera of SIV and HIV as the 
challenge virus, to confirm the ability of the construct to create immune responses that are 
effective in an actual virus encounter. Based on the data gained so far, successful completion 
of this step is expected.  
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7 Zusammenfassung 
Das Hundestaupevirus als möglicher Vektor für SIV-Antigene – Etablierung rekombinanter 
Vektoren mit und ohne SIVgag-Insert, und Evaluierung dieser Vektoren auf klinische 




Das Humane Immunodefizienz-Virus (HIV) und das durch die Infektion letztendlich 
verursachte erworbene Immundefizienzsyndrom (AIDS) werden oft als eine moderne Plage 
der Menschheit bezeichnet. Aufgrund der besonderen Biologie des HI-Virus kann mit 
medikamentöser Behandlung nur das Fortschreiten der Erkrankung verlangsamt, nicht aber 
das Virus eliminiert werden. Vorbeugende Maßnahmen wie verbesserte Aufklärung über die 
HIV-Infektion, weiter verbreitete Verwendung von Kondomen und Mikrobiziden, oder die 
Anwendung antiretroviraler Medikamente während Schwangerschaft und Stillzeit infizierter 
Frauen haben zwar weltweit die Neuinfektionsrate vermindert, aber es wird davon 
ausgegangen, dass letztendlich nur ein Impfstoff für ein Ende des Ausbreitens der Epidemie 
sorgen kann.  
Um die Pathogenese, Behandlung und Prävention einer HIV-Infektion wissenschaftlich zu 
untersuchen, wird häufig auf das simian immunodeficiency virus (SIV) als Modellorganismus 
zurückgegriffen. Dieses Virus ist ein enger Verwandter des HI-Virus, der nicht für Menschen 
pathogen ist, aber in Rhesusaffen eine vergleichbare Erkrankung auslöst. Die Entwicklung 
möglicher Impfstoffkandidaten hat sich allerdings auch trotz verfügbarer Modellsysteme als 
schwierig erwiesen. Zahlreiche verschiedene Ansätze sind in der Entwicklung, wobei die 
Verwendung viraler Vektoren sich über die letzten Jahre als erfolgversprechend erwiesen 
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hat. Speziell die Applikation solcher Vektoren über die Schleimhäute hat wiederholt zu der 
verstärkten Ausbildung mukosaler Immunantworten geführt und ist deshalb von Interesse 
auch im Bereich der HIV-Impfstoffentwicklung. Ein geeigneter Vektor verfügt über ähnliche 
Charakteristiken wie das pathogene Virus, gegen das geimpft werden soll, vor allem in Bezug 
auf Zelltropismus und Ort der Virusreplikation im Körper. Dadurch werden die im Vektor 
inkorporierten Fremd-Antigene direkt an die während einer natürlichen Infektion relevanten 
anatomischen Strukturen geführt.  
Natürliche Infektionen mit Mitgliedern des Genus Morbillivirus beginnen in der Regel mit 
dem Eindringen des Virus über die Schleimhäute. Daraufhin infiziert das Virus bevorzug T-
Zellen, vor allem im gastrointestinalen lymphatischen System, und sorgt damit für eine 
Immunsuppression des natürlichen Wirtes. Im Rahmen der hier vorgestellten 
Untersuchungen wurde ein attenuierter Stamm des zu den Morbilliviren gehörenden 
Hundestaupevirus als Vektor für SIV-Antigene evaluiert. Das Hundestaupe-Virus ist zwar in 
vitro fähig Primatenzellen zu infizieren, ist aber für den Menschen nicht pathogen. Das Virus 
wurde als rekombinantes Virus aus Zellkultur isoliert und genetisch modifiziert, sodass die 
Erbinformation für das SIV gag Protein in den Vektor eingebaut wurde. Gag ist ein wichtiges 
virales Strukturprotein und das immunogenste alle SIV-Proteine. Im Rahmen dieser 
Forschungsarbeit wurden die Replikationsfähigkeit und Infektiosität der rekombinanten 
Vektoren in vitro sowie das Vorhandensein der Gag-Sequenz überprüft. Die rekombinanten 
Vektoren wurden dann auf intranasalem Wege an Frettchen verabreicht, die für natürliche 
Staupeinfektion sehr empfänglich sind. Während des gesamten Versuchsverlaufs wurde der 
klinische Zustand der Frettchen genau auf das Vorhandensein von Staupesymptomen 
überprüft. Wiederholt wurden Blut- und Gewebeproben genommen, die auf Virusgehalt und 
Hinweise auf Immunreaktionen untersucht wurden. Das rekombinante Staupevirus mit SIV 
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Gag-Insert hat sich in dieser Studie in einer hochempfindlichen Spezies als klinisch 
unbedenklich, aber dennoch replikationsfähig erwiesen. Die Blut- und Gewebeproben 
weisen Anzeichen humoraler und zellulärer Immunreaktionen sowohl auf den Vektor selbst 
als auch auf das Insert auf. Dies deutet darauf hin, dass rekombinantes Staupevirus mit SIV 
gag Insert ein erfolgversprechender Kandidat für weitere Entwicklungsschritte ist. Seit 
Beendigung der hier beschriebenen Arbeiten sind im Gastinstitut mehrere weitere Studien 
mit diesem Kandidaten durchgeführt worden, um Effektivität und Immunogenität sowohl in 
Frettchen als auch in Rhesusmakaken weiter zu eruieren. Diese Studien waren ebenfalls 
erfolgreich, sodass zum Zeitpunkt des Schreibens dieser Dissertation in einer weiteren Studie 
Rhesusmakaken mit dem rekombinanten Staupevirus mit SIV gag Insert inokuliert wurden, 
um sie dann mit einer pathogenen HIV/SIV-Chimäre zu infizieren. Diese sogenannten 
Challenge-Studien belegen letztendlich die Existenz einer belastbaren Immunität im Falle 
einer Infektion, und sind eine der wichtigsten Hürden in der Entwicklung von Impfstoffen. 
Basierend auf den bisher gewonnenen Daten wird von einem erfolgreichen Abschluss dieser 
Studie ausgegangen.  
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